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1. Introduction 
Maintenance of a reduced intracellular environment is crucial for the survival of cells. 
This is underscored by the fact that life evolved in an anaerobic, non-oxidative 
environment, which not only prevented the destruction of nascent macromolecules 
from oxidation, but also provided the conditions in which fundamental enzymatic and 
biochemical reactions were invented and integrated in simple metabolic pathways. 
The products of anaerobic metabolisms like ethanol, sulfide and nitrite have 
antioxidant properties. So when aerobic life forms began to appear and oxygen was 
used for respiration, antioxidants were probably available to protect them against 
oxygen radicals produced during aerobic metabolism (Symons and Gutteridge, 
1998). Subsequently, microorganisms acquired oxygen tolerance in a gradually 
oxidizing environment by inventing the antioxidant defense systems and abandoning 
the molecules which were highly prone to oxidation. Even today, oxidative 
microenvironments are compartmentalized within cells (mitochondria, endoplasmic 
reticulum, peroxisomes, and phagosomes), and the cytoplasm displays a network of 
enzymes and molecules exclusively dedicated to maintain the reduced 
intracytoplasmic condition (Lopez-Mirabal and Winther, 2008). Being known for their 
antimicrobial and apoptosis-inducing capabilities, reactive oxygen species (ROS) 
were initially considered to exert detrimental effects on cell survival. However, a 
clearer understanding of redox chemistry showed that mammalian cells produce 
H2O2 also to mediate various physiological responses (Rhee et al., 2000). 
Compelling evidence established that “redox” regulation of protein function is an 
additional regulatory mechanism of normal cell physiology, and perturbation of which 
may lead to oxidative stress-mediated patho-physiological processes like Alzheimer 
and cancer (Rhee, 2006). The present study aims to dissect the role of one 
component of the antioxidant defense system, the cytosolic thioredoxin reductase, 
in physiology and disease. 
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2. Review of Literature 
2.1 Reactive oxygen species in physiology and disease 
development 
2.1.1 Reactive oxygen species- sources and effects 
With the emergence of free oxygen in the environment, the metabolic processes 
ultimately shifted from fermentation to oxidative respiration; the latter being 
considerably more efficient in energy generation. The leakage of electrons from the 
electron transport chain during a stepwise single electron reduction of molecular 
oxygen to water (Figure 1) generates partially reduced oxygen-derived intermediates, 
so-called ROS, as inevitable by-products of the aerobic metabolism. Although ROS 
include superoxide anion (O2-), hydrogen peroxide (H2O2), the highly reactive 
hydroxyl radical (HO•), singlet oxygen (1O2), peroxyl radical (RO2•), alkoxyl radical 
(RO•) and hydroperoxyl radical (HO2•), H2O2 is the most extensively studied. H2O2 is 
very stable per se, but in presence of transition metal like iron and copper, its 
reduction generates highly reactive species. Being more reactive than molecular 
oxygen itself, ROS are primarily responsible for oxygen-mediated toxicity (Imlay, 
2008).  
 
 
 
Figure 1. ROS are by-products of aerobic metabolism. Reactive oxygen species are generated 
during single electron reduction of oxygen. The redox state and standard reduction potential of each 
intermediate are depicted (O2 molecular oxygen, O2- superoxide anion, H2O2 hydrogen peroxide, HO• 
hydroxyl radical, OH- hydroxide) (Imlay, J.A.; 2008). 
 
ROS can be generated by both exogenous and endogenous sources. Within the cell, 
ROS are mainly produced by the mitochondrial respiratory chain. 2% of the oxygen 
consumed by an organism is believed to be converted to O2- and H2O2 during normal 
respiratory processes in mitochondria due to single electron transfer through the 
respiratory chain to molecular oxygen. The concentration of ROS within normal cells 
has been estimated to be around 10-11 M for superoxide, 10-9 M for hydrogen 
peroxide, and 10-15 M for hydroxyl radicals. Additionally, xanthine oxidase, 
cytochrome P450, NADPH oxidase, peroxisomes and microsomes, arachidonic acid 
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metabolites, growth factor stimulation, and inflammatory responses against invading 
microorganisms contribute substantially to the overall ROS burden. Exogenous 
sources of ROS include environmental factors like radiation, non-genotoxic 
carcinogens, and xenobiotics that directly or indirectly inflict their deleterious effects 
by increasing ROS production (Valko et al., 2006). During evolution, biological 
systems have developed elaborate antioxidant defense systems and ROS-
scavenging enzymes in order to adapt to the aerobic habitats and to harness the 
potential of ROS for purposeful chemistry in a highly controlled manner. Therefore, 
modern life forms maintain high titers of antioxidant systems. 
 
2.1.2 ROS as signaling molecules 
Over the last two decades, an extensive amount of research has revealed that ROS 
have dual functions in both physiology and diseases. Meanwhile, the implications of 
ROS as second messenger molecules in cellular signaling has been 
comprehensively elucidated and incorporated into the existing signaling pathways 
(Veal et al., 2007). A growing body of evidence indicates that redox signaling by ROS 
is an integral part of the normal metabolism in non-stressed cells, which is 
dramatically amplified or modulated under oxidative stress. 
 
Unlike ligand-receptor interactions, which occur at macromolecular levels, ROS-
mediated signaling involves chemical reactions at the atomic level, resulting in 
reversible covalent protein modifications (Nathan, 2003). Because of that, ROS have 
the ability to react indiscriminately with biological macromolecules. For example, a 
transient burst of oxidants generated in the vicinity of a receptor upon engagement 
provides specificity to the otherwise fleeting and short-lived ROS molecules. Thus, 
they act as second messengers for numerous receptor-agonists such as growth 
factors and hormones. Transient production of H2O2 has been shown as an important 
signaling event (Rhee, 2006; Valko et al., 2007) for many cell surface receptors like 
platelet derived growth factor (PDGF) (Sundaresan et al., 1995), epidermal growth 
factor (EGF) (Bae et al., 1997), basic fibroblast growth factor (bFGF) (Lo and Cruz, 
1995), insulin (May and de Haen, 1979), granulocyte-macrophage colony stimulating 
factor (GM-CSF) (Sattler et al., 1999), cytokines like interleukin-1 (IL-1) (Krieger-
Brauer and Kather, 1995), IL-3 (Sattler et al., 1999), interferon-γ (IFN-γ) (Lo and 
Cruz, 1995), tumor necrosis factor-α (TNF- α) (Krieger-Brauer and Kather, 1995; Lo 
3
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and Cruz, 1995), T cell receptor (Tatla et al., 1999) and GTP-binding protein (G-
protein)-coupled receptors (GPCRs) like angiotensin II (Ushio-Fukai et al., 1999; 
Zafari et al., 1998). Results from PDGF or EGF receptor signaling studies showed 
that ligand-induced H2O2 production is required for the oxidation of the catalytically 
essential Cys residue and thus inactivation of protein tyrosine phosphatase (PTPs) to 
achieve a steady state level of protein tyrosine phosphorylation (Bae et al., 1997; 
Sundaresan et al., 1995). Subsequent reactivation of PTPs by electron donors (like 
thioredoxin in the case of PTP1B (Lee et al., 1998)) leads to the inactivation of the 
kinase and to an attenuation of the signal. The fact that receptor kinase-driven 
signaling can be inhibited by exogenous catalase (Sundaresan et al., 1995; Ushio-
Fukai et al., 1999), the addition of the NADPH oxidase inhibitor diphenylene 
iodonium (Ushio-Fukai et al., 1999), or the administration of NAC (Cunnick et al., 
1998; Greene et al., 2000) provides further evidence for a role of H2O2 in receptor 
signal transduction. The underlying molecular mechanism responsible for H2O2-
mediated activation of several protein tyrosine kinases (PTKs) is the selective 
oxidation of redox-sensitive cysteine residues which are highly conserved in various 
non-receptor PTKs including Abl, Src, Lck and c-Ret and are crucial for their catalytic 
or transforming abilities (Rhee et al., 2000). 
 
2.1.3 Thiol-based regulatory switches and principles of redox regulation 
Reversible oxidation-reduction of the thiol group of cysteine residues in proteins is 
thought to be the major mechanism by which ROS modulate signal transduction 
pathways. Redox-sensitive cysteine residues in these proteins function as switches 
that exploit the unique chemistry of sulfur to flip from one oxidation state to the other 
on exposure to ROS (D'Autreaux and Toledano, 2007; Paget and Buttner, 2003). 
The mechanisms of redox signaling by selective thiol-disulfide exchange reactions 
and signal transmission can be explained by three models/pathways. The 
thermodynamic model implicates a change in cellular redox buffer (like oxidation of 
glutathione: GSH to GSSG) leading to the oxidation of the protein´s thiol groups, 
based on the redox potential of target cysteines. The direct targeting model takes 
the local environment of specific target cysteines into consideration for selectively 
enhanced reactivity towards the oxidants. In the facilitated targeting model, 
extremely reactive sensor proteins scavenge the signaling oxidant and facilitate the 
oxidation of target proteins through specific protein interactions and thiol exchange 
reactions (Figure 2) (Winterbourn and Hampton, 2008). The thiol-disulfide exchange 
4
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reaction is an evolutionary conserved mechanism of redox regulation for many 
transcription factors from prokaryotes (OxyR, OhrR, PpsR, SoxR) to eukaryotes 
(Yap1, Pap1, and Sty1 in yeast) and finally to mammalian cells (p53, AP1, NFκB, and 
NRF2 etc.) (D'Autreaux and Toledano, 2007; Paget and Buttner, 2003). Thus, redox 
regulation of cell signaling comprises the major regulatory networks of cells and has 
the capacity to modulate important aspects of cell physiology.  
 
 
 
 
Figure 2. Generalized mechanisms of redox regulation of cell signaling. Exposure of cells to ROS 
causes selective oxidation of thiols of sensor/target proteins, change in redox balance and signal 
transmission. (1) Thermodynamic model (2) Direct targeting model (3) Facilitated targeting model. Pr: 
protein, sensor protein (in red) and target protein (blue) (modified from Winterbourn and Hampton; 2008) 
 
2.1.4 Oxidative stress: The dark side of ROS 
A state of oxidative stress ensues when the formation of ROS is greatly increased 
and/or protective mechanisms are compromised. If persistent, this can lead to 
oxidative damage of macromolecules (DNA, RNA, protein and lipid). ROS has been 
implicated in pro-inflammatory cytokine TNF-α, INF-γ and IL-1β-induced inflammatory 
responses (Yang et al., 2007), and in the induction of tissue injury as exemplified by 
oxidative damage in eye disorders like macular degeneration (Winkler et al., 1999) 
and cataracts (Truscott, 2000) and septic shock (Andresen et al., 2008; Victor et al., 
5
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2004). While oxidative stress is one of the causes of aging, chronic oxidative stress 
has been implicated in conditions like diabetes mellitus, uremia, atherosclerosis, 
hyperlipidemia, rheumatoid arthritis, adult respiratory distress syndrome, 
ischemia/reperfusion injury, human immunodeficiency virus infection, cystic fibrosis, 
Friedreich’s ataxia, neuro-degenerative disorders (Alzheimer, Parkinson), and cancer 
(Chinta and Andersen, 2008; Niwa, 2007; Ozben, 2007; Shi and Gibson, 2007; Valko 
et al., 2007). Since a major part of the present work is devoted to address the role of 
cytosolic thioredoxin reductase in tumor development, the role of oxidative stress in 
cancer shall be outlined in more detail in section 2.7. 
 
2.2 Antioxidant defense systems 
To antagonize the deleterious effects of ROS, numerous antioxidants have been 
invented during evolution. An antioxidant is defined as any substance that when 
present at a low concentration, compared to those of the oxidizable substrate, 
significantly delays, or inhibits, oxidation of that substrate (Halliwell, 1989). 
Antioxidants can act at many different stages in an oxidative sequence. For example, 
antioxidants can prevent radical formation by removing catalytic metal ions or by 
quenching oxygen, intercept formed radicals by scavenging key reactive oxygen 
species and initiating radicals, or by breaking the chain of an initiated sequence 
(Symons and Gutteridge, 1998). Many antioxidants have more than one mechanism 
of action. Based on their mode of action, they can be classified into enzymatic and 
non-enzymatic antioxidants. 
 
2.2.1 Non-enzymatic antioxidants 
Glutathione (GSH) is the major component of the non-enzymatic antioxidant pool 
which is present in millimolar concentration within cells. Vitamin E is an extremely 
efficient antioxidant when incorporated into the membrane bilayer. Together with β-
carotene, vitamin E prevents lipid peroxidation. System Xc- is a transmembrane anti-
porter of cysteine. By regulating the extracellular and intracellular levels of cysteine, it 
contributes to the over-all antioxidant defense. Other non-enzymatic antioxidants 
include vitamin C, albumin, transferrin, metallothioneins, celuroplasmine, bilirubin, 
glucose, protein and non-protein thiols (β-mercaptoethanol, N-acetyl cysteine), free 
amino acids, metabolic intermediates, and small molecules. 
6
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2.2.2 Enzymatic antioxidants 
The major enzymatic antioxidants are superoxide dismutases, catalases, cytochrome 
oxidase, glutathione peroxidases, glutaredoxins, glutathione reductase and 
thioredoxin/thioredoxin reductases. Their localization and function are summarized in 
Table1. Due to their relevance for the present study, system Xc-, the glutathione-
dependent system, and the thioredoxin/thioredoxin reductase system, shall be 
described in detail in the following sections. 
 
Table1: Enzymatic antioxidant defense systems within cells 
Antioxidants Location Functions 
Superoxide dismutases (Cu, Zn, Mn) c, m Conversion of superoxide to H2O2 
Catalases C Removes H2O2 at high concentration 
Glutathione peroxidases c, n, m 
Removes H2O2 (at low concentration) 
and organic hydroperoxides 
Thioredoxins/thioredoxin reductases c, m Thiol-disulfide oxidoreductase 
Peroxiredoxins c, m Reduction of H2O2 and organic hydroperoxides 
Cytochrome oxidase (Cu) M 
Prevention of ROS formation during reduction of O2   
to H2O 
Glutaredoxin c, m Thiol-disulfide oxidoreductase 
Glutathione reductase C Reduction of GSH and glutahionylated proteins 
c= cytosol, n= nucleus, m= mitochondria 
 
2.3 System Xc- and the cystine/cysteine cycle  
Cysteine (Cys) is a sulfur-containing amino acid in which the sulfur is contained in a 
sulfhydryl (-SH) group. By virtue of the ability of sulfur to exist in several oxidation 
states, thiols can exist in diverse forms like sulfhydryl (-SH), thiolate anion (-S-), thilyl 
radical, disulfide (-S-S-), sulfenic (-SOH), sulfinic (-SO2H), sulfonic (-SO3H) and 
selenodisulfide (-Se-S-) groups depending on the oxidation status of the surrounding 
milieu. Thus, the oxidation of sulfhydryl groups serves as an important post-
translational modification of redox-regulated proteins and makes them to work as 
molecular sensors or switches to perceive ROS burden and oxidative stress (Paget 
and Buttner, 2003). Cysteine residues not only determine the tertiary structure of 
proteins, but also regulate the functions by undergoing reversible oxidation-reduction. 
 
Since the extracellular milieu is oxidizing, any free cysteine (Cys) is immediately 
7
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oxidized into cystine (Cys)2. The extracellular cystine is imported across the 
membrane by system Xc-, a trans-membrane cystine/glutamate anti-porter that 
consists of xCT light chain which mediates cystine-transport specificity, and the 4F2 
heavy chain (Sato et al., 1999). System Xc- facilitates the uptake of cystine in 
exchange to glutamate at an equimolar ratio (Figure 3). Intracellularly, the imported 
cystine is reduced to cysteine. GSH has been considered as the major reducing 
power being present in millimolar concentration. Yet the mechanism of intracellular 
reduction of cystine is poorly understood as under GSH-depleted conditions the 
reduction of cystine is unperturbed (Banjac et al., 2008). The cysteine is then utilized 
for various processes. It mainly acts as precursor for GSH synthesis, it is used for 
protein biosynthesis or it remains as a source of free thiol. Although xCT knockout 
mice develop normally and are fully viable, xCT-/- mouse embryonic fibroblasts 
(MEFs) failed to survive in routine culture medium which can be rescued by 
supplementation with thiol-containing compounds like ß-mercaptoethanol and NAC 
(Sato et al., 2005). In fact, it has been shown that xCT overexpression sustains the 
proliferation of Burkitt´s lymphoma cells at low cell density (Banjac et al., 2008), and 
rescues GSH deficiency in γ-GCS knockout cells (Seiler, 2008). Thus, system Xc- is 
the main driving force for the (Cys)2/Cys cycle across the membrane and exerts its 
cyto-protective effect by facilitating cellular uptake of cystine, increasing intracellular 
cysteine concentration and strongly boosting the level of extracellular cysteine. 
 
2.4 The glutathione-dependent system 
2.4.1 Glutathione 
Glutathione (L-gammaglutamyl-L-cysteinylglycine or GSH) is the predominant non-
protein sulfhydryl compound in the cell (up to 10 mM) and serves as a ROS 
scavenger and co-factor of GSH utilizing enzymes. γ-glutamylcysteine synthetase (γ-
GCS) is the rate limiting enzyme in glutathione synthesis. Deletion of γ-GCS in mice 
causes early embryonic lethality (E7.5) (Shi et al., 2000), which underscores the 
importance of GSH for viability. BSO was shown to be a selective inhibitor of γ-GCS 
(Spyrou and Holmgren, 1996) as the γ-GCS-/- ES-like cells were highly resistant to 
BSO treatment (Seiler, 2008). It is thus an important means to deplete GSH from the 
cells. γ-GCS along with glutathione synthetase (GSS) directs the synthesis of the 
tripeptide from cysteine (Cys), glutamate (Glu) and glycine (Gly). Glutathione has a 
multitude of functions. Being present in millimolar concentration, it serves as redox 
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buffer that maintains the redox state of the cell (Meister, 1994; Meister and 
Anderson, 1983). The cellular redox state, which largely depends on external stimuli, 
ROS burden, and antioxidant status, determines the cell fate. For example, 
proliferation occurs at a redox state of approximately -240 mV, differentiation at -200 
mV and apoptosis at -170 mV (Watson et al., 2003). Within cells, GSH exists either in 
the reduced (GSH) form, the oxidized (GSSG) form or as mixed disulfide form with 
other proteins. Under normal conditions, about 1% of total cellular GSH is in the 
oxidized (GSSG) form.  
 
 
 
Figure 3. Schematic representation of the cysteine-glutathione-glutathione reductase axis. 
Cystine (Cys)2 is imported into cells by system Xc- in exchange for glutamate (Glu) and is then reduced 
intracellularly to cysteine (Cys). Cysteine is used for glutathione (GSH) and protein synthesis. A fraction 
of Cys is released into the extracellular space to maintain the redox balance of the surrounding 
environment. Protein-S-SG mixed disulfides are reduced by glutaredoxin (GRx). Oxidized GRx is 
recycled by GSH which is maintained in the reduced form at the expense of NADPH by glutathione 
reductase (GR). ASC: a shared amino acid transporter for Ala, Ser, and Cys, BSO: L-buthionine 
sulfoximine, a specific inhibitor of γ-GCS, GPx: glutathione peroxidase. 
 
Although, the GSH/GSSG ratio may not have physiological significance per se, it is 
an important factor in determining the redox state of redox-sensitive cysteines in 
some proteins (e.g. glutaredoxins) involved in the redox regulation of cell signaling 
(Lillig et al., 2008). In conjunction with glutathione peroxidases, GSH is involved in 
the scavenging of ROS, in the inactivation of hydroperoxides, and in the 
detoxification of xenobiotics along with glutathione S-transferase. In addition, it also 
serves as a source of cysteine. Upon oxidative stress, GSH undergoes disulfide bond 
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formation either with itself (GSSG) or with other proteins (mixed disulfide: protein S-
glutathionylation). 
 
2.4.2 Glutaredoxin and glutathione reductase 
Reversible protein S-glutathionylation is an important post-translational modification 
which not only provides protection to redox-active cysteines from irreversible 
oxidation, but also modulates the activities of diverse proteins. Thus, reversible S-
glutathionylation of proteins has regulatory roles in cell signaling (Gallogly and 
Mieyal, 2007; Ghezzi, 2005) and has been reported for a number of key proteins like 
actin (Wang et al., 2001), glyceraldehyde 3-phosphate dehydrogenase (Mohr et al., 
1999), protein tyrosine phosphatase 1B (Barrett et al., 1999; Kanda et al., 2006) , c-
Jun (Klatt et al., 1999), the p50 subunit of NFκB (Pineda-Molina et al., 2001; 
Reynaert et al., 2006), caspase-3 (Sykes et al., 2007), and the Ras protein (Adachi et 
al., 2004).  
 
The family of GSH-dependent oxidoreductases, the glutaredoxins (GRx), is 
responsible for the deglutathionylation of proteins. Glutaredoxins are small proteins 
of 9-15 kDa, which exist in all GSH-containing life forms in numerous isoforms. They 
are usually classified into two categories: the dithiol GRxs, which have two 
cysteines in their active site (-Cys-Pro-Tyr-Cys), and the monothiol GRxs, that are 
characterized by one redox-sensitive cysteine in their active sites (-Cys-Gly-Phe-Ser-
). The cytosolic GRx (GRx1) and the mitochondrial GRx (GRx2) are two dithiol GRxs 
in yeast and mammals. Dithiol GRxs are general thiol-disulfide oxidoreductases with 
higher specificity towards protein-SSG mixed disulfide. Monothiol GRxs from E. coli, 
yeast and vertebrates including humans are crucially involved in iron-sulfur cluster 
biogenesis and the regulation of iron homeostasis (Fernandes and Holmgren, 2004; 
Lillig et al., 2008; Lillig et al., 2005). 
 
Cytosolic glutaredoxin (GRx1) is the best characterized and probably the 
predominant deglutathionylating enzyme in mammalian cells as Glrx1 knockout mice 
exhibited no deglutahionylating activity in tissues (Ho et al., 2007). Like GRx1, the 
mitochondrial isoform, GRx2, exhibits deglutathionylating activity, albeit 10-fold lower 
than GRx1. Human GRx2 was identified as the first glutaredoxin that contains a 
10
 
Review of Literature 
redox-sensitive iron-sulfur cluster [2Fe-2S]2+.  
 
Glutaredoxins are the donors of reducing equivalents to ribonucleotide reductase and 
thus are involved in DNA synthesis together with thioredoxin/thioredoxin reductase 
(Camier et al., 2007; Gon et al., 2006; Ortenberg et al., 2004; Padovani et al., 2001). 
Glutaredoxins play important roles in diverse physiological processes like iron 
homeostasis and heme biosynthesis, maintenance of mitochondrial integrity and 
prevention of mitochondria-mediated cell death (GRx2), protection of airways from 
oxidative stress (GRx1and GRx2), protection of cardiac tissue from ischemia-
reperfusion injuries, and protection of neurons from dopamine-induced apoptosis 
(GRx1). Glutathione reductase is the enzyme that keeps GSH in its reduced state by 
utilizing the reducing equivalents from NADPH/H+. Thus, it is the driving force behind 
the GSH-dependent antioxidant system which provides a redox buffer and maintains 
the redox balance within the cell. 
 
2.4.3 Glutathione peroxidase (GPx) 
Mammalian GPxs are GSH-dependent peroxidases that reduce H2O2 and alkyl 
hydroperoxides to H2O and the respective alcohols. Out of seven isoforms (GPx1-7), 
GPx1-4 and GPx6 (in human) are selenoproteins. GPx5, GPx7 and mouse GPx6 are 
non-Sec containing Cys homologues. GPx4 is a phospholipid hydroperoxidase and is 
essential for embryonic development (Garry et al., 2008; Imai and Nakagawa, 2003; 
Yant et al., 2003) and male fertility (mitochondrial GPx4; Schneider et al., submitted). 
Recently it has been shown by Seiler et al. that GPx4 is involved in the prevention of 
lipid peroxidation and is crucial for the viability of cells and neurons (Seiler et al., 
2008).  
 
2.5 The thioredoxin/thioredoxin reductase (Trx-TrxR) system 
The thioredoxin-dependent system is another NADPH-driven thiol/disulfide 
oxidoreductase system, ubiquitously presents in the 3 kingdoms, archaea, bacteria 
and eukarya which is involved in redox regulation and antioxidant defense 
responses. Additionally, the Trx-TrxR system of bacteria, yeast and mammals is 
involved in regulating DNA synthesis, gene transcription, cell growth and apoptosis. It 
consists of thioredoxin, thioredoxin reductase and thioredoxin-dependent 
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peroxidases (peroxiredoxins) (Hirota et al., 2002; Mustacich and Powis, 2000; 
Nakamura, 2005). As thiol-disulfide oxidoreductases, all thioredoxins catalyze the 
reduction of protein disulfides with much higher efficiency than dithiothreitol (DTT) or 
GSH. Across the phylum, two distinct thioredoxin reductases are found which have 
different catalytic mechanisms and a mutually exclusive distribution, reflecting a 
complex evolutionary origin (Figure 4). Most of the archaea, bacteria, eukarya 
including fungi, plants and the protozoan parasites contain a low molecular weight 
dimeric thioredoxin reductase (L-TrxR) apparently originating from bacteria. L-TrxR is 
a specific 35 kDa flavoprotein with a disulfide/dithiol active site (Hirt et al., 2002). 
 
 
 
Figure 4. Phylogenetic relationships among members of the oxidoreductase family. H-TrxR: high 
molecular weight thioredoxin reductase, TryR: trypanothione reductase, GR: glutathione reductase, 
MerR: mercuric reductase, LipD: lipoamide dehydrogenase, L-TrxR: low molecular weight thioredoxin 
reductase, AhpF: alkyl hydroperoxide reductase F52A. (Adapted from Hirt et al.; 2002). 
 
By contrast, in higher eukaryotes (including humans, C. elegans and Drosophila) and 
apicomplexan protozoa, this enzyme has been replaced by a high molecular weight 
thioredoxin reductase (H-TrxR) which also exists as dimer. Unlike L-TrxR, H-TrxR is 
a larger, 56-65 kDa, selenium-containing flavoprotein with two redox-active catalytic 
centers and a broad substrate specificity that includes non-disulfide substrates such 
as hydroperoxides, vitamin C or selenite. H-TrxR is related to glutathione reductase 
(GR), trypanothione reductase (TyrR), mercuric reductase (MerR), and lipoamide 
dehydrogenase (LipD), while L-TrxR is related to the alkyl hydroperoxide reductase 
F52A (AhpF). Although L-TrxR and H-TrxR are homologous proteins, they have 
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evolved in different ways and probably have converged to the same substrate 
specificity independently (Hirt et al., 2002). 
 
2.5.1 The mammalian thioredoxin system 
The mammalian thioredoxin system is highly complex in organization, regulation and 
function. It consists of mainly two forms: the well characterized cytosolic form 
comprises thioredoxin 1 (Trx1) and thioredoxin reductase 1 (TrxR1), while the 
mitochondrial form is composed of thioredoxin 2 and its respective reductase 
(TrxR2). Although both systems are general protein disulfide-oxidoreductases, they 
display some unique functions in their different subcellular compartments. In addition 
to the mitochondrial and cytosolic thioredoxin reductases, a third thioredoxin 
reductase, designated thioredoxin/glutaredoxin reductase (TGR), which is 
predominantly expressed in testis, has been reported in mammals. Due to an 
additional monothiol glutaredoxin domain extension at its N-terminal end, it can 
reduce both, Trx as well as GSSG and GSH-linked disulfides in in vitro assays (Sun 
et al., 2001a). The cytosolic thioredoxin system will be described in detail in the 
following sections with reference to the mitochondrial thioredoxin system.  
 
2.5.2 Thioredoxins 
Thioredoxin is a small 10-12 kDa protein, with two redox-active cysteinyl residues 
organized in a characteristic thioredoxin fold with the sequence -Cyc-Gly-Pro-Cys- 
(Martin, 1995). It catalyzes thiol-disulfide exchange reactions (Holmgren, 1985). 
Thioredoxin was originally purified from E. coli in 1964 (Laurent et al., 1964) and 
identified as electron donor to ribonucleotide reductase. The human thioredoxin was 
originally cloned as a cytokine-like factor, named adult T-cell leukemia-derived factor, 
produced by human T-cell leukemia virus type I-transformed cells (Tagaya et al., 
1989) and as an autocrine growth factor produced by Epstein-Barr virus-transformed 
cells (Wollman et al., 1988). 
 
Unlike glutathione and glutathione-dependent enzymes, which are ROS scavengers, 
thioredoxin plays a crucial role in the redox regulation of gene expression. It shows 
more than 1000-fold higher activity for the transcription factors NFκB and AP-1 than 
GSH. Thus, thioredoxin is actively involved in the activation of transcription factors 
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regulating the expression of stress responsive genes and oxidative stress-induced 
apoptosis (Nakamura, 2004). In fact, it has been shown that binding of thioredoxin 
inhibits the kinase activity of ASK-1 (Saitoh et al., 1998), and the oxidation of 
thioredoxin 1 upon oxidative stress liberates ASK-1 to activate the downstream MAP 
kinase p38 dependent apoptosis pathway (Nadeau et al., 2007). Trx1 and Trx2 are 
essential in mammals because genetic disruption of both genes is embryonic lethal 
(Matsui et al., 1996; Nonn et al., 2003b). Conversely, overexpression of human 
thioredoxin in transgenic mice not only enhances the longevity (Mitsui et al., 2002), 
but also confers resistance towards various stress-inducing agents including 
adriamycin-induced cardiotoxicity, thioacetamide-induced acute hepatic injury and 
inflammatory cytokine- or bleomycin-induced acute lung injury (Nakamura et al., 
2002), and prevents retinal photic injury (Tanito et al., 2002). Conversely, impaired 
induction of thioredoxin has been associated with increased oxidative stress, 
immune-dysfunction, cardio-vascular diseases, and hypertension in spontaneous 
hypertensive rats (Tanito et al., 2004). It has been shown that thioredoxin 1 is 
secreted by leukocytes and exhibits cytokine-like properties. Truncated thioredoxin 
(Trx-80), a truncated form of the human cytosolic thioredoxin, is also secreted from 
cells and even displays greater cytokine-like activity than thioredoxin (Pekkari et al., 
2001; Pekkari et al., 2003; Pekkari and Holmgren, 2004). Serum/plasma levels of 
thioredoxin are elevated after infection, ischemia-reperfusion and oxidative stress 
and it correlated positively with the severity of cardiac disease (Kishimoto et al., 
2001). Increased plasma levels of thioredoxin in HIV-patients are associated with 
poor prognosis (Nakamura et al., 2001), while in hepatitis C patients increased 
plasma levels predict clinical responses to interferon therapy (Sumida et al., 2001). 
Recently it has been shown that thioredoxin 1 interferes with the binding of the CD30 
ligand (CD30L) to its receptor and prevents the CD30-induced decrease in cytotoxic 
effector functions of effector cells (Schwertassek et al., 2007). The role of thioredoxin 
in cancer is discussed in section 2.7.2.  
 
2.5.3 The mammalian thioredoxin reductases 
Several of the proteins involved in antioxidant defense and redox regulations are 
selenoproteins, including mammalian thioredoxin reductases. The incorporation of 
selenium as selenocysteine in these proteins is partly responsible for their antioxidant 
function. Mice lacking the gene encoding selenocysteine (Sec)-specific tRNA are 
early embryonic lethal (Bosl et al., 1997). Selenium is incorporated co-translationally 
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in the form of Sec at the C-terminus of TrxR within a tetrapeptide motif (-Gly-Cys-
Sec-Gly-COOH). Selenium is essential for TrxR activity since a mutation leading to 
the exchange of selenocysteine to cysteine causes a marked decrease in the 
catalytic activity of TrxR (to or below 5%) (Gladyshev et al., 1996; Lee et al., 2000; 
Nordberg et al., 1998; Tamura and Stadtman, 1996; Zhong et al., 2000; Zhong and 
Holmgren, 2000). Moreover, TrxR activity is severely impaired in selenium-deficient 
animals. While addition of nanomolar concentrations of selenium increases TrxR 
activity several-fold without increasing protein levels significantly in human cancer 
cells lines (Gallegos et al., 1997) and in the human endothelial cell line EAhy926 
(Lewin et al., 2002), TrxR activity in cell lines of lymphoid origin seem to be 
unaffected by selenium supplementation (Gallegos et al., 1997; Spyrou et al., 1996). 
In contrast to mammalian TrxR, TrxR from Drosophila melanogaster (DmTrxR) is a 
Cys-containing variant (Bauer et al., 2003); yet its catalytic competence towards Trx 
is similar to Sec-containing orthologues. Thus, it seems that the role of selenium in 
TrxR activity is rather complex. Accordingly, it has been proposed that the 
incorporation of selenium in TrxR increases the number of substrates, improves the 
enzyme efficiency and sustains enzyme activity in diverse microenvironments 
(Gromer et al., 2003).  
 
2.5.3.1 The mitochondrial thioredoxin reductase (TrxR2) 
The mitochondrial thioredoxin reductase (TrxR2 also known as TR3 or Txnrd2) along 
with mitochondrial thioredoxin (Trx2) and thioredoxin-dependent peroxidase, 
peroxiredoxin 3 (Prx3), make up the mitochondrial thioredoxin-dependent antioxidant 
system. The mouse Txnrd2 gene was mapped to chromosome 16 (Kawai et al., 
2000) and encodes a 57 kDa protein of 527 amino acid residues with a mitochondrial 
leader sequence. Several splice variants of TrxR2 have been reported with one form 
encoding a cytosolic version of TrxR2 (Turanov et al., 2006). However, the biological 
implications of these variations have not been resolved and additional biochemical 
and structural characterizations of the enzymes are awaited. TrxR2 is highly 
expressed in liver, heart, hematopoietic system and kidney. The involvement of 
TrxR2 in the maintenance of mitochondrial integrity and the regulation of 
mitochondria-dependent apoptosis was revealed by targeted disruption of Txnrd2 in 
mice, which resulted in embryonic lethality (E13.5) (Conrad et al., 2004). Txnrd2 null 
embryos showed severe anemia due to increased apoptosis of fetal blood cells in the 
liver, perturbed cardiac development, and growth retardation. Txnrd2-deficient 
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fibroblasts were susceptible to GSH depletion and showed increased ROS levels 
which can be prevented by NAC supplementation (Conrad et al., 2004). Cardiac 
tissue-specific deletion of Txnrd2 led to post-natal death due to biventricular dilated 
cardiomyopathy and mitochondrial abnormalities in cardiomyocytes. 
 
2.5.3.2 The cytosolic thioredoxin reductase (TrxR1) 
2.5.3.2.1 Genomic organization of mouse and human cytosolic thioredoxin 
reductase 
Cytosolic thioredoxin reductase is located on mouse chromosome 10 (Kawai et al., 
2000) and encoded by 15 exons (Osborne and Tonissen, 2001). Exon 15 contains 
the coding region for the C-terminal catalytic center, including the Sec codon UGA, 
the selenocysteine insertion sequence (SECIS) element, the AU-rich elements, and 
the translation termination signal. The overall organization of the mouse Txnrd1 gene 
is similar to that of the human gene, which is on chromosome 12 and consists of 16 
exons (Gasdaska et al., 1996). Alternative splicing of human TrxR1 gives rise to 21 
different transcript variants which differ at the 5´end (Rundlof et al., 2007; Rundlof et 
al., 2004). Translation of the protein can initiate at two ATG start codons located in 
exons 3b and 4 of mouse Txnrd1 that are in the same reading frame (Figure 5). 
Translation initiation from the ATG in exon 4 produces the originally reported 54.5 
kDa protein, while translation initiation at the start codon in exon 3b yields a protein 
with a predicted molecular mass of 67 kDa (Sun et al., 2001b). The core promoter of 
the human TrxR1 gene has a high GC contents, contains binding sites for Oct1, Sp1, 
and Sp3, and lacks a classical TATA box. This indicates that TrxR1 is a house 
keeping gene, although it is up-regulated at the mRNA and protein level in response 
to various exogenous stimuli. The mouse Txnrd1 promoter lacks binding sites for 
Oct1, Sp1 and Sp3, but has two conserved AP-1 binding sites (Osborne and 
Tonissen, 2001). The complex promoter structure and the numerous alternatively 
spliced transcripts are probably an indication of a tissue-specific gene regulation 
mediated by various control elements (Rundlof et al., 2000).  
 
Apart from the complex genomic organization and alternative splicing, the mRNA of 
mouse and human thioredoxin reductase 1 shows non-AU-rich and AU-rich instability 
elements (AREs) in the 3´UTR (4 in human and 3 in mouse), that mediate rapid 
degradation of the mRNA (Gasdaska et al., 1999). AREs are typically found in 
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transcripts that undergo rapid turnover like mRNA encoding for cytokines, proto-
oncogenes, growth factors and transcription factors (Chen and Shyu, 1995), and the 
inactivation of AREs have been implicated in the promotion of cellular transformation 
and oncogenesis (Aghib et al., 1990). Both human TrxR1 and mouse Txnrd1 mRNA 
have SECIS elements in the 3´UTR that facilitate the incorporation of Sec by the 
UGA codon.  
 
 
 
Figure 5. Genomic organization and alternative splicing of the mouse Txnrd1 gene. Located on 
chromosome 10, the mouse thioredoxin reductase1 gene consists of 15 exons (1-15). Three isoforms 
are generated by alternative splicing. Exon 15 encodes the C-terminal catalytic center, including the Sec 
codon UGA (marked with *), the SECIS element, the AU-rich elements, and the translation termination 
signal. Arrows indicate translational start codon (Modified from Osborne & Tonissen; 2001) 
 
2.5.3.2.2 Structural organization and catalytic mechanism of TrxR1 
The homodimeric selenoprotein TrxR1 consists of two identical subunits of 54 kDa, 
arranged in a head to tail fashion. Each subunit has one FAD-binding domain, one 
NADPH-binding site, and an interface domain. There are two redox-active catalytic 
centers; one located in the N-terminal FAD-binding domain formed by the -Cys-Val-
Asn-Val-Gly-Cys- sequence and the other is formed by the C-terminal tetrapeptide 
motif -Gly-Cys-Sec-Gly-COOH. The C-terminal catalytic center is exposed and 
located in a flexible arm and is believed to be responsible for the broad substrate 
activity of mammalian TrxR1 (Gromer et al., 1998). The catalytically active reaction 
center is formed by the N-terminal redox active site (C59-XXXX-C64) of one subunit 
and the C-terminal redox active site (-Cys497-Sec498-) of the other subunit. Thus, each 
homodimer has two independent, catalytically active centers and the enzyme is only 
active after dimerization. Catalysis of mammalian thioredoxin reductase shows a 
ping-pong mechanism, which involves reversible transfer of electrons from 
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NADPH/H+ via a system of redox-active disulfides (Figure 6B). It is proposed that 
electrons flow from NADPH/H+ to the FAD, from there to the N-terminal redox-active 
disulfide in the enzyme and then to the C-terminal catalytic center of the other 
monomer which finally reduces thioredoxin or other substrates (Holmgren, 1985; Lee 
et al., 2000; Zhong and Holmgren, 2000). The reaction catalyzed by thioredoxin 
reductase is readily reversible and NADPH/H+ may be formed from reduced 
thioredoxin (Trx-(SH)2) and NADP+. Recently, the crystal structure of rat TrxR1 was 
resolved by Arner´s group (Cheng et al., 2009), which supports the previously 
proposed mechanism and provided additional insight (Figure 6A). 
 
 
 
Figure 6. Crystal structure and catalytic mechanism of mammalian thioredoxin reductase. (A) 
Crystal structure of rat thioredoxin reductase 1. Two subunits are shown in yellow and green, Trx in red 
(Cheng et al.; 2009). (B) Proposed catalytic mechanism by mammalian TrxR1. Trx is the natural 
substrate for thioredoxin reductase. Two subunits are shown in gray and blue, catalytic cysteine and 
selenocysteine are depicted with their amino acid numbers, the flow of electrons is depicted by a red 
arrow, disulfide bonds are in red, hexagonal boxes represent FAD. Trx: Thioredoxin, TrxR1: Thioredoxin 
reductase (adapted from Zhong et al.; 2000). 
 
2.5.3.2.3 Physiological function of TrxR1 
Mammalian TrxRs are promiscuous enzymes as they reduce diverse classes of 
physiological substrates including protein-disulfides and non-disulfide substrates 
such as hydroperoxides (including lipid peroxides), vitamin C (May, 2002; May et al., 
1998), selenite (Kumar et al., 1992), α-lipoic acid (Arner et al., 1996), α-tocopherol, 
ubiquinone, NK-lysin (Andersson et al., 1996), L-cystine (Luthman and Holmgren, 
1982), alloxan, and vitamin K as well as non-physiological compounds like DTNB and 
NBT (Nordberg and Arner, 2001). Since Trx is involved in a large number of 
physiological functions like antioxidant defense, control of transcription factor activity 
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(p53, AP-1, NFκB and HIF), growth and proliferation, a majority of biological functions 
assigned to thioredoxin reductase are actually thioredoxin dependent (as depicted in 
Figure 7). Also, the expression of Trx in tissues is more abundant than TrxR at the 
mRNA level (Jurado et al., 2003), and the deletion of the Trxs has more severe 
effects than when thioredoxin reductases are disrupted (Conrad et al., 2004; 
Jakupoglu et al., 2005; Matsui et al., 1996; Nonn et al., 2003b). To date it has 
remained difficult to distinguish between the thioredoxin-dependent and thioredoxin-
independent functions of thioredoxin reductases. 
 
 
 
Figure 7. Physiological functions of the mammalian thioredoxin system. As depicted, the majority 
of the functions of thioredoxin reductase are thioredoxin-dependent. Peroxiredoxins are thioredoxin-
dependent peroxidases that play an important role in the removal of H2O2. Additionally, thioredoxin 
reductase plays an important role in the reduction of non-enzymatic antioxidant compounds like 
dehydroascorbic acid, α-tocopherol and lipoic acid. Prx: peroxiredoxin, GPx: glutathione peroxidase, 
PDI: protein disulfide isomerase, ASK-1: apoptosis stimulating kinase-1, DHLA: dihydrolipoic acid, TR: 
thioredoxin reductase (Adapted from Nordberg & Arner; 2001) 
 
Thioredoxin is one of the electron donors for ribonucleotide reductase which 
maintains the dNTP pool required for DNA synthesis. In all organisms studied so far, 
loss of Trx and/or TrxR leads to severe proliferation defects, decreased DNA 
synthesis, and retarded growth. Targeted disruption of thioredoxin reductase 1 in 
mice resulted in embryonic lethality at E10.5 due to severe growth retardation and 
widespread developmental abnormalities, indicating that it is indispensable for cell 
proliferation (Jakupoglu et al., 2005). Additionally, TrxR1 is a direct target of the 
oncogene c-myc (Schuhmacher et al., 2001) and is reported to be up-regulated in 
various tumors, further emphasizing the role of TrxR1 in cell proliferation. The role of 
TrxR1 in tumorigenesis is discussed in section 2.7.2 
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The thioredoxin-dependent system is an important antioxidant system within the cell 
that provides protection against ROS. The antioxidant function of TrxR1 seems to be 
dependent on Trx1 as Trx1 has been shown to prevent apoptosis in cells treated with 
agents known to produce ROS (Spector et al., 1988). TrxR can directly reduce 
peroxides including hydrogen peroxide and lipid hydroperoxides (Bjornstedt et al., 
1995) and act as H2O2 scavenger at elevated levels (Zhong and Holmgren, 2000). 
Furthermore, TrxR1 has an important role in the reduction and recycling of many 
non-enzymatic antioxidants like ascorbic acid, vitamin E and α-lipoic acid, which, in 
addition to GSH, contribute to the cellular redox buffer (Nordberg and Arner, 2001). 
By reducing dehydroascorbate to ascorbic acid, TrxR1 plays an important indirect 
role in protecting cells from oxidative stress. Since ascorbate is involved in the 
reduction of α-tocopherol radicals, TrxR1 may play an important role in the 
antioxidant function of vitamin E. Thus, by scavenging hydroperoxides (especially 
lipid hydroperoxides), recycling ascorbate and regenerating vitamin E, TrxR1 plays 
an important role in the protection of membrane from oxidative damage. In fact, the 
sparing effects of vitamin E and selenium can be attributed to TrxR (Tamura et al., 
1995). Owing to its pleiotropic effects, it is not surprising that alterations in TrxR1 
function have been implicated in several patho-physiological conditions like 
rheumatoid arthritis, atherosclerosis, reperfusion injuries, and cancer (Gromer et al., 
2004).  
 
2.5.4 Peroxiredoxins 
Peroxiredoxins are thioredoxin-dependent peroxidases which are critically involved in 
H2O2 scavenging (Wood et al., 2003a). Mammalian peroxiredoxins are classified into 
three sub-groups: 1) 2-Cys peroxiredoxins, 2) Atypical 2-Cys peroxiredoxins 3) 
1-Cys peroxiredoxin. 2-Cys peroxiredoxins require 2 redox-active cysteines (a 
peroxidatic and a resolving cysteine) for catalysis and include the cytosolic isoforms 
Prx1 and Prx2, the mitochondrial isoform Prx3, whereas Prx4 is located in the 
endoplasmatic reticulum and may be secreted as well. Atypical 2-Cys peroxiredoxins 
and 1-Cys peroxiredoxins have only N-terminal redox-active cysteines and are 
represented by Prx5 and Prx6, respectively (Rhee et al., 2005a).  
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All Prxs exist as homodimers and contain a conserved N-terminal cysteine residue, 
which is the primary site for oxidation by H2O2. Prxs are involved in reducing 
hydroperoxide, alkyl hydroperoxides and peroxynitrite. They also regulate peroxide-
mediated signaling cascades (Rhee et al., 2005b; Wood et al., 2003b). Prxs have 
been implicated in c-Myc-mediated transformation and apoptosis. Over-expression of 
Prxs protects tumor cells against hypoxia (Nonn et al., 2003a), and the over-
expression of Prxs in many cancers is correlated with resistance to apoptosis 
induced by radiation therapy (Park et al., 2000) or the anticancer drug cisplatin 
(Chung et al., 2001). 
 
2.6 Redundancies between the GSH-dependent and the 
thioredoxin-dependent antioxidant systems 
It is currently not known why there are two separate classes of thiol/disulfide 
oxidoreductases operating in the same compartment. Although both enzymes, 
thioredoxin reductase and glutathione reductase, are related evolutionary (Hirt et al., 
2002), there is a fundamental difference between the two systems. That is there is a 
direct link between the reduction of disulfide bonds by thioredoxin and the oxidation 
of NADPH (The direct targeting model). But the involvement of GSH in the 
thiol/disulfide reduction by glutaredoxins adds another tier of complexity to the GSH-
dependent system (The facilitated targeting model). Although under physiological 
conditions the reaction rates of GSH and GSSG are too slow to be of great 
importance, the values of the GSH-GSSG redox potential are close to the midpoint 
redox potential for GRxs which are ideal candidates for sensing and transducing the 
signals associated with changes in the GSH-GSSG redox state as they can be GSH-
dependent reductases at -240 mV and GSSG-dependent oxidases at -170 mV 
(Aslund et al., 1997; Lillig et al., 2008). Thus the glutaredoxin-dependent 
thiol/disulfide reduction is coupled with the change in the glutathione pool, which is 
the deciding denominator of the efficiency and direction of the glutaredoxin pathway. 
In all likelihood it is conceivable that the GSH-dependent system is involved in the 
maintenance of redox homeostasis, while the thioredoxin-dependent system fulfills 
specialized functions in proliferation, differentiation etc. Both, thioredoxin and 
glutaredoxin are donors of reducing equivalents to ribonucleotide reductase and thus 
involved in the maintenance of the dNTP pool and DNA synthesis (Figure 8).  
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The redundancies between the two pathways are apparent by the fact that in the 
absence of only one of the pathways, bacterial and yeast strains can survive and 
grow reasonably well. As reported in yeast, the deletion of both thioredoxins (Δtrx1 
and Δtrx2) results in slow DNA replication and impaired sulfate assimilation, but 
viability is only compromised when both cytosolic isozymes thioredoxin and 
glutaredoxin were lacking (Muller, 1996; Trotter and Grant, 2003; Trotter and Grant, 
2005). Limited growth of the triple mutant (trx1 trx2 glr1 mutant) can be restored 
under anaerobic condition which showed that although both the systems are involved 
in the maintenance of the dNTP pool, the lethality is due to perturbation of the redox 
balance rather than DNA synthesis. This is further supported by the fact that reduced 
GSH failed to rescue the growth of the triple mutant. Elevated levels of GSSG in trx1 
trx2 mutants showed a link between the thioredoxin system and the redox status of 
GSH in the cell (Muller, 1996).  
 
 
 
Figure 8. Maintenance of the dNTP pool by thioredoxin and the GSH/glutaredoxin systems. 
Thioredoxin and glutaredoxin are known donosr of reducing equivalents to the ribonucleotide reductase 
that maintains the dNTP pool and thus DNA synthesis. Trx: Thioredoxin, TrxR1: Thioredoxin reductase 
1, GR: Glutathione reductase, GRx: Glutaredoxin, GSH: Glutathione, GSSG: Oxidized GSH 
 
The redundancy between the two systems in mammals is still unclear and rather 
complex. The deletion of the thioredoxin system is embryonic lethal (Trx1, Trx2, 
Txnrd1, Txnrd2) in mice. The individual disruption of Glrx 1, Glrx2 and Gsr is 
dispensable but the deletion of γ-GCS is lethal in mice. This could be due to the 
complex organization of the mammalian redox systems. In mice, members of the 
thioredoxin pathway (Trx1, Trx2, Txnrd1 and Txnrd2) are more regularly 
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expressed in different organs than mRNA species of the glutathione-dependent 
pathway (Glrx1, Glrx2 and Gsr) (Jurado et al., 2003), indicating a broader 
involvement of the thioredoxin system in diverse metabolic functions. Hence, both 
systems appear to have redundant functions, but the extent of redundancy as well as 
common targets have not been identified yet. A better understanding of these two 
systems is mandatory for exploring the possibility of targeting these enzymes to treat 
oxidative stress-associated diseases. 
 
2.7 Interplay of ROS and antioxidants in tumor development 
Cancer is a multi-factorial metabolic syndrome characterized by novel acquired 
capabilities of self-sufficiency in growth with unlimited replicative potential by 
suppressing the growth-inhibitory pathway or evading the apoptotic machinery 
(Hanahan and Weinberg, 2000). Whether ROS play a pivotal role in cancer biology is 
still contentious even though it has been known for a long time that tumor cells in 
culture produce more ROS than non-transformed cells (Szatrowski and Nathan, 
1991). Owing to the chicken/egg nature of the question, it is hard to define a causal 
link between ROS and tumor formation. Recently, Trachootham et al. showed in an 
elegant study that the transformation event is followed by an increase in ROS 
production (Trachootham et al., 2006), presumably due to oncogene-induced 
replicative stress. Thus, accumulating evidence indicates that ROS are playing a 
crucial role in tumor initiation, progression, proliferation, and metastasis as well as 
necrosis and regression as discussed below (Figure 9).  
 
A state of chronic oxidative stress resulting from increased ROS production or loss of 
antioxidant function can irreversibly inactivate the regulatory circuitry of various 
signaling pathways and render them constitutively active (like receptor tyrosine 
kinase signaling, Ras signaling, MAP kinase signaling), which has long been 
implicated in the causation of various cancers. This self-sufficiency in growth signals 
drives the cells into continuous proliferation which may eventually lead to cancer. 
 
ROS are notorious for their damaging effects on bio-macromolecules of which DNA 
damage is most detrimental, because it is stable, cumulative and inheritable. If sub-
lethal, these mutations may either cause the activation of proto-oncogenes and/or 
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inactivation of tumor suppressor genes; thereby increase the likelihood of cancer 
initiation and progression. The subsequent accumulation of mutations in the genome 
can result in genomic instability which is one of the hallmarks of cancer (Kopnin, 
2007; Rodrigues et al., 2008). 
 
 
 
Figure 9. The role of ROS in cancer. By acting as mitogen and/or mutagen, ROS contribute to the 
formation and progression of tumors. Given that in transformed cells ROS production is higher than in 
non-transformed cells, agents that inhibit the antioxidant defense system or augment ROS production 
are novel chemotherapeutics against cancer. Events in red are barriers against cancer while events in 
blue promote tumorigenesis. Modified from (Schumacker, 2006).  
 
In vivo growing solid tumors contain areas of low oxygen concentration (hypoxia), 
which was first postulated by Thomlinson and Gray in 1955 (Thomlinson and Gray, 
1955). During the course of progression, fluctuations in oxygen concentration put a 
selective pressure on the cells. By shifting metabolism from aerobic respiration to 
anaerobic glycolysis, the cells can adapt to and grow in hypoxic conditions, an effect 
first observed by Warburg 50 years ago (Warburg, 1956). Increased nutritional and 
oxygen demand in growing tumors induces neo-vascularization. Aberrant blood flow 
in neo-vascularized tissue causes re-oxygenation, and these cycles of intermittent 
hypoxia followed by re-oxygenation result in increased ROS levels. The fluctuating 
microenvironment keeps the tumor cells in a state of persistent oxidative stress. 
Thus, ROS are thought to play an important role in maintaining the cancer phenotype 
by stimulating cell growth and proliferation (Hu et al., 2005), increasing genetic 
instability (Radisky et al., 2005), and facilitating evasion from senescence. Owing to 
their cancer-promoting effect, increased levels of ROS in cancer cells are often 
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considered as an adverse prognostic factor. Thus, the role of ROS in tumor 
development by promoting proliferation and genomic instability is a well-proven and 
established paradigm in cancer biology. 
 
By contrast, Takahashi et al. reported that ROS have an unexpected role in tumor 
suppression by inducing and maintaining senescence in tumor cells (Takahashi et 
al., 2006). If this holds true, then the role of ROS and the redox balance will have an 
even more complex role in cancer causation and progression. Most likely, the 
diametrically opposed roles of ROS in tumor causation, growth and maintenance 
depend on the amount and tempo-spatial production of ROS, the antioxidant status 
and their interplay within the tumor microenvironment. 
 
2.7.1 Components of the antioxidant system as drug targets for cancer 
chemotherapy  
Selective toxicity against cancer cells is the key for the success of any 
chemotherapeutic compound. Although tumor cells maintain a high titer of 
antioxidants, the constitutive oxidative stress caused by the increased 
production/accumulation of ROS leads to the saturation of the antioxidant system in 
tumor cells, which can not afford to accommodate further accumulations of ROS. 
This limited availability of antioxidants in tumor cells may offer novel therapeutic 
options. A massive outburst of ROS in tumor cells may be achieved selectively by 
agents that increase ROS production or inhibit the antioxidant system. Thus 
individual components of the antioxidant system may constitute suitable drug targets 
for cancer chemotherapy. By targeting the glutathione-dependent antioxidant system 
with phenyl-ethyl isothiocyanate (PEITC), Trachootham et al. showed that the 
preferential accumulation of ROS in transformed cells causes oxidative damage to 
mitochondria, inactivation of redox-sensitive molecules, massive cell death and 
increased survival of tumor-bearing mice treated with PEITC (Trachootham et al., 
2006). Likewise, targeting the thioredoxin-dependent system by knocking-down 
Txnrd1 in tumor cells led to a loss of their tumorigenic potential (Yoo et al., 2006). 
Also Lu et al. has shown that the therapeutic efficacy of arsenic oxide against cancer 
is based on the inhibition of TrxR1 (Lu et al., 2007). These reports clearly show that 
components of the antioxidant system are promising targets for the treatment of 
cancer. Unfortunately, the above studies failed to assess the long term out-come of 
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inhibiting an antioxidant system. More importantly, the mechanisms of action of the 
tested compounds are poorly defined. Thus, off-target effects and inhibition of other 
molecules can not be ruled out at present. Thus, although it is not clear yet what is 
the molecular role of ROS in tumors, members of the antioxidant defense system 
seem to be promising candidates for novel therapeutic targets against cancer.  
 
2.7.2 The thioredoxin system in cancer 
A number of reports have linked the thioredoxin 1/thioredoxin reductase 1 system to 
cell proliferation, cancer development, invasiveness, and drug resistance of tumor 
cells. Previous work in the lab identified TrxR1 and thioredoxin 1 as targets of the 
proto-oncogene c-myc (Schuhmacher et al., 2001). Immunocytochemical and mRNA 
expression studies revealed high expression of thioredoxin and/or thioredoxin 
reductase in primary colorectal cancer (Berggren et al., 1996; Raffel et al., 2003), 
breast cancer (Matsutani et al., 2001; Ueno et al., 2000), gastric cancer (Grogan et 
al., 2000), small cell and non-small cell lung cancer (Kakolyris et al., 2001; Soini et 
al., 2001), pancreatic cancer (Han et al., 2002; Nakamura et al., 2000), malignant 
pleural mesothelioma (Kahlos et al., 2001), adult T-cell leukemia (Wakasugi et al., 
1990), hepatocellular carcinoma (Kawahara et al., 1996; Nakamura et al., 1992), 
invasive mammary carcinomas (Lincoln et al., 2003), and malignant melanomas 
(Barral et al., 2000; Lincoln et al., 2003). High expression of thioredoxin 1 and/or 
thioredoxin reductase has been correlated with high proliferative capacity, low 
apoptosis and elevated metastatic potential of cells (Lincoln et al., 2003), increased 
drug resistance (Arnold et al., 2004; Iwao-Koizumi et al., 2005; Kawahara et al., 
1996; Yokomizo et al., 1995), and decreased patient survival (Raffel et al., 2003). 
These findings have been corroborated by transfection studies revealing that 
expression of thioredoxin 1 and TrxR1 increases cell proliferation and confers 
resistance to cisplatin (Sasada et al., 1996; Sasada et al., 1999) (Sasada et al., 
2000), whereas thioredoxin reductase 1 antisense expression sensitizes cells to 
cisplatin treatment (Sasada et al., 1999). Likewise, a dominant-negative mutant of 
thioredoxin 1 (C32S/C35S) reverses the transformed phenotype of human breast 
cancer cells (Gallegos et al., 1996). 
 
It has been shown that Trx1 and its truncated form (Trx80) are secreted by 
transformed cells and may have growth factor or cytokine-like properties (Pekkari et 
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al., 2003; Rubartelli et al., 1992; Schenk et al., 1996; Wakasugi et al., 1990). Hypoxic 
conditions induce the expression of thioredoxin (Hedley et al., 2004; Kim et al., 
2003), which, in turn, increases the expression of hypoxia-inducible factor 1α (HIF-
1α) and a number of other transcription factors including AP-1. Through this 
mechanism, thioredoxin increases the production of vascular endothelial growth 
factor (VEGF) and contributes to tumor angiogenesis (Welsh et al., 2002). Finally, 
thioredoxin inhibits inhibitors of metalloproteases, TIMP-1 and TIMP-2, and thus 
shifts the balance between metalloproteases (namely MMP-9) and their inhibitors 
towards increased activity of MMPs (Farina et al., 2001) that promotes metastasis. 
 
Since Trx1 and TrxR1 are often up-regulated in various tumors, they represent a 
suitable drug target for the treatment of cancer. Knock-down of Txnrd1 inhibits self-
sufficiency of tumor cells and reverts the malignant phenotype (Yoo et al., 2006; Yoo 
et al., 2007). Inhibition of TrxR1 inhibits NFκB and AP-1, induces G1-phase growth 
delay and sensitizes the tumor cells towards the agents that induce oxidative stress 
like H2O2 or ionizing radiation (Smart et al., 2004). Known inhibitors of thioredoxin 
reductase are nitrosourea, gold compounds (Auranofin, aurothioglucose), cis-
platinum complexes (Cisplatin, carboplatin), dinitrohalobenzenes (1-chloro-2,4-
dinitobenzene (2,4-CDNB)),  arsenicals (Arsenic(III) oxide) and antitumor quinoid 
compounds (diaziquone, doxorubicin, menadione, plamarumycin CP1), some of 
which are potent anti-cancer agents (Gromer et al., 2004; Powis et al., 2006). In fact, 
it has been shown that the therapeutic efficacy of arsenic oxide against cancer is 
based on the inhibition of TrxR1 (Lu et al., 2007). However, the lack of specificity is a 
major drawback of this group of drugs as many other flavoenzymes are inhibited as 
well (Gromer et al., 2004).  
 
Histone deacetylase (HDAC) inhibitors are a new class of anti-cancerous drugs that 
exert their antitumor effects by preferentially increasing ROS production and inducing 
polyploidy in transformed cells (Rosato and Grant, 2003; Xu et al., 2005). HDAC 
inhibitors are supposed to repress the thioredoxin system by up regulating 
thioredoxin binding protein 2 (Butler et al., 2002; Ungerstedt et al., 2005). HDAC 
inhibitor-induced cell death is independent of caspases and p53 or p21 status. Due to 
mutations, p53-dependent functions are compromised in many tumors. Thus, acting 
through inhibiting the thioredoxin-dependent pathway, HDAC inhibitors can be 
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effective against those tumors in which p53-dependent apoptosis and/or senescence 
pathways are defective. Since the thioredoxin/thioredoxin reductase1 system is up-
regulated in many tumors and many known anti-tumor compounds act through 
inhibiting these molecules, thioredoxin/thioredoxin reductase1 are promising drug 
targets against cancer. 
 
2.8 Aims of the present study 
The thioredoxin-dependent system plays pivotal roles in different aspects of cell 
physiology like cell proliferation, redox regulation of cell signaling, and apoptosis. 
More importantly, it is up-regulated in many solid tumors and thus a promising novel 
drug target for cancer chemotherapy. Previous work in the lab has shown that mouse 
Txnrd1 is indispensable for cell proliferation (Jakupoglu et al.; 2005). By using a 
conditional Txnrd1 knockout mouse and mouse embryonic fibroblast (MEFs) cell 
lines derived from these mice, the present study was carried out with the following 
objectives:  
 
1. To address the role of thioredoxin reductase 1 in proliferation and growth. 
2. To study the effects of thioredoxin reductase 1 inactivation on cellular 
redox homeostasis. 
3. To study possible redundancies between the thioredoxin- and the GSH-
dependent systems. 
4. To explore the role of thioredoxin reductase 1 in tumor development.  
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3. Materials and Methods 
3.1 Materials 
Reagents    Company           Catalog No. 
Acrylamide    Bio-Rad, Munich, Germany     161-0158 
Agarose, electrophoresis grade Invitrogen, Karlsruhe, Germany      15510-027 
Agarose, low melting point  Fermentas GmbH, St. Leon-Rot, Germany   R0801 
Ammonium persulfate  Sigma-Aldrich GmbH, Taufkirchen, Germany  A3678 
Ampicillin     Sigma-Aldrich GmbH, Taufkirchen, Germany  A9518 
Arsenic (III) oxide   Sigma-Aldrich GmbH, Taufkirchen, Germany  202673 
β-Mercaptoethanol (2-ME)  Roth Carl GmbH & Co., Karlsruhe, Germany  4227.1 
Bovine albumin    MP Biomedicals, Eschwege, Germany   840043 
Bromophenol blue sodium salt Merck KGaA, Darmstadt, Germany    111746 
Buthionine sulfoximine (BSO) Sigma-Aldrich GmbH, Taufkirchen, Germany  B2640 
t-Butyl hydroperoxide   Sigma-Aldrich GmbH, Taufkirchen, Germany  B-2633 
Cadmium chloride   Sigma-Aldrich GmbH, Taufkirchen, Germany  C3141 
Calcium chloride   Sigma-Aldrich GmbH, Taufkirchen, Germany  C7902 
Chloroquine    Sigma-Aldrich GmbH, Taufkirchen, Germany  C6628 
Crystal violet    Sigma-Aldrich GmbH, Taufkirchen, Germany  C3886 
DAPI     Invitrogen, Karlsruhe, Germany     D1306 
dNTP Mix     Fermentas GmbH, St. Leon-Rot, Germany   R0241 
DMSO     Sigma-Aldrich GmbH, Taufkirchen, Germany  D2650 
Doxorubicin    Sigma-Aldrich GmbH, Taufkirchen, Germany  D-1515 
ECL      GE Healthcare, Freiburg, Germany    RPN2106 
EDTA     Sigma-Aldrich GmbH, Taufkirchen, Germany  E9884 
Ethanol p.a.    Merck, Darmstadt, Germany     1.00983.2500 
Ethidiumbromide    Merck, Darmstadt, Germany     70257083 
L-Glutathione oxidized (GSSG) Sigma-Aldrich GmbH, Taufkirchen, Germany  G4626 
Glutathione reductase (Yeast) Sigma-Aldrich GmbH, Taufkirchen, Germany  G3664 
Glycine      MP Biomedicals, Eschwege, Germany   808831 
Hydrogenperoxide   Sigma-Aldrich GmbH, Taufkirchen, Germany  H1009 
Isopropanol p.a.   Merck, Darmstadt, Germany     1.09634.2511 
Luria Broth base   Invitrogen, Karlsruhe, Germany     12795-019 
Magnesium sulfate   Sigma-Aldrich GmbH, Taufkirchen, Germany  M2643 
Mounting medium   Dako Cytomation, Hamburg, Germany   S3023 
MTT      Sigma-Aldrich GmbH, Taufkirchen, Germany  M2128  
N-Acetyl-L-Cysteine   Sigma-Aldrich GmbH, Taufkirchen, Germany  A9165 
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NADPH (reduced)   Sigma-Aldrich GmbH, Taufkirchen, Germany  N6505 
Oligonucleotides    Metabion International AG, Martinsried, Germany 
Paraformaldehyde (PFA)  Roth Carl GmbH & Co., Karlsruhe, Germany  0335.3 
Phenol     Roth Carl GmbH & Co., Karlsruhe, Germany  0038.3 
Phenol/Chloroform   Roth Carl GmbH & Co., Karlsruhe, Germany  A156.2 
PhosSTOP    Roche Diagnostics, Mannheim, Germany   04906837001 
Protease Inhibitor Cocktail  Roche Diagnostics, Mannheim, Germany   1 697 498 
Proteinase K    Roth Carl GmbH & Co., Karlsruhe, Germany  7528.1 
Rubidium chloride   Sigma-Aldrich GmbH, Taufkirchen, Germany  83979 
SDB-F     Fluka Chemie GmbH, Buchs, Switzerland   46640 
Select Agar    Invitrogen, Karlsruhe, Germany     30391-023 
Skim milkt powder   Fluka Chemie GmbH, Buchs, Switzerland   70166 
Sodium chloride   MP Biomedicals, Eschwege, Germany   194848 
Sodium dodecyl sulfate (SDS) Fluka Chemie GmbH, Buchs, Switzerland   71729 
Sodium phosphate tetrabasic Sigma-Aldrich GmbH, Taufkirchen, Germany  S6422 
TEMED     Fluka Chemie GmbH, Buchs, Switzerland   87689 
Triethylphosphine gold(I) chlorideSigma-Aldrich GmbH, Taufkirchen, Germany  288225 
Tris-Base     Merck, Darmstadt, Germany     1.08382 
Triton X-100    Sigma-Aldrich GmbH, Taufkirchen, Germany  T9284 
Trolox®     Fluka Chemie GmbH, Buchs, Switzerland   56510 
Tween 20     Sigma-Aldrich GmbH, Taufkirchen, Germany  P5927 
 
Cell culture reagents   Company          Catalog No. 
β-Mercaptoethanol (2-ME)  Invitrogen, Karlsruhe, Germany     31350-010 
CD-CHO medium   Invitrogen, Karlsruhe, Germany     10743011 
DMEM 1 x     Invitrogen, Karlsruhe, Germany     41966 
Doxycycline HCl   Sigma-Aldrich GmbH, Taufkirchen, Germany  D9891 
Fetal Bovine Serum   PAA, Pasching, Austria       A15-043 
Glutamine (100 x)   Invitrogen, Karlsruhe, Germany     25030 
HEPES     Invitrogen, Karlsruhe, Germany     15630056 
Hygromycin B    Invitorgen, Karlsruhe, Germany     10687010 
OPTI-MEM     Invitrogen, Karlsruhe, Germany     31985 
Penicillin-Streptomycin  Invitrogen, Karlsruhe, Germany     15140-122 
Puromycin     Sigma-Aldrich GmbH, Taufkirchen, Germany  P7255 
Trypan Blue (0.4%)   Sigma-Aldrich GmbH, Taufkirchen, Germany  T8154 
Trypsin-EDTA    Invitrogen, Karlsruhe, Germany     25300 
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Molecular probes  Company           Catalog No. 
Annexin V-FITC   BD Biosciences, Heidelberg, Germany   556419  
CM-H2DCFDA    Invitrogen, Karlsruhe, Germany     C-6827 
Propidium Iodide (PI)    Sigma-Aldrich GmbH, Taufkirchen, Germany P4170 
 
Molecular biology products Company          Catalog No. 
DNA Polymerase I (Klenow)  New England Biolabs GmbH, Frankfurt, GermanyM0210S 
Phosphorylated EcoRI linker  New England Biolabs GmbH, Frankfurt, GermanyS1078S 
Pfx DNA Polymerase    Invitrogen, Karlsruhe, Germany    11708-021 
Phosphatase, alkaline   Roche Diagnostics, Mannheim, Germany  713 023 
Proteinase K     Roth Carl GmbH & Co., Karlsruhe, Germany 7528.1 
Restriction Endonucleases   New England Biolabs GmbH, Frankfurt, Germany 
MBI Fermentas GmbH, St. Leon-Rot, Germany 
RNase A      QIAGEN GmbH, Hilden, Germany   1007885 
T4 DNA Ligase     New England Biolabs GmbH, Frankfurt, GermanyM0202S 
Taq DNA Polymerase   Invitrogen, Karlsruhe, Germany    18038-026 
 
Immunologicals    Company          Catalog No. 
α-FLAG (M2) (mouse)   Sigma-Aldrich GmbH, Taufkirchen, Germany F1804 
α-mouse IgG-Cy3 conjugate (goat) Jackson Immunoresearch Europe Ltd., UK  115-165-003 
α-Mouse-HRP conjugate (goat)  Santa Cruz       SC-2031 
α-Rabbit-HRP conjugate (goat)  Santa Cruz       SC-2030 
α-Rat-HRP conjugate (goat)  Jackson Immunoresearch Europe Ltd., UK  212-165-168 
α-Tubulin (mouse)     Sigma-Aldrich GmbH, Taufkirchen, Germany T8203 
phospho-SAPK/JNK (Thr183/Tyr185) Cell signaling technology     9251S 
 
Disposables and Kits   Company          Catalog No. 
Cell strainer (40 µm Nylon)  BD Falcon (BD Biosciences)    7355837 
DC Protein Assay    Bio-Rad, Munich, Germany    500-0112 
Gel Extraction Kit    QIAGEN GmbH, Hilden, Germany   28704 
Hybond-C super membrane   GE Healthcare, Freiburg, Germany   RPN203G 
Hyperfilm      GE Healthcare, Freiburg, Germany   RPN3103K 
JETstar Plasmid purification system Genomed GmbH, Löhne, Germany   220020 
LightCycler Capillaries   Roche Diagnostics, Mannheim, Germany  11 909 339 001 
LightCycler FastStart DNA MasterPLUS 
SYBR Green I   Roche Diagnostics, Mannheim, Germany  03 515 869 001 
Millex GP Filter 0.22 µm   Millipore, Carrighwohill, Co. Cork, Ireland  SLGP033RS 
Plasmid Maxi Kit     QIAGEN GmbH, Hilden, Germany    12163 
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PCR Cloning Kit     QIAGEN GmbH, Hilden, Germany    231122 
Reverse Transcription System  Promega GmbH, Mannheim, Germany   A3500 
RNeasy Mini Kit    QIAGEN GmbH, Hilden, Germany   74104 
 
Equipments       Company 
Centrifuge 5810R      Eppendorf, Hamburg, Germany 
FACS Calibur        BD GmbH, Heidelberg, Germany 
GenAmp PCR system 2700    Applied Biosystems, Darmstadt, Germany 
Gene Pulser II System     Bio-Rad, Munich, Germany 
Gene Pulser Electroporation Cuvettes, 0.4 cm Bio-Rad, Munich, Germany 
Heraeus Biofuge centrifuge    Heraeus Holding GmbH, Hanau, Germany 
Heraeus Incubator, Modell B 5060    Heraeus Holding GmbH, Hanau, Germany 
Light-Cycler 1.5       Roche Diagnostics, Mannheim, Germany 
Microscope Axiovert 135     Carl Zeiss Jena GmbH, Göttingen, Germany 
Microscope Axiovert 200M     Carl Zeiss Jena GmbH, Göttingen, Germany 
Olympus FV1000      Olympus  
OTD Combi Ultracentrifuge    Sorvall, Langenselbold, Germany 
Photometer Bio       Eppendorf, Hamburg, Germany 
PowerPac 200 Power Supply    Bio-Rad, Munich, Germany 
Spectrophotometer      DU-64 Beckman Coulter GmbH, Krefeld, Germany 
Tecan spectrophotometer     Tecan, Austria 
UZ-PA-38,5-1 Ultracentrifuge Tubes   Kisker GbR, Steinfurt, Germany 
 
Oligonucleotides    Sequence 
 
Genotyping primers 
TR1floxf1:    5’-TCC ACC TCA CAG GAG TGA TCC C-3’ 
TR1floxr1    5’-TGC CTA AAG ATG AAC TCG CAG C-3’ 
 
Delete-PCR primers 
TR1wtforw2   5’-GGTCTGAGCTAGCGTGAAGTGTTCC-3’ 
Neopromrev1   5’-ACGTGCTACTTCCATTTGTCACGTCCTGC-3’ 
 
Cloning primers 
5’ Puro fw    5’-CCACAACCATGACCGAGTACAAGCCCACGGTG-3’ 
3’ Puro BsrG1 rev  5’-CTAGCTGTACAGCGTCAGGCACCGGGCTTGCGGGTC-3’ 
Lenti-Linker 1a   5´-GATCCTTCGAAGAATTCTCTAGAACGCGTCTCGAGACCGGTTAC-3´ 
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Lenti-Linker 1b (rev)  5´-GTAACCGGTCTCGAGACGCGTTGTATAGAATTCTTCGAAG-3´ 
Oligo-Nhe1-Txnrd1 for1 5’-ATGATGCTAGCAATGGCTCCAAAGATCCCCCTG-3’ 
Oligo-Xba1-Txnrd1 rev 5’-ACGTCTAGACAGGAAAAGGTTGAGCTCAACAG-3’ 
Oligo Txnrd1 CT for  5’-CAGGTCGAAGGAGGCTGCAGCATCGCACTG-3’ 
Oligo Txnrd1 CT rev  5’-CAGTGCGATGCTGCAGCCTCCTTCGACCTG-3’ 
Oligo Txnrd1 C59S for 5’-CTCGGAGGAACGTCCGTGAATGTGGGTTG-3’ 
Oligo Txnrd1 C59S rev 5’-CAACCCACATTCACGGACGTTCCTCCGAG-3’ 
Oligo Txnrd11 C64S for 5’- GAATGTGGGTTCCATACCTAAGAAGCTG-3’ 
Oligo Txnrd1 C64S rev 5’- CAGCTTCTTAGGTATGGAACCCACATTC-3’ 
Oligo Txnrd1 CS for  5’- CTCCAGTCTGGCTCCTGAGGTTAAGCCCCAGT-3’ 
Oligo Txnrd1 CS rev  5’- ACTGGGGCTTAACCTCAGGAGCCAGACTGGAG-3’ 
Oligo Txnrd1 UC for  5’- CTCCAGTCTGGCTGCTGCGGTTAAGCCCCAGT-3’ 
Oligo Txnrd1 UC rev  5’- ACTGGGGCTTAACCGCAGCAGCCAGACTGGAG-3’ 
Oligo Txnrd1 US for  5’- CTCCAGTCTGGCTGCTCCGGTTAAGCCCCAGT-3’ 
Oligo Txnrd1 US rev  5’- ACTGGGGCTTAACCGGAGCAGCCAGACTGGAG-3’ 
Oligo Txnrd1 UAA for  5’- TCCAGTCTGGCTGCTAAGGTTAAGC-3’ 
Oliog Txnrd1 UAA rev 5’- GCTTAACCTTAGCAGCCAGACTGGA-3’ 
 
RT-PCR primers 
18 S for    5’-GGACAGGATTGACAGATTGATAG-3’ 
18 S rev    5’-CTCGTTCGTTATCGGAATTAAC-3’ 
Aldolase A   5’-GGTCACAGCACTTCGTCGCACAG-3’ 
Aldolase B   5’-TCCTTGACAAGCGAGGCTGTTGGC-3’ 
Gclc for    5’-TGGGCAACTGCTGTCTCCAG-3’ 
Gclc rev    5’-GGCTCCAGGCCTCTCTCCTC-3’ 
Gclm for    5’-GCTTCGCCTCCGATTGAAGA-3’ 
Gclm rev    5’-TCTGGTGGCATCACACAGCA-3’ 
Gsr for    5’-ATCGCGGGCATCCTCTCTGC-3’ 
Gsr rev    5’-TCATGGTCGTGGTGGGCTTCC-3’ 
Gss for    5’-GTGCTGAAGCCCCAGAGAGA-3’ 
Gss rev    5’-CAGGCCGTAGCAAGCAATTC-3’ 
Txnrd1-E13f   5´-TTGGCCATTGGAATGGACAGTCC-3´ 
Txnrd1-E15r   5´-AGCACCTTGAATTGGCGCCTAGG-3´ 
Txnrd1-59    5´-CGAAGACACAGTGAAGCATGACTGGG-3´ 
Txnrd1-60    5´-TCCCCTCCAGGATGTCACCGATGGCG-3´ 
xCT for1    5’-GGCACCGTCATCGGATCAGGCATC-3’ 
xCT rev1    5’-CACGAGCTTGATTGCAAGTTCAGG-3’ 
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Sequencing 
T7 promoter   5’-TAATACGACTCACTATAGGG-3’ 
Sp6 promoter   5’-ATTTAGGTGACACTATAGAA-3’ 
LTR 3’-for1   5’-GCTCACAACCCCTCACTC-3’ 
IRES rev1    5’-CTTCGGCCAGTAACGTTAGG-3’ 
 
All DNA-oligonucleotides were obtained from Metabion GmbH, Martinsried, Germany. 
 
Biologicals 
Plasmids      Vector Type    Source 
pBJ3Ω c-myc      Expression    Hartmut Land 
pUC EJ6.6 Ha-rasV12     Expression    Hartmut Land 
pHC-BZ-SVpuro     Expression    In house 
pHL 2823       Expression    In house 
pHL 2823 Ds Red C1     Expression    Present work 
391 K73  pEcoEnv-IRES-puro   Expression    Tim Schröder 
392 pRSV_Rev      Expression    Tim Schröder 
393 pMDLg_pRRE     Expression    Tim Schröder 
441 pRRL.PPT.SF.IRES-golgiVENUS Expression    Tim Schröder 
442 pRRL.PPT.SF.IRES-VENUSnucmem Expression    Tim Schröder 
443 pRRL.PPT.SF.IRES-mitoVENUS  Expression    Tim Schröder 
441 PL       Intermediate    Present work 
442 PL       Intermediate    Present work 
443 PL       Intermediate    Present work 
441 L1 IRES-golgiVENUS    Expression    Present work 
442 L1 IRES-VENUSnucmem   Expression    Present work 
443 L1 IRES-mitoVENUS    Expression    Present work 
442 L1 IRES-puro     Expression    Present work 
441 L1 Ha-rasV12-IRES-golgiVENUS  Expression    Present work 
443 L1 c-myc IRES-mitoVENUS   Expression    Present work  
442 L1-SF-IRES puro    Expression    Present work 
442 L1-SF-Txnrd1 wt (2ATG) IRES puro Expression    Present work 
442 L1-SF- Txnrd1 C59S IRES puro  Expression    Present work 
442 L1-SF- Txnrd1 C64S IRES puro  Expression    Present work 
442 L1-SF- Txnrd1 C497S IRES puro  Expression    Present work 
442 L1-SF- Txnrd1 U498C IRES puro  Expression    Present work 
442 L1-SF- Txnrd1 U498S IRES puro  Expression    Present work 
442 L1-SF- Txnrd1 U498 STOP IRES puro Expression    Present work 
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pdrive       Cloning     Qiagen PCR cloning kit 
pdrive Puro      Intermediate    Present work  
pdrive Txnrd1 wt (2ATG)    Intermediate    Present work 
pcDNA3.0 SF-TAP      Expression    Johannes Gloeckner 
pcDNA3.0 SF-TAP ASA     Intermediate    Present work 
pSF- Txnrd1 wt (2ATG)    Intermediate    Present work 
pSF- Txnrd1 C59S     Intermediate    Present work 
pSF- Txnrd1 C64S     Intermediate    Present work 
pSF- Txnrd1 C497S     Intermediate    Present work 
pSF- Txnrd1 U498C     Intermediate    Present work 
pSF- Txnrd1 U498S     Intermediate    Present work 
pSF- Txnrd1 U498 Stop    Intermediate    Present work 
pRTS-1(pRTS-GL-SVH-rtTA)   Expression    In house 
pRTS-1-SF-Txnrd1 wt (2ATG)   Expression    Present work 
 
Bacterial strains 
XL-1 Blue competent cells (Stratagene USA Catalogue# 200249). 
E.coli K12 GM2163 Dam- and Dcm- competent cells (New England Biolabs GmbH, 
Frankfurt, Germany Catalogue# E4105S). 
 
Cell lines 
HEK 293-T cells were used as packaging cell line for lentivirus production. 
The cell lines used in the present study were isolated and established from mouse 
embryonic fibroblasts (MEFs) derived from conditional Txnrd1 knockout mice. The 
conditional Txnrd1 knockout mice harbor two loxP sites flanking exon 15 (fl). loxP is a 
34 base pair sequence which is recognized by Cre recombinase and depending up 
on orientation of the two loxP sites, the loxP-flanked part of a gene can either be 
deleted or inverted. E12.5 embryos, isolated from the breeding of conditional Txnrd1 
knockout mice were used to generate the following cells lines and their derivatives:  
 
Floxed (fl) Txnrd1 cell lines: Txnrd1fl/fl (Üa51 and Üa53) and Txnrd1+/fl (Üa46). 
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Txnrd1 deleted cell lines: Txnrd1-/- (51ΔD4 and 53ΔE1) and Txnrd1+/- (46ΔB5) were 
derived from the floxed cell lines (mentioned before) after Tat-Cre treatment and 
single cell cloning. 
Transformed cell lines: The above cell lines were transformed by transducing them 
with lentiviruses encoding the c-myc and Ha-rasV12 oncogenes. The following 
transformed cell lines were generated after single cell cloning: 46MRA3, 51MRB3 
and 53MRC4. As mentioned above, Txnrd1 was deleted in these cell lines by Tat-Cre 
treatment and the respective knockout cell lines were generated after single cell 
cloning. One heterozygous cell line 46MRA3Δ1C6 and two knockout cell lines 
51MRB3ΔF1 and 53MRC4ΔE3 were used in this study. 
 
Mouse strains/mouse lines 
C57BL/6 (Charles river). 
Conditional Txnrd1 knockout mice (Jakupoglu et al., 2005). 
 
Miscellaneous reagents 
The Tat-Cre fusion protein was a kind gift from Dr. Wolfgang Hammerschmidt (Gene 
Vector Group, Helmholtz Zentrum München). 
Anti-human thioredoxin reductase 1 antibody was generously provided by Dr. 
Gladyshev (Director Redox Biology Center, Department of Biochemistry, University 
of Nebraska, Lincoln, USA). 
 
3.2 Methods 
3.2.1 Cloning techniques 
Preparation of competent bacteria 
Chemically competent XL-1 E. coli bacteria were produced using the rubidium 
chloride method. A single cell colony on an agar plate was used to inoculate 3 ml of 
LB medium without antibiotic. The suspension was incubated overnight at 37°C with 
constant shaking. This starter culture was used to inoculate 250 ml of LB medium, 
containing 20 mM magnesium sulfate and kept at 37°C under constant shaking until 
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the ODλ600 reached 0.4-0.6. Subsequently, the cells were harvested at 4,500 rpm for 
5 min at 4°C. All subsequent steps were performed at 4°C with pre-chilled pipettes, 
tubes and flasks. The pellet was resuspended in 100 ml of ice-cold TFB1 and was 
incubated for 5 min on ice. Then, the cells were centrifuged again at 4,500 rpm for 5 
min at 4°C. Finally, the pellet was resuspended gently in 10 ml TFB2 and incubated 
for 30 min on ice. The chemically competent cells were snap-frozen in liquid nitrogen 
in 200 μl aliquots and stored at -80°C. The efficiency of transformation was 
determined by transforming the bacteria with serial dilutions of a plasmid. 
Buffer TFB1: 30 mM Potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl, 
15 % glycerol. pH adjusted to 5.8 with1 M acetic acid 
Buffer TFB2: 10 mM MOPS/PIPES, 75 mM CaCl2, 10 mM RbCl, 15 % glycerol. pH 
adjusted to 6.5 with 1 M KOH.  
 
Transformation of bacteria 
Transformation of bacteria was achieved by heat shock treatment. Frozen competent 
cells were thawed on ice, mixed with 10 μl of the ligation mixture or 100 ng to 1 µg of 
plasmid DNA, and the mixture incubated for 10 min on ice. Heat shock was 
performed by incubating the bacteria at 42°C for 2 min followed by 10 min incubation 
on ice. 500 μl LB medium without antibiotics was added to the cell suspension and 
the mixture was incubated for 45 min at 37°C with shaking. The transformation 
mixture was plated on an LB plate containing the appropriate antibiotic. Agar plates 
were incubated for 12-16 h at 37°C until single cell colonies became visible.  
 
Preparation of plasmid DNA 
The plasmid DNA was isolated from the bacteria using the JETstar plasmid 
purification system. For screening purposes, single cell colonies were picked from LB 
plates and grown as suspension cultures at 37°C for 6 h with shaking in 2 ml LB 
medium containing the appropriate antibiotic. The cells were harvested by 
centrifugation at 10,000 x g for 1 min and resuspended in 200 μl of buffer E1 
containing RNaseA by vortexing. 200 μl of cell lysis buffer E2 was added to the cell 
suspension and mixed gently by inverting the tube and then incubated for 5 min at 
room temperature. Next, 200 µl of the denaturation buffer E3 was added. After 
mixing gently by inverting, the mixture was centrifuged for 6 min at 10,000 x g. To 
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remove proteins and lipids, 400 μl of phenol-chloroform was added to the 
supernatant. After mixing, centrifugation was carried out at 10,000 x g for 5 min. The 
upper aqueous phase containing the plasmid DNA was collected carefully in a 
separate Eppendorf microfuge tube. 500 µl isopropanol was added to the 
supernatant. The plasmid DNA was precipitated by centrifugation for 12 min at 4°C at 
10,000 x g. The DNA pellet was washed once with 70% ethanol, air dried and 
resuspended in 50 μl 1 x TE buffer pH 8.0. Analytic restriction digestions were 
carried out with suitable restriction endonucleases to check the correctness of the 
plasmid. After screening, the correct clone was taken for higher scale preparation 
using the JETstar maxi-prep kit. The concentration of the plasmid DNA was 
determined by measuring the absorbance at 260 nm wavelength (A260) in a 
spectrophotometer. 
E1: 50 mM Tris, 10 mM EDTA, pH 8,0 
E2: 200 mM NaOH, 1% w/v SDS 
E3: 3.1 M potassium acetate, adjust to pH 5.5 with acetic acid 
1 x TE:  10 mM Tris HCl, 1 mM EDTA. pH adjusted to 8.0 
 
Restriction digestion 
Restriction digestion was performed with the corresponding endonucleases 
according to manufacturers’ instructions (New England Biolabs GmbH or MBI 
Fermentas GmbH). The DNA fragments were separated by electrophoresis in a 1% 
agarose gel at 100 V in 1 x TAE buffer. For cloning purposes, the fragments were 
separated in 0.8% low melting point (LMP) agarose (MBI Fermentas GmbH, St. 
Leon-Rot, Germany). The fragment of appropriate size was excised from the gel with 
a scalpel. 50 µl of solution A was added to the gel piece and the final volume was 
adjusted to 500 µl with H2O. The mixture was kept at 60°C for 10 min for melting. 300 
µl of phenol was added to the mixture, vortexed vigorously and centrifuged at 10,000 
x g for 7 min at room temperature. The upper phase was collected and extracted with 
butanol several times until the volume of the mix was reduced to 50 µl. Then, 150 µl 
of 100% ethanol p.a. was added to the samples and centrifuged at 10,000 x g for 10 
min at 4°C. Finally, the sample was washed with 70% ethanol and air dried. The 
pellet was suspended in 25 µl of 1 x TE.  
Solution A: 1 M NaCl, 10 mM Tris HCl, 1 mM EDTA, pH 7.5 
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TAE (50 x): 2 M Tris Acetate (2 M Tris base, 5.71% acetic acid (v/v), 50 mM 
EDTA/NaOH). pH adjusted to 8.0 
 
Phenol-chloroform extraction and ethanol precipitation of DNA 
Purification of DNA fragments after restriction digestion was done by phenol-
chloroform treatment followed by ethanol precipitation. An equal volume of phenol-
chloroform was added to the digestion reaction, briefly mixed and centrifuged for 6 
min at 10,000 x g. The upper aqueous phase was recovered and DNA was 
precipitated by adding 2.5 x volumes of ethanol and NaCl at a final concentration of 
50 mM, followed by centrifugation at 10,000 x g at 4°C. The precipitated DNA was 
washed once with 70 % ethanol, centrifuged as above and air dried. The dried DNA 
pellet was dissolved in 30 μl of 1 x TE. 
 
Klenow fragment fill-in reaction 
In order to generate blunt-end DNA fragments, single-stranded 5’ overhangs 
generated by restriction enzyme digests (sticky ends) were filled-in with DNA 
Polymerase I (Klenow fragment) according to the manufacturer’s instructions (New 
England Biolabs GmbH). The Klenow fragment has retained the 5´-3´ polymerase 
activity and the 3’-5’ exonuclease activity, but is devoid of the 5’-3’ exonuclease 
activity of DNA polymerase I. Hence, the Klenow fragment forms blunt ends by either 
filling-in 5’-overhangs or by removing 3’-overhangs. DNA fragments were purified by 
phenol-chloroform extraction as described above. 
 
Dephosphorylation of linearized plasmid DNA 
To prevent religation of the vector, vector DNA was dephosphorylated with calf 
intestine alkaline phosphatase according to manufacturer’s instructions (Roche 
Diagnostics). After dephosphorylation, DNA fragments were purified by phenol-
chloroform extraction as described above. 
 
DNA ligation 
The ligation of the insert with the plasmid back-bone was conducted by using T4 
DNA ligase according to the manufacturer’s instructions (New England Biolabs 
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GmbH). A typical ligation mixture contained 2 µl vector, 4 µl insert, 1 µl 10 x T4 ligase 
buffer and 1 µl T4 DNA ligase in a final reaction volume of 10 µl; the ligation was 
carried out at 16°C overnight. Subsequently, the ligation mixture was used for the 
transformation of competent bacteria. 
 
Annealing of synthetic oligonucleotides 
Sense and anti-sense synthetic oligonucleotides were mixed in equimolar ratios, 
heated to 95°C in a waterbath, and allowed to cool down slowly to room temperature 
by turning off the heating. The annealed DNA duplex was then ligated into suitable 
vectors.  
 
Isolation of RNA and cDNA synthesis 
Total RNA from mammalian cells was isolated using the RNeasy Mini Kit (Qiagen) 
according to manufacturer’s instructions. Approximately 1x106 cells were lysed on the 
plate by the addition of 600 μl buffer RLT, containing 10 μl β-mercaptoethanol/ml RLT 
buffer. The samples were stored at -80°C if needed. To avoid DNA contamination, 
on-column DNaseI digestion was performed. RNA was eluted from the column with 
30 μl elution buffer. The RNA concentration was determined by measuring the 
absorbance at 260 nm wavelength (A260) in a spectrophotometer. For cDNA 
synthesis, 1 μg of the isolated RNA was used. cDNA synthesis was performed by 
using the Reverse Transcription System (Promega) according to manufacturer’s 
instructions with random primers at 42°C in a reaction volume of 20 μl. The first-
strand cDNA synthesis reaction mix was finally diluted to 100 μl with nuclease-free 
water and subjected to RT-PCR. 
 
Quantitative RT-PCR 
The quantitative RT-PCR was carried out by using the LightCycler FastStart DNA 
MasterPLUS SYBR Green I Kit in combination with the LightCycler 1.5 System 
(Roche diagnostic, Mannheim, Germany). For each RT-PCR reaction, 6 μl H2O, 1 μl 
primer mix, 2 μl Master Mix and 1 μl cDNA were mixed in a pre-cooled LightCycler 
Capillary. RT-PCR primers were designed with software Primer3 (Rozen and 
Skaletsky, 2000), with a product size of 150-300 base pairs. The house-keeping 
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gene aldolase or S18 was used for normalization. The specificity of the RT-PCR 
reaction was monitored by determining the melting point, which was done by running 
a melting curve program. 
 
3.2.2 Methods of gene delivery into target cells 
Electroporation of MEFs 
Logarithmically growing mammalian cells were harvested by trypsinization and 
washed in PBS. Approximately 3x106 cells in 500 μl PBS were used per 
electroporation. The cells were mixed with 20-30 μg of plasmid DNA in 0.4 cm 
cuvettes and electroporated using the GenePulser II apparatus (Bio Rad, Munich, 
Germany) with standard settings of 240 Volt and 950 μF capacitance. The 
transfected cells were seeded on a 10 cm cell culture dish in standard DMEM 
medium with 10% FCS. The selection of transfected cells was initiated 24 h after 
electroporation with the appropriate selection marker (puromycin (up to 2 µg/ml) or 
hygromycin B (up to 300 µg/ml)), with gradually increasing doses. Stably transfected 
transgene-expressing cells lines were obtained after long term selection over suitable 
selection markers. 
 
Transduction of cells using lentiviruses 
Lentiviral-transduction is a fast and efficient method of gene delivery into cells. Due 
to the high infection rates of even non-dividing and hardly transfectable cells, the 
absence of adverse effects on target cells, and the stable transgene expression after 
provirus integration, this method was used to transduce primary MEFs. The HIV-
based 3rd generation ecotropic lentiviral vector system was used for the in vitro 
delivery of genes of interest into different mouse cell lines. In order to avoid any 
recombination events, all necessary proteins for lentivirus production including Env, 
Gag, Pol and Rev are encoded by three different plasmids. To ensure maximum bio-
safety, the natural promoter is replaced by promoters from other viruses (e.g. Rous 
sarcoma virus), the 5´and 3´-LTRs are truncated, all the accessory genes are 
removed, and the virus is pseudotyped with glycoproteins from other viruses. 
 
 
Materials and Methods 
 
42
Lentiviral vector system and their modifications 
The lentiviral vector system consists of the following components: 
Packaging vectors: 
391 K73 pEcoEnv-IRES-puro 
392 pRSV_Rev 
393 pMDLg_pRRE 
Transfer vectors:  
441 pRRL.PPT.SF.IRES-golgiVENUS 
442 pRRL.PPT.SF.IRES-VENUSnucmem 
443 pRRL.PPT.SF.IRES-mitoVENUS 
 
The aforementioned transfer vectors 441, 442, and 443 were modified by deleting the 
EcoRI and XhoI restriction sites to generate pre-linker (PL) intermediates. These 
were digested with BamHI and SnaBI. Subsequently, the lenti-linker 1 was inserted 
that contains multiple unique restriction sites to generate the 441 L1, 442 L1 and 443 
L1 transfer vectors. The puromycin acetyltransferase gene was amplified by PCR 
from pHC-BZ-SVpuro. SnaBI and BsrG1 sites were attached to the ends of the PCR 
product by the primers used for amplification. The SnaB1and BsrGI digested PCR 
fragment was cloned into the MscI- and BsrGI-digested 442 L1 nucmembVENUS 
plasmid to generate the 442 L1 IRES Puro vector (Figure 10). 
 
Cloning of the Ha-ras and c-myc oncogenes into the lentiviral vectors 
pBJ3Ω c-myc and pUC EJ6.6 Ha-rasV12 were obtained from Dr. Hartmut Land. A 1.7 
kb fragment covering the mutated (Val12) Ha-ras coding sequence was amplified by 
PCR using pUC EJ6.6 Ha-rasV12 as template. Two EcoRI sites were introduced by 
the primers used for amplification. Then, the 1.7 kb fragment was digested with 
EcoRI and cloned into the same site of 441 L1 golgiVENUS to generate 441 L1 Ha-
rasV12 golgiVENUS. The pBJ3Ω c-myc vector was digested with Ecl136II and an 
EcoRI linker (New England Biolabs GmbH, Frankfurt, Germany) was inserted. Then, 
the plasmid was digested with EcoRI and the excised 1.3 kb fragment containing the 
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443 L1 c-myc mitoVENUS. 
 
 
 
Figure 10. Schematic representation of the HIV-based lentiviral vector. The transfer vector carries 
the gene of interest and consists of the truncated genome of the virus that is needed for infection and 
integration. The transgene is expressed from the SFFV promoter. By incorporating the sequence for an 
internal ribosomal entry site (IRES), bicistronic messages are created. RSV: Rous sarcoma virus 
promoter, PPT: polypurine tract, SFFV: spleen foci forming virus, pac: puromycin acetyltransferase 
(resistance gene), PRE: Post-transcriptional regulatory element, RRE: Rev-responsive element, SIN: 
self-inactivating. Several restriction sites are incorporated into the lenti-linker 1 to facilitate the insertion 
of the gene of interest. 
 
Cloning of mouse thioredoxin reductase 1 gene into the lentiviral vector 
Mouse Txnrd1 (transcript variant 2 or 2ATG, Accession number: NM_001042513.1) 
containing the SECIS element was amplified from brain cDNA by PCR using Pfx 
DNA polymerase and the following primers: Oligo-Nhe1-Txnrd1 for1 (5’-
TGATGCTAGCAATGGCTCCAAAGATCCCCCTG-3’) and Oligo-Xba1-Txnrd1 rev 
(5’-ACGTCTAGACAGGAAAAGGTTGAGCTCAACAG-3´). This PCR product was 
cloned into the pDrive vector using the PCR cloning kit (Qiagen, Hilden, Germany) 
generating pDrive-Txnrd1 wt (2ATG). The sequencing of the amplified product 
revealed a T to C nucleotide exchange in the non-coding SECIS sequence, which 
was reverted by site-directed mutagenesis. Subsequently, the plasmid pDrive-Txnrd1 
was digested with NheI and OliI, the Txnrd1 fragment isolated and cloned into the 
pcDNA3.1 SF-TAP ASA vector, which was generated by site-directed mutagenesis 
from pcDNA3.1 SF-TAP. The pcDNA3.1 SF-TAP ASA vector was digested with XhoI, 
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treated with Klenow enzyme, and then digested with NheI. The NheI/OliI-digested 
Txnrd1 fragment was cloned into this vector to generate pSF-Txnrd1. From this 
plasmid, the Txnrd1 fragment was cloned as an EcoRI-XbaI fragment into the 442 L1 
IRES-Puro (Puro = puromycin acetyltransferase) plasmid to generate 442 L1 SF-
Txnrd1 wt (2ATG) IRES-Puro. 
 
Site-directed mutagensis of Txnrd1  
Thioredoxin reductase1 has two catalytic centers: one at the N-terminus containing 2 
cysteine residues (C59 and C64) and the second at the C-terminus formed by 
cysteine and selenocysteine (C497 and U498). All three cysteine residues and the 
Sec were individually mutated to serine and cysteine, respectively. The following 
mutants were created by site-directed mutagenesis using the respective pairs of 
oligonucleotides. The mutated bases are depicted in red. 
 
wt (N-terminal) GGA GGA ACG TGT GTG AAT GTG GGT TGC ATA 
C59S    GGA GGA ACG TCC GTG AAT GTG GGT TGC ATA 
C64S   GGA GGA ACG TGT GTG AAT GTG GGT TCC ATA 
 
wt (C-terminus) CTC CAG TCT GGC TGC TGA GGT TAA GCC CC 
C497S   CTC CAG TCT GGC TCC TGA GGT TAA GCC CC   
U498C   CTC CAG TCT GGC TGC TGC GGT TAA GCC CC 
U498S   CTC CAG TCT GGC TGC TCC GGT TAA GCC CC 
U498STOP  CTC CAG TCT GGC TGC TAA GGT TAA GCC CC 
 
All mutations were carried out with the pDrive-Txnrd1 wt (2ATG) plasmid. From these 
plasmids, the different C-terminal mutant DNA fragments were isolated with Eco47III 
and XbaI and inserted into the 442 L1 SF-Txnrd1 wt (2ATG) IRES Puro plasmid 
digested with the same enzymes. For generating the N-terminal mutants (C59S, 
C64S and SS), the BclI and Eco47III restriction enzymes were used to exchange the 
wild-type for the mutated sequences.  
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Lentiviral production and transduction of target cells 
HEK 293-T cells were used for virus production. 5x106 HEK 293-T cells were seeded 
in a 10 cm cell culture dish and incubated for 12 h prior to transfection. Cells were 
grown to 70% confluency and then used for transfection. The packaging cell line was 
transfected simultaneously with four plasmids by the calcium phosphate method.  
 
A typical transfection mix for one 10 cm plate consisted of: 
2 μg pEcoEnv-IRES-puro 
5 μg pMDLg_pRRE 
10 μg pRSV_Rev 
5 μg transfer vectors 
 
The above vectors were mixed with 50 µl of 2.5 M calcium chloride in water to a final 
volume of 500 µl. To this mixture, 500 µl of 2 x HeBS (HEPES buffered saline, pH 
7.5) was added while air was bubbled through the mixture and then kept for 20 min at 
room temperature. 10 ml of transfection medium containing 25 μM chloroquine was 
added to the cell monolayer. 1 ml of the transfection mix was added to each plate 
and the cells were incubated for 8-12 h. After incubation, the transfection medium 
was replaced with 8 ml of fresh transfection medium without chloroquine and the 
cells were incubated for further 36 h (Figure 11). The supernatant containing the 
virus particles was collected after 36 h, filtrated through a 0.22 µm sterile filter, and 
concentrated by ultracentrifugation at 8000 rpm for at least 16 h. The virus pellet was 
resuspended in 200 µl of cell culture medium and stored at -80°C until further use. 
For transduction, 1x105 MEFs were infected with 10 µl of virus suspension for 24 h. 
The transduction efficiency was analyzed by FACS 48 h thereafter by monitoring 
VENUS expression (in case of 441 L1 Ha-rasV12 IRES golgiVENUS and 443 L1 c-
myc IRES mitoVENUS). Stable cell lines were generated by transducing the cells 
with viruses carrying the puromycin resistance gene (for 442 L1 IRES-Puro) and 
subsequently selected with puromycin, starting form 0.5 µg/ml to the final 
concentration of 2 µg/ml. 
Chloroquine (1000 x): 25 mM chloroquine in PBS 
Calcium chloride: 2.5 M in water 
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HeBS (2 x): 50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 7.05 adjusted with 
NaOH 
TF medium: Standard DMEM, 20 mM HEPES 
 
 
 
Figure 11. Lentivirus production in packaging cell lines. All four plasmids were co-transfected in 
HEK 293-T cells using the calcium phosphate method. The supernatant was collected after 36 h. The 
virus particles were recovered by ultra-centrifugation and then used for the transduction of target cells. 
env: gene encoding for the viral envelope, gag: gene coding for the viral glycoprotein, rev: gene 
encoding the reverse transcriptase, goi: gene of interest. 
 
3.2.3 Immunoblotting and immunocytochemistry 
Antibody generation against mouse thioredoxin reductase 1 
A monoclonal antibody against mouse thioredoxin reductase 1 was generated by Dr. 
Elisabeth Kremmer, Helmholtz Zentrum München. Rats were immunized with a 
mouse thioredoxin reductase 1-specific peptide (N-VTKRSGGDILQSGC-) coupled to 
ovalbumin (OVA)/Keyhole limpet hemocyanin (KHL). The peptide was obtained from 
Peptide Specialty Laboratories (Heidelberg, Germany). After screening 40 hybridoma 
clones, clone 1E12 was found to be immunoreactive against mouse Txnrd1. The 
antibody-rich supernatant of hybridoma clone 1E12 was then used in the present 
study. 
 
Western blot 
Whole cell lysates were prepared by incubating cells for 15 min on ice with LCW 
Lysis Buffer, containing Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, 
Germany). Subsequently, the cell debris was removed by centrifugation for 15 min at 
4°C at 10,000 x g. The protein concentration of the supernatant was determined by 
the DC Protein Assay kit (Bio-Rad), according to manufacturer’s instructions. 30 µg 
of protein was mixed with 6 x Laemmli buffer and boiled for 3-5 min at 95°C. Proteins 
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were size-separated in a 12 % SDS-PAGE gel. Stacking was done at 80 V, while 
separation was carried out at 125 V in a Mini-PROTEAN 3 Electrophoresis Cell. 
Proteins were transferred from the gel onto a Hybond-C super nitrocellulose 
membrane in Blotting Buffer by submerge blotting at 130 V, 400 mA for 75-90 min. 
Membranes were blocked with 5% skim milk powder in TBS-T for 60 min and 
hybridized with a primary antibody at 4°C overnight. Membranes were washed three 
times in TBS-T for 5 min each. Then, the membrane was incubated with the HRP-
conjugated secondary antibody for 90 min. After that, the membranes were washed 
repeatedly in TBS-T (3 x 5 min) and proteins were visualized by the ECL detection 
system (GE Healthcare, Freiburg, Germany). For re-blotting, the membranes were 
stripped in 0.4 M NaOH for 10 min. prior to the incubation with the second antibody; 
the membranes were blocked with 5% skim milk powder in TBS-T for 60 min as 
described above.  
 
LCW Lysis Buffer: 0.5% TritonX-100, 0.5% Sodium deoxocholate salt, 150 mM 
NaCl, 20 mM TRIS, 10 mM EDTA, 30 mM Na-pyrophosphate, pH 7.5 
12% Separating gel: 3.3 ml water, 4 ml Acrylamide bis-acrylamide (29:1), 2.5 ml 1.5 
M Tris HCl pH 8.8, 100 µl 10% SDS, 100 µl 10% Ammonium persulfate (APS) and 4 
µl TEMED 
5% Stacking gel: 4.1 ml water, 1ml Acrylamide bis-acrylamide (29:1), 750 µl 1 M Tris 
HCl pH 6.8, 60 µl 10% SDS, 60 µl APS, 8 µl TEMED 
Sample Loading Buffer (6 x): 375 mM TrisHCl pH 6.8, 9% SDS, 50% Glycerol, 
0.3% Bromophenol Blue, 9% 2-ME 
Running Buffer (10 x): 250 mM TRIS-Base, 1% SDS, 2.5 M Glycine 
Blotting Buffer: 4.5 g Tris base, 21 g Glycine, 300 ml Methanol, 1.2 l water  
TBS-T: 25 mM TRIS, 125 mM NaCl, 0.1% Tween-20, pH 8.0 
Blocking buffer: 5% BSA or skimmed milk in TBS-T 
Stripping solution: 0.4 M NaOH in water 
 
Immunocytochemistry and confocal microscopy 
For immunocytochemistry, cells were plated onto UV-sterilized cover slips in 6-well 
cell culture dishes. The cells were fixed for 5 min in a 2% para-formaldehyde (PFA) 
solution after aspirating the medium. The cover slips were washed 3 x with PBS and 
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permeabilized for 15 min with 0.1% Triton X-100 in PBS. Subsequently, the cells 
were blocked for 2 h with 10% normal goat serum in PBS. For detection of SF-
Txnrd1, the cover slips were incubated overnight with the α-FLAG antibody (clone 
M2 mouse monoclonal, Sigma-Aldrich GmbH, Taufkirchen, Germany) at 4°C in a 
humidified chamber. The cover slips were washed 3 x with PBS/Tween and 
subsequently incubated with the α-mouse-Cy3-conjugated secondary antibody for 45 
min in the dark. The cover slips were washed 3 x with PBS/Tween and then 
incubated for 2 min in DAPI solution. The cover slips were briefly rinsed in PBS and 
then mounted onto microscope slides, using mounting medium (Dako Cytomation, 
Hamburg, Germany). The slides were dried overnight at 4°C, protected from light and 
eventually sealed with nail polish. Pictures were taken by confocal microscopy with 
the Olympus FV1000 microscope and image was analyzed by FV10-ASW 1.6 viewer 
software. 
 
PFA solution: 4% (w/v) PFA in PBS, pH 7.4 adjusted with HCl 
α-FLAG antibody: 1:200 in PBS/10% normal goat serum 
α-mouse IgG-Cy3: 1:500 in PBS/10% normal goat serum  
DAPI-solution: 1 μg/ml DAPI diluted in PBS (5 mg/ml stock solution in H2O) 
PBS/Tween: 0.1% (v/v) Tween 20 in PBS 
Triton X-100 solution: 0.1% (v/v) Triton X-100 in PBS 
 
3.2.4 Cell culture related techniques 
Isolation of MEFs and establishment of cell lines 
MEFs were isolated from the conditional knockout mice at E12.5 embryos. Embryos 
were dissected from the uterus. After removing the appendages and visceral organs, 
the remaining parts were minced with forceps and incubated with trypsin/EDTA for 10 
min. Finally, the cell suspension was incubated with cell culture medium and allowed 
to grow in culture for 2 days. Then, they were splitted every 3rd day. All the cell lines 
were genotyped for Txnrd1 and were cryo-preserved for future use in liquid nitrogen. 
Immortalized cell lines were established after passaging the primary cell lines for at 
least 20 passages at 5 % oxygen, because cultivation of MEFs at normal 
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atmospheric oxygen concentration severely limits the replicative potential of the cells 
(Parrinello et al., 2003). 
 PBS (without Ca2+, Mg2+):   80.0 g NaCl, 2.0 g KCl, 14.4 g Na2HPO4,  2.4 g KH2PO4 in 
1 l H2O, pH 7.4 
Standard DMEM:  DMEM 1 x, 10% FCS, 1% glutamine, 50 U/ml penicillin G, 50 μg/ml        
streptomycin 
 
Measurement of cell proliferation/viability 
Trypan Blue dye exclusion method 
Trypan blue dye exclusion method was used for measuring the viability of 
MEFs. Trypan blue is excluded from viable cells due to intact plasma 
membrane while dead cells stain blue. The cells were trypsinized and an 
equal volume of medium was added to the cell suspension to neutralize 
trypsin. 10 µl of cell suspension was mixed with 40 µl of 0.4% trypan blue, and 
cells were counted using a Neubauer haemocytometer. Viable cells were 
counted in 4 WBC-counting chambers.  
Trypan blue: 0.4% solution (Sigma-AldrichGmbH, Taufkirchen, Germany) 
 
MTT assay 
MTT assay was performed to measure the proliferation of the transformed cells and 
their response to different cytotoxic agents in 96-well plates as described by 
Mosmann, T. (Mosmann, 1983) with some modifications. 10,000 cells/well were 
plated in quadruplicate in 100 µl of cell culture medium. The cells were incubated 
with 50 µg of MTT for 4 hours at 37°C to measure the proliferation. For cytotoxic 
assay, 10,000 cells/well were plated in quadruplicate in 50 µl of cell culture medium 
and allowed to settle for 4-6 hrs after plating. Then 50 µl of cell culture medium 
containing the required concentration of different drugs was added to the cells. The 
cells were treated with drugs for 72 h. Subsequently, cells were incubated with 50 µg 
of MTT for 4 hrs at 37°C. Finally, 200 µl of acidified isopopanol was added to each 
well to dissolve the formazan crystals. Absorbance was measured at 570 nm (670 
nm as reference wavelength) in a Tecan spectrophotometer and data was acquired 
by Magelan software version 4. To evaluate the cytotoxic effect, the OD value of 
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untreated cells was taken as 100% viable and data was normalized against this value 
and expressed as percentage viability. 
MTT (Thiazolyl blue) reagent: 
Stock solution (5mg Thiazolyl blue) in PBS, filter sterilized and stored in dark at 4°C. 
Working solution: 1:1000 dilution in cell culture medium. 
0.04 M HCl in isopropanol: 1.57 ml 32% HCl, 398.43 ml isopropanol.  
 
Flow cytometry (FACS analysis) 
Cell cycle analysis 
The cells cycle analysis of transformed Txnrd1 knockout cells was done by the PI 
method which measures the DNA content of the cells. PI intercalates into DNA. Since 
the DNA content of cells in G2/M phase is twice as that of G0/G1 phase, they can be 
distinguished from each other in FACS due to difference in amount of PI intercalated 
into DNA. 1x106 cells from asynchronously proliferating cell cultures were harvested 
by trypsinization, washed twice with ice-cold PBS, and fixed in ice-cold 70% ethanol 
overnight. Then, the cells were washed again twice in ice-cold PBS and treated with 
DNase free RNase A (50-100 µg) for 30 min at room temperature. Subsequently, 10-
20 µg of PI was added to each sample, and the cell suspensions were incubated for 
additional 15 min at room temperature in the dark. Then the samples were analyzed 
by FACS (BD FACS Calibur) in FL3 channel and data was analyzed by ModFitLT 
V3.0 software. 
PI: 1 mg/ml in water 
DNase free RNase A: 100 mg/ml 
Ethanol p.a: 70% 
 
Intracellular peroxide detection 
Intracellular peroxide levels were detected by DCF staining. The acetylated forms of 
DCF, such as CM-H2DCFDA, are non-fluorescent until the acetyl groups are 
removed by intracellular esterases and oxidation occurs inside the cell. 1x105 cells 
were loaded with 1 μM CM-H2DCFDA for 60 min at 37°C in DMEM without FCS. 
After staining, cells were harvested by trypsinization, followed by centrifugation (1200 
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rpm, 5 min) and 3 x washing with PBS. Finally, the cells were resuspended in 200 μl 
PBS. Samples were analyzed in a flow cytometer (BD FACS Calibur) in which cells 
were excited with 488 nm UV line argon ion laser and emission was recorded on 
channel FL1 at 530 nm. Data was analyzed by BD CellQuestTM Pro software (BD 
Biosciences). 
DCF solution: 1 μM CM-H2DCFDA in ethanol 
 
Annexin V-PI staining for the detection of cell death 
Annexin V-PI staining is a classical method to discriminate between apoptotic and 
necrotic cell death. In apoptotic cells, the membrane phospholipid phosphatidylserine 
(PS) is translocated from the inner to the outer leaflet of the plasma membrane. 
Annexin V binds PS with high affinity in a Ca2+-dependent fashion. PI is excluded by 
cells with intact membranes. So the combination of annexin V-PI allows 
distinguishing apoptosis from necrosis. While Annexin-V positive and PI-negative 
cells are defined as apoptotic cells, double-positive cells are either late apoptotic or 
necrotic. For Annexin V-PI analysis, the cells were washed twice with cold PBS and 
resuspended in 100 µl annexin-binding buffer. Then the cells were incubated with 5 
μl of Annexin V-FITC (BD PharMingen, Heidelberg, Germany) and 5 μl of PI (20 
mg/ml stock solution, Sigma-Aldrich GmbH Taufkirchen, Germany) for 15 min in the 
dark at room temperature. The cells were then analyzed by FACS (BD FACS 
Calibur) and data was analyzed by the BD CellQuestTM Pro software (BD 
Biosciences) 
Annexin V-binding buffer: 10 mM N-(2- hydroxyethyl)piperazin-N’-
(propansulfonicacid)/ NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2  
PI solution: 1 mg propidium iodide in PBS 
 
Soft-agarose assay 
To assess the effect of Txnrd1 knockout on the colonigenic potential of myc-ras-
transformed cells, soft-agarose assays were performed. Approximately 500 cells/well 
were plated in 0.3% soft agarose prepared in cell culture medium in a 6-well cell 
culture plate. The agarose was allowed to cool by keeping it at 4°C for 15 min and 
then the plate was returned to the incubator. The cell culture medium was replaced at 
a 3 days interval. The single cell colonies appeared after 10 days. The colonies were 
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fixed in methanol and stained with crystal violet. They were allowed to dry and then 
counted visually.  
Crystal violet: 0.5% in PBS 
 
3.2.5 Biochemical techniques 
Measurement of L-cystine uptake activity 
Cystine uptake activity in xCT over-expressing Txnrd1 knockout cells was measured 
by uptake of radio-labelled cystine in collaboration with Dr. Hideyo Sato (Yamagata 
University, Japan). Uptake of cystine was measured by techniques essentially as 
described by Sagara et al. and Novogrodsky et al. (Novogrodsky et al., 1979; Sagara 
et al., 1993). About 2 x 106 cells were washed in PBS and resuspended in 0.125 ml 
of pre-warmed PBS containing 0.1% glucose and 0.01% Ca2+and Mg2+. 125 μl of 
isotope labeled cystine (0.1 μCi/sample) (L- [14C (U)] Cystine (250 mCi/ mmol/ 0.02 
mCi/ ml) (Perkin Elmer Life Sciences, Inc., Boston, USA) in uptake solution was 
added to the cell suspension and the suspension was incubated at 37°C. 100 μl 
aliquots were taken after the given time intervals and layered on a mixture of mineral 
oil and di-n-butyl phthalate 15:85 (vol/vol; total 200 μl) previously put in a small 
plastic tube. After centrifugation at 13,000 rpm for 10 sec in a microfuge, the tip of 
the tube containing the cell pellet was cut off, and the cells were solubilized in 200 μl 
of 0.5 M NaOH in a scintillation vial overnight at 37°C. Afterwards 3 ml of scintillation 
liquid and 100 μl of Tris-HCl were added to the vials and the radioactivity was 
determined using a scintillation counter (Beckman Instruments, LIQUID 
SCINTILATION SYSTEM, LS 5000 TA, Fullerton, CA). To compare basic activity of 
uptake solution with uptake activity of the cells, 5 μl of isotope labeled uptake 
solution was taken and mixed with 200 μl of 0.5 M NaOH for the determination of 
specific activity. 
Uptake solution (for 10 samples):  1% (w/v) Ca2+, Mg2+ 
50 μl [14C] (Cys)2 (0.1 μCi/sample) MgCl2 x 6 H2O 1 g 
5 mM (Cys)2 15 μl * CaCl2 x 2 H2O 1.324 g 
5 x PBS 50 μl dissolved in 100 ml of H2O 
10% (w/v) glucose 2.5 μl 
1% (w/v) Ca2+, Mg2+ 2.5 μl 
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H2O 130 μl 
*5 mM (Cys)2 dissolved in 0.05 M HCl under stirring for a few hours at room 
temperature 
 
Measurement of GSH concentration by HPLC 
The total GSH (GSH+GSSG), reduced GSH and oxidized GSH (GSSG) 
concentration in transformed Txnrd1 knockout cells were measured by the isocratic 
high-performance liquid chromatography (HPLC) method described for the estimation 
of total homocysteine (Feussner et al., 1997) with slight modification. This method is 
based on the derivatization of thiol group with a thiol-specific fluorogenic marker, 7-
fluoro-benzo-2-oxa-1,3-diazole-4-sulphonate (SBD-F), which can be separated 
isocratically by reversed-phase HPLC using a Superspher 100 RP-18 column as 
stationary phase.  
 
In brief, about 1x106 cells were plated on a 10 cm dish 36 h before determination. 
Cells growing in log phase of growth were washed twice with PBS, then harvested 
by cell scrapers and collected in 6 ml of PBS. Cells were pelleted by centrifugation 
for 10 min at 2000 rpm at 4°C. Cells were resuspended in 300-500 μl of 2 M borate 
buffer (containing 5 mM Na2EDTA, pH 9.5). Then the suspension was sonicated to 
lyse the cells. For reduction of disulfide bonds (in order to measure oxidized GSH), 
200 µl of sample was mixed with 20 µl of tri-n-butylphosphine and incubated for 30 
min at 4°C. To measure the reduced GSH 200 µl of samples were treated with 20 µl 
of Borate buffer. The reaction was stopped by adding 200 µl of 4 M percholric acid. 
Then the samples were centrifuged at 10,000 rpm for 10 min at 4°C.  Finally, 100 µl 
samples or standard solution was mixed with 250 µl of Borate buffer (pH 10.5) and 
100 µl of SBD-F and incubated for 1 h at 60°C in a water bath. After derivatization 
with SBD-F, samples were cooled to 4°C.  50 μl of the samples were applied on a 
HPLC column (Separation column - LiChroCART 250-4 and precolumn -LiChrospher 
60 RP-select B (5 μM), MERCK KGgA (Darmstadt, Germany); Beckman detector 
System Gold, Pump Model 126 and Beckman counter Autosampler System Gold 
508). The mobile phase consisted of a 30 mmol/l ammonium-formiate – 40 mmol/l 
ammonium-nitrate buffer (pH 3.65 adjuste with formic acid) and acetonitrile (95 + 5, 
by vol) at a flow rate of 1 ml/min. The column effluent was monitored by fluorescence 
detection (Fluorescence Detector RF 10Axl (Shimadzu, Japan)) with an excitation 
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were prepared by 2-fold serial dilution of 250 µmol/l of GSH in 0.1 mol/l Borate 
buffer, containing 2 mmol/l Na2EDTA, for the calibration. The concentration of GSH 
was determined for the peak area in the chromatogram. 
Borate buffer: 2 M Borate buffer containing 5 mM Na2EDTA, pH 10.05 
SDB-F: 1 mg/ml in borate buffer 
 
Estimation of glutathione reductase activity 
Glutathione reductase (GR) together with its co-factor, NADPH/H+, catalyzes the 
reduction of oxidized glutathione (GSSG) to reduced glutathione (GSH). In this assay 
the oxidation of NADPH to NADP+ is monitored by the decrease in absorbance at 
340 nm (Equation (I)).  
 
  (I) 
 
This rate of decrease in absorbance at 340 nm is directly proportional to the 
glutathione reductase activity in the sample, because the enzyme is present at rate-
limiting concentrations. The unit definition for glutathione reductase activity may be 
expressed in terms of the oxidation of NADPH/H+ or the reduction of GSSG since 
their molar ratio is 1:1. One unit of glutathione reductase oxidizes 1 μmol of 
NADPH/H+ per minute at 25°C, pH 7.5. 
 
The GR activity in transformed Txnrd1 knockout cells was measured by the assay 
mentioned above. Briefly, 1x106 exponentially growing cells were trypsinized, 
washed twice with ice-cold PBS, and then lysed in 200-300 µl of lysis buffer and 
further incubated for 30 min on ice. The lysate was kept for 30 min on ice and then 
centrifuged at 10,000 x g for 15 min at 4°C. The protein concentration was measured 
by the BCA method, adjusted to 2.5 mg protein/ml, and 25 µg of protein was used for 
measuring GR activity at 340 nm wavelength in a Tecan spectrophotometer with UV 
filter. Reading was taken every 2 min and the decrease in absorbance was monitored 
for 10 min. Yeast GR was used to prepare a standard curve which allowed 
 
54
Materials and Methods 
 
55
determining GR activity in the samples. The change in absorbance/min was used to 
calculate the GR activity in the sample from the standard curve of Yeast GR. 
        Lysis buffer: 0.2 M potassium phosphate buffer, 100 µM PMSF, 20% Triton X-100 
       Solution A: 0.2 M potassium phosphate buffer, 10 mM EDTA, pH 7.2 
        Solution B: 30 mM oxidized glutathione in water 
        Solution C: 0.8 mM NADPH in solution A 
        Solution D: 1% BSA in solution A 
 
3.2.6 Tumor transplantation protocol 
Implantation of transformed cells in mice 
To investiagte the effects of Txnrd1-deficiency on the tumorigenic potential of myc-
ras transformed cells; cells were transplanted in C57BL/6 mice. 1x106 transformed 
cells in a final volume of 100 µl were injected subcutaneously into C57BL/6 mice, and 
tumors were allowed to develop. After 10 days the mice were sacrificed and the 
tumor volume and tumor mass were determined.  
 
Treatment of Txnrd1-deficient tumor-bearing mice with BSO 
To analyze the effectiveness of BSO treatment on Txnrd1-deficient tumor, 1x105 
transformed Txnrd1 knockout cells were implanted subcutaneously into both flanks of 
C57BL/6 mice. Tumors were allowed to grow for 3 days. After 3 days BSO (20 mM) 
was provided in drinking water for 10 days. Untreated group was provided with 
drinking water without BSO. Parental cell line was injected and treated similarly. At 
the end of the experiments mice were sacrificed and tumor mass and tumor volume 
was determined. 
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4. RESULTS  
4.1 Analysis of thioredoxin reductase 1 function ex vivo 
4.1.1 Establishment of mouse embryonic fibroblast cell lines from 
conditional Txnrd1 knockout mice  
Thioredoxin reductase 1 (Txnrd1) has been implicated in cell proliferation and 
growth, and is indispensable for embryonic development (Bondareva et al., 2007; 
Jakupoglu et al., 2005). Using an siRNA knock-down approach in established cell 
lines, Yoo et al. reported that Txnrd1 is not essential for the survival of the cells in 
vitro (Yoo et al., 2006). As all attempts of establishing MEFs directly from knockout 
embryos invariably failed (Jakupoglu et al., 2005), the conditional Txnrd1 knockout 
mouse generated by Jakupoglu et al., and cell lines derived there from, were used in 
the present study. 
 
MEFs cell lines were established from conditional Txnrd1 knockout mice, in which the 
knockout of Txnrd1 can be achieved by expressing Cre recombinase. The strategy 
used for conditional disruption of Txnrd1 is depicted in figure 12A. The procedure for 
the in vitro induction of the Txnrd1 knockout is illustrated in figure 12B. MEFs were 
isolated from E12.5 embryos, obtained from the breeding of Txnrd1fl/fl mice with 
Txnrd1+/fl mice. Txnrd1fl/fl and Txnrd1+/fl MEFs cell lines were established and their 
genotype was confirmed by PCR (Figure 12C). Two Txnrd1fl/fl (Üa51 and Üa53) and 
one Txnrd1+/fl (Üa46) cell line were immortalized by cultivating them for at least 20 
passages at 5% oxygen (Parrinello et al., 2003). In vitro deletion of Txnrd1 was 
achieved by treating the cells with a Tat-Cre fusion protein (kindly provided by Dr. W. 
Hammerschmidt). Briefly, 5x104 cells were incubated with 1 µg Tat-Cre protein for 16 
h in CHO medium, and then the medium was exchanged for normal cell culture 
medium. After 24 hours the cells were washed, trypsinized, and single cell-cloned in 
96-well plates by limiting dilution. Single cell clones were individually expanded and 
screened for deletion of Txnrd1 by PCR (Figure 12C). The two knockout clones 
51ΔD4 and 53ΔE1 and the heterozygous clone 46ΔB5 were expanded to establish 
cell lines. These three cell lines together with the respective parental cell lines Üa51, 
Üa53 and Üa46 were used throughout the present study. The presence/absence of 
Txnrd1 in these cell lines was verified by Western blotting (Figure 12D) using an 
antibody against human TrxR1. 
Results 
 
 
 
Figure 12. Disruption of thioredoxin reductase 1 in MEFs by Cre recombinase ex vivo. A) 
Schematic representation of the generation of Txnrd1 conditional knockout mice (Jakupoglu et al.; 
2005). Exon 15 of the Txnrd1 gene, harboring the C-terminal catalytic center, was flanked by two loxP 
sites (shown as white triangles), which can be targeted by Cre recombinase. Primer pairs used for 
genotyping of mice and cells are depicted as black and gray arrows. B) Outline of procedure to establish 
the Txnrd1 knockout cell lines. C) Genotype of different MEFs cell lines. Successful deletion of the gene 
was verified by PCR using the deletion-specific primer pairs (depicted in blue and cyan arrows in A). 
The 66 bp band corresponds to the wild-type allele, the 130 bp band corresponds to the floxed allele, 
and the 320 bp band is obtained after successful deletion of the loxP-flanked allele. D) Deletion in these 
cell lines was confirmed by immunoblotting using an antibody raised against human TrxR1 in rabbit. The 
SF-Txnrd1 expressing cell line was used as positive control. Anti-human TrxR1 antibody was a kind gift 
form Dr. Gladyshev (University of Nebraska, Lincoln, USA). 
 
4.1.2 Txnrd1 knockout cells are highly susceptible to GSH depletion 
Mitochondrial thioredoxin reductase (Txnrd2) knockout cells were previously shown 
to be highly susceptible to GSH depletion induced by BSO (Conrad et al., 2004). To 
test whether Txnrd1 knockout cells are equally susceptible to BSO, Txnrd1 knockout 
cells were treated with increasing concentrations of BSO; the viability of cells was 
assessed 72 h later by the trypan blue dye exclusion method. As shown in figure 13, 
Txnrd1 knockout cells (53ΔE1) were highly sensitive to BSO treatment. While the 
heterozygous control cell line died in a similar manner with increasing BSO 
concentrations as the parental cell lines (46ΔB5 v/s Üa46), the knockout cell line 
(53ΔE1) died already at lower BSO concentrations than the respective parental cell 
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line (Üa53). Thus, like Txnrd2 knockout cells, viability of Txnrd1 knockout cells was 
severely compromised after BSO-mediated GSH depletion. The same results were 
obtained with a second pair of cell lines (Üa51 and 51ΔD4) (data not shown). 
 
 
 
Figure 13. Txnrd1 knockout cells were susceptible to experimental GSH depletion. Txnrd1 
knockout cells 53ΔE1 and heterozygous control cells 46ΔB5 were treated with the indicated 
concentrations of BSO for 72 h, and the viability was determined by the trypan blue exclusion method. 
Txnrd1 knockout cells (53ΔE1) were highly susceptible to BSO as compared to the parental cell line 
Üa53 (4.14±0.46 % v/s 113.56±12.41 % at 5 µM BSO). The heterozygous control cell line 46ΔB5 
behaved similar to the parental cell line Üa46 (30.22±7.65 % v/s 28.7±4.7 % at 10 µM BSO) (mean ± 
SD). Data shown here is representative of two independent sets of experiments. This was confirmed 
with another knockout cell line, yielding the same results (data not shown). 
 
4.1.3 Reconstitution of Txnrd1 expression restored resistance against 
BSO 
To prove that the above finding was due to the loss of function of Txnrd1, the Strep-
FLAG-tagged mouse Txnrd1 cDNA, including the SECIS element (SF-Txnrd1 wt 
(2ATG)), was stably expressed in Txnrd1 knockout cells by lentiviral transduction 
(Figure 14A). In parallel, various mutant forms of Txnrd1, in which the Sec (U498) 
and the three cysteines (C59, C64 and C497) involved in Txnrd1 catalysis, were 
mutated individually to cysteine and serine (for U498) and serine (for C59, C64 and 
C497), respectively, by site-directed mutagenesis. Those were then stably expressed 
in the Txnrd1 knockout cells to elucidate their catalytic significance in vivo. Different 
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cell lines expressing either wild-type or mutated Txnrd1 genes were established by 
puromycin selection. Expression of the tagged Txnrd1 (SF-Txnrd1) was confirmed by 
Western blotting using an antibody against FLAG (Figure 14B).  
  
The different cell lines were treated with 15 µM of BSO, and cell viability was 
determined 72 h later. As shown in figure 14C, the expression of SF-Txnrd1 wt 
(2ATG) provided rescue against BSO-mediated toxicity (38.79±7.35%) as compared 
to the mock control (0.36±0.56%). The functionality of different Txnrd1 mutant forms 
was compared with wild-type Txnrd1. As shown in figure 14C, the N-terminal Cys 
mutants (C59S, C64S) provided rescue in comparable fashion to the wild-type 
protein (38.75±22.75% and 34.04±7.96%), while the C-terminal mutants were less 
efficient in compensating the loss of Txnrd1 function. The C497S mutant was 
functionally almost inactive and did not rescue knockout cells from cell death induced 
by GSH depletion (3.6±5.09%). With about 25% remaining viability (24.23±11.23%), 
the U498C mutant was able to partially rescue the phenotype, whereas the U498S 
and U498STOP mutants were less active and only a small proportion survived BSO 
treatment (8.6±8.9% and 12.79±3.09%, respectively). These results suggested that 
mutation of one of the N-terminal Cys residues has little impact on enzyme function. 
The C-terminal cysteine residue C497 is the most critical cysteine residue involved in 
catalysis as it is the releasing cysteine.  
 
The subcellular localization of SF-Txnrd1 wt (2ATG) and the various mutants was 
determined by confocal microscopy using an anti-FLAG antibody (Figure 14D). 
Although Txnrd1 has been reported to be located in the cytosol, the wt (2ATG) 
protein was also detected in the nucleus. Also the U498STOP mutant and to a lesser 
extent the C497S mutant displayed nuclear localization. By contrast, all other 
mutants were predominant cytosolic in distribution. The staining pattern for C64S and 
C497S exhibited granularity, so localization to other sub-cellular compartments can 
not be ruled out at the moment and further studies are needed to firmly establish the 
intracellular localization of these mutants. 
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Figure 14. Reconstitution of Txnrd1 function provided rescue against BSO-mediated GSH 
depletion. A) Schematic representation of various strep-FLAG-tagged mouse Txnrd1 (SF-Txnrd1) 
constructs which were stably expressed in knockout cells by lentiviral transduction. B) Expression of the 
different forms was analyzed by Western blotting using a FLAG-specific antibody. Immunoblotting 
revealed differential expression in the cells although they were expressed from the same promoter. C) 
The viability was determined for each form after 72 h of BSO treatment. The % viability was calculated 
by setting the cell number in the untreated controls as 100%. The reconstitution of Txnrd1 provided 
substantial rescue against BSO-mediated cell death (38.79±7.35% as compared to the mock control 
0.36±0.56%). Data is pooled from two sets of experiments (mean±SD). Out of all the mutants tested, the 
C497S mutant was functionally inactive, while the C-terminal mutants were less efficient in 
complementing the loss of endogenous Txnrd1. D) Sub-cellular localization of the different constructs 
was confirmed by immunocytochemistry and confocal microscopy. Although Txnrd1 has been reported 
to be a cytosolic enzyme, the wild-type protein was localized in the nucleus as well (600 x 
magnification). 
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4.1.4 Txnrd1 knockout cells were not rescued by antioxidants 
It has been shown that mitochondrial thioredoxin reductase (Txnrd2) knockout cells 
can be rescued from BSO-mediated GSH depletion by antioxidant supplementation 
like NAC (Conrad et al., 2004)(Tamara Perisic, unpublished observation). Moreover, 
γ-GCS knockout cells, which are devoid of endogenous GSH synthesis, can be 
grown in culture in the presence of thiol-containing compounds (Shi et al., 2000). 
These reports suggested that the requirement of GSH for cell survival and 
proliferation can be bypassed by antioxidant supplementation. To test whether the 
decrease in cell viability following BSO-mediated GSH depletion in Txnrd1 knockout 
cells can be antagonized by antioxidants, the Txnrd1 knockout cell line 53ΔE1 and 
the heterozygous control cell line 46ΔB5 were treated with 10 µM BSO in the 
presence or absence of the antioxidants NAC, Trolox® and 2-mercaptoethanol (2-
ME) for 72 h. Subsequently, cell numbers were determined using trypan blue. As 
shown in figure 15, all antioxidants tested antagonized the BSO-induced decline in 
cell viability in wild-type (Üa53 and Üa46) and heterozygous control (46ΔB5) cell 
lines, but they invariably failed to rescue the Txnrd1 knockout cells (right panel Figure 
15). These experiments were repeated in another knockout cell line yielding similar 
results (data not shown). These findings indicated that the GSH requirement can not 
be bypassed by antioxidants in the absence of Txnrd1. Thus, either Txnrd1 is 
required for the utilization of the antioxidants, or in the absence of GSH, viability of 
Txnrd1 deficient cells cannot be sustained by antioxidant supplementation. 
 
4.1.5 Txnrd1 knockout cells underwent necrosis or oxidative stress-
induced cell death upon BSO treatment  
To study the mode of cell death following BSO-mediated GSH depletion, the 
knockout cell lines 53ΔE1 and 51ΔD4 were treated with 10 µM BSO. Since the 
heterozygous cell line 46ΔB5 was more resistant towards BSO as compared to the 
knockout cell lines (Figure 13), these cells were treated with 20 µM BSO to study the 
cytotoxic effect within the same time period. The cells were treated with BSO in the 
presence or absence of antioxidants for 24 hours and then stained with annexin V 
and PI. The samples were analyzed by FACS and the data was quantified by Cell 
QuestTM Pro software (BD Bioscience). 
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Figure 15. Antioxidant supplementation was unable to rescue the Txnrd1 knockout cells against 
BSO-mediated GSH depletion. Three antioxidants NAC, Trolox® and 2-ME were tested at the given 
concentrations for rescuing cells from cell death induced by treatment with 10 µM BSO. While they 
provided resistance against BSO in wild-type (Üa53 and Üa46) and heterozygous (46ΔB5) cell lines, 
they failed to rescue the knockout (53ΔE1) cells from cell death induced by BSO-mediated GSH 
depletion. While the viability of BSO-treated Üa53 wild-type cells was 79% compared to untreated cells,  
Üa53 cells were efficiently rescued from BSO-induced cell death with 2.5mM NAC (109.97% viability), 
5mM NAC (144.5%),  250 µM Trolox® (92%), 500 µM Trolox® (78%), 25 µM 2-ME (85%), and with 50 
µM 2-ME (96% viability). Knockout cells could not be rescued from BSO-induced cell death by any of 
these antioxidants. The data is representative of two sets of experiments, which was further confirmed in 
another knockout cell line with similar findings (mean±SD). 
 
BSO-treated knockout cells exhibited very late apoptotic or necrotic characteristics 
(Annexin V-positive and PI-positive) and underwent rapid cell death presumably due 
to massive oxidative stress. As shown in figure 16, BSO treatment of the control cell 
line (46ΔB5) resulted in 18.7% Annexin V- and PI double-positive cells which was 
reduced to 1.8%, 4.3% and 4% when the cells were simultaneously treated BSO plus 
either 5 mM NAC, 250 µM Trolox® or 50 µM 2-ME, respectively.  
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Figure 16. Antioxidant supplementation failed to rescue the Txnrd1 knockout cells from BSO-
induced cell death. Cells were treated with BSO with or without antioxidant supplements for 24 h and 
then stained with Annexin V and PI and analyzed by FACS. The tested antioxidants were able to rescue 
the heterozygous control cell line 46ΔB5 (18.7% Annexin V-PI positive cells in case of BSO alone v/s 
1.8% with NAC, 4.3% with Trolox® and 4.0% with 2-ME), but were ineffective in preventing BSO-induced 
cell death in the knockout cell lines 53ΔE1 (61.8% BSO alone, 72.6% with BSO plus NAC, 55.2% with 
BSO plus Trolox® and 64% with BSO plus 2-ME) and 51ΔD4 (67% with BSO alone, 58% with BSO plus 
NAC, 61% with BSO plus Trolox® and 68.4% with BSO plus 2-ME).  
 
But in the case of both knockout cells lines (53ΔE1 and 51ΔD4), none of the 
antioxidants was able to prevent BSO-induced cell death (72.6% with NAC, 55.2% 
with Trolox® and 64.1% with 2-ME as compared to 61.8% Annexin V and PI double-
positive cells with 10 µM BSO alone). Thus, these antioxidants were ineffective in 
rescuing Txnrd1 knockout cells from BSO-induced cell death.  
 
4.1.6 xCT over-expression failed to rescue Txnrd1 knockout cells from 
GSH depletion 
Previous work in the lab had shown that over-expression of xCT, the substrate-
specific subunit of the cystine/glutamate antiporter system Xc-, confers high 
resistance to oxidative stress in Burkitt’s lymphoma cells (Banjac et al., 2008), and 
effectively bypasses GSH-deficiency in γ-GCS knockout cells (Seiler, 2008). System 
Xc- facilitates the uptake of cystine, (Cys)2, from the extracellular space, which is 
rapidly reduced to cysteine (Cys) within the cell by a still unknown mechanism. Thus, 
by increasing the cellular uptake of cystine and strongly boosting the intracellular and 
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extracellular cysteine levels, xCT over-expression bypasses the requirement for 
GSH. To test whether xCT over-expression rescues Txnrd1 knockout cells, the 
Txnrd1 knockout cells 53ΔE1 and the heterozygous control cell line 46ΔB5 were 
transfected with the mouse xCT expression plasmid 141pCAG-3SIP-xCT. An eGFP-
expression plasmid (141pCAG-3SIP-eGFP) and empty vector (141pCAG-3SIP) were 
used as controls. The following cell lines were established after puromycin selection: 
53ΔE1-mock, 53ΔE1-eGFP, 53ΔE1-xCT, and 46ΔB5-mock, 46ΔB5-eGFP, and 
46ΔB5-xCT. Over-expression of xCT in these cell lines was confirmed by qRT-PCR. 
Compared to 53ΔE1-eGFP cells, 53ΔE1-xCT cells showed a 22-fold increase in the 
xCT mRNA levels, which resulted in a 7-fold higher uptake of radiolabelled cystine 
(0.208±0.022 versus 1.385±0.347 nmol cystine/min/mg protein) (Figure 17A and B). 
Even though the control cell line 46ΔB5-xCT showed a 4-fold increase in xCT 
transcripts, the cystine uptake in these cells was only marginally increased 
(0.182±0.05 nmol cystine/min/mg protein) compared to the 46ΔB5-eGFP control cells 
(0.141±0.03 nmol cystine/min/mg protein).  
 
These cells were then challenged with BSO to assess whether xCT over-expression 
is able to rescue Txnrd1 knockout cells from BSO-induced cell death as previously 
shown for Burkitt’s lymphoma cells and γ-GCS knockout cells. As illustrated in figure 
17C, xCT over-expressing cells (53ΔE1-xCT) not only died at a much lower 
concentration of BSO (2.5 µM) than eGFP-transfected cells (53ΔE1-eGFP) (10 µM), 
they also died at a much faster rate (Figure 17D). Although xCT was only marginally 
over-expressed in the heterozygous control cell line (46ΔB5-xCT), it conferred 
resistance against BSO in a dose-dependent manner (at 10 µM BSO 79.84±4.8% of 
the cells were viable as compared to 30.43±1.45% for eGFP-transfected cells) 
(Figure 17C). This was reflected in a marginal growth advantage provided to the 
46ΔB5-xCT control cell line when cultivated in presence of 10 µM BSO (Figure 17D). 
 
Results 
 
 
Figure 17. Enforced expression of xCT in Txnrd1 knockout cells was ineffective in rescuing the 
cells from BSO-induced cell death. xCT over-expression was confirmed by (A) qRT-PCR and (B) 
specific cystine uptake activity. As compared to eGFP-transfected 53ΔE1-eGFP control cells, the xCT 
over-expressing cells 53ΔE1-xCT showed a 22-fold increase in xCT mRNA and a 7-fold increase in 
cystine uptake activity. Only a 4-fold increase in xCT mRNA levels in 46ΔB5-xCT cells resulted in a 
marginal increase in cystine uptake (0.182±0.05 v/s 0.141±0.03 nmol cystine/min/mg protein). (C) Even 
the marginal increase in cystine uptake caused increased resistance towards BSO in the heterozygous 
cell line 46ΔB5-xCT compared to 46ΔB5-eGFP control cells (80% v/s 30% at 10 µM BSO) and in 
addition (D) provided a growth advantage to the cells in a time-dependent manner. In stark contrast, 
xCT over-expression in Txnrd1 knockout cells 53ΔE1-xCT failed to rescue knockout cells against BSO-
induced cell death. Data is representative of two separate sets of experiments (mean±SD). 
 
4.1.7 xCT over-expressing Txnrd1 knockout cells underwent rapid cell 
death as compared to mock-transfected control cells upon GSH 
depletion 
The above experiments showed that xCT over-expressing Txnrd1 knockout cells 
(53ΔE1-xCT) died rapidly and at a much lower concentration of BSO than eGFP-
expressing cells (53ΔE1-eGFP). For further quantification of cell death, 53ΔE1-mock 
and 53ΔE1-xCT cells were treated with 10 µM of BSO for 24 h and then stained with 
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Annexin V and PI, and analyzed by FACS. Compared to mock-transfected cells 
(53ΔE1-mock) (7.5±0.8%), xCT over-expressing Txnrd1 knockout cells were more 
susceptible to induction of cell death by BSO (53ΔE1-xCT) (23.8±5.4) (Figure 18). 
These results suggested that BSO treatment of xCT over-expressing Txnrd1 
knockout cells causes induction of cell death at a faster rate compared to mock-
transfected cells. Thus, rather than conferring resistance against BSO-induced cell 
death, xCT over-expression in Txnrd1 knockout cells accelerated the induction of 
BSO-induced cell death.  
 
 
 
Figure 18. Over-expression of xCT in Txnrd1 knockout cells induced rapid cell death upon BSO 
treatment. Mock-transfected and xCT over-expressing cells were treated with 10 µM of BSO for 24 h, 
subsequently stained with Annexin V and PI, and analyzed by FACS. As compared to 53ΔE1-mock cells 
(7.5±0.8%), 53ΔE1-xCT cells revealed a higher percentage of dying cells (23.8±5.4%). Pooled data from 
two separate experiments is represented with the mean±SD in percentage.  
 
4.1.8 xCT over-expressing Txnrd1 knockout cells suffered from severe 
oxidative stress upon GSH depletion 
If the induction of cell death is the sole effect of GSH depletion, xCT over-expressing 
Txnrd1 knockout cells should undergo cell death at the same pace as the control cell 
line. Based on the above findings, it was speculated that the accumulation of 
imported cystine leads to or mimics the state of massive oxidative stress due to the 
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high abundance of disulfide. It has also been known that under oxidative stress, 
proteins undergo mixed disulfide formation, which positively correlates with the extent 
of oxidative stress. 
 
4.1.8.1 ROS accumulation in xCT over-expressing Txnrd1 knockout cells was 
comparable to that in mock-transfected cells 
To investigate whether BSO-treatment leads to increased accumulation of ROS in 
xCT-over-expressing Txnrd1 knockout cells as compared to mock-transfected 
controls, cells were treated with 10 µM BSO for 24 h. These were subsequently 
stained with DCF and analyzed by FACS to detect the level of soluble ROS. As 
shown in figure 19A and B, ROS accumulation in xCT over-expressing Txnrd1 
knockout cells 53ΔE1-xCT (mean fluorescent intensity MFI=190.9±87.7) was 
comparable to that in mock transfected Txnrd1 knockout cells (53ΔE1-mock) 
(MFI=177.5±61.5) after BSO treatment. Furthermore, a lower level of ROS was 
detected in heterozygous cells over-expressing xCT (46ΔB5-xCT) (MFI=22.35±5.8) 
and mock-transfected cells (46ΔB5-mock) (MFI=26.8±8.4) upon BSO treatment. The 
result of the above experiment led to the conclusion that the accelerated cell death 
induced by BSO-induced cell death in xCT-over-expressing Txnrd1 knockout cells 
was not due to increased ROS accumulation upon GSH depletion. It suggested a 
contribution of “disulfide stress” due to an accumulation of imported cystine. 
 
4.1.8.2 Activation of the SAPK/JNK pathways led to execution of rapid cell 
death in xCT-over-expressing Txnrd1 knockout cells 
The SAPK/JNK and p38 MAPK pathways are stress-induced signalling pathways. 
Upon various kinds of stress stimuli, SAPK/JNK and p38 become phosphorylated at 
serine/threonine residues and induce the downstream target genes responsible for 
induction of cell death. As it was hypothesized that rapid induction of cell death in 
xCT over-expressing Txnrd1 knockout cells was due to disulfide overload-mediated 
oxidative stress, the phosphorylation status of these SAPK/JNK was determined by 
Western blot using phospho-specific antibodies raised against Thr183/Tyr185 amino 
acid residues of human SAPK/JNK. xCT over-expressing cells along with control cell 
lines were treated with 10 µM BSO for 10-12 h and cell lysate was prepared in LCW 
buffer in the presence of PhosSTOP phosphatase inhibitor cocktail (Roche 
Results 
diagnostics) and protease inhibitor cocktail (Roche diagnostics) and analyzed by 
immunoblotting. As shown in figure 20, there was a preferential activation of the 
SAPK/JNK pathway in xCT over-expressing Txnrd1 knockout cells upon GSH 
depletion than in eGFP expressing control cells, as more accumulation of phospho- 
SAPK/JNK was detected by western blot.  
 
 
 
Figure 19. Accumulation of ROS in xCT over-expressing Txnrd1 knockout cells upon BSO 
treatment. Cells were treated for 24 h with BSO and stained with DCF to detect soluble ROS. (A) 
Histogram showing ROS accumulation after BSO treatment. As indicated by a shift in the histogram to 
the left, xCT-over-expressing heterozygous cells (46ΔB5-xCT) showed less ROS accumulation (thick 
green line) than mock-transduced cells (thick grey line). Knockout 53ΔE3 cells accumulated significantly 
more ROS than heterozygous 46ΔB5 cells and there was no left shift in the histogram in case of xCT-
over-expressing Txnrd1 knockout cells, (B) Mean fluorescence intensity (MFI) in FL1. The accumulation 
of soluble ROS in xCT over-expressing Txnrd1 knockout cells was comparable to that in mock 
transfected cells (MFI=190.9±87.7 v/s 177.5±61.5). Pooled data from two sets of experiments is shown 
as mean fluorescent intensity of FL1±SD. 
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Figure 20. Preferential activation of SAPK/JNK in xCT over-expressing Txnrd1 knockout cells 
after BSO treatment. The higher level of phospho- SAPK/JNK may be indicative of increased oxidative 
stress due to an accumulation of imported cystine (“Disulfide overload”).  
 
4.1.9 Co-culture of Txnrd1 knockout cells with xCT over-expressing 
cells failed to prevent BSO-induced cell death  
xCT overexpressing Burkitt´s lymphoma, γ-GCS knockout cells, and Txnrd2 knockout 
cells take up cystine very efficiently, reduce it intracellularly and secrete large 
amounts of cysteine into the medium (Perisic, T., unpublished and (Banjac et al., 
2008; Seiler, 2008)). It was found previously in our lab that xCT over-expressing 
cells, by providing cysteine and generating a reducing extra-cellular environment, can 
serve as feeder cells and render co-cultivated control cells that are otherwise 
dependent on a thiol-containing compound, independent from antioxidant 
supplementation to the medium. The secreted cysteine is then taken up by the 
control cells, and by providing the reducing equivalents, maintains the reducing 
intracellular environment. Thus, the GSH or NAC requirement of eGFP-transfected γ-
GCS knockout cells could be bypassed by co-culture with xCT over-expressing γ-
GCS knockout cells (Seiler, 2008). Under GSH depletion, the major redox buffer 
GSH can thus be replaced by the readily available cysteine in xCT over-expressing 
cells. Yet, the mechanism of intracellular reduction of cystine to cysteine is unknown.  
 
Since over-expression of xCT failed to rescue the Txnrd1 knockout cells, it was 
hypothesized that Txnrd1 knockout cells may fail to reduce the imported cystine. If 
cystine can not be reduced, xCT over-expression would apparently not prove 
beneficial to these cells. However, culturing Txnrd1 knockout cells in a reducing 
extra-cellular milieu that is already conditioned with cysteine might improve their 
survival. To test this possibility, eGFP-expressing Txnrd1 knockout cells or 
heterozygous control cells were co-cultured at a 1:1 ratio (Figure 21A) with xCT over-
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expressing Txnrd2 knockout cells. These xCT over-expressing Txnrd2 knockout cells 
had been shown to be capable to protect eGFP-transfected Txnrd2 knockout cells 
from BSO-induced cell death (Perisic, T., unpublished results).  
 
The co-cultures were treated with BSO for 48 hours and subsequently analyzed by 
FACS for the presence of eGFP-positive cells. The results of the co-culture 
experiment revealed that xCT over-expressing Txnrd2 knockout cells were unable to 
rescue Txnrd1 knockout out cells from cell death induced by BSO-mediated GSH 
depletion (Figure 21B). In contrast, BSO-induced cell death was prevented in the 
heterozygous control cell line 46ΔB5-eGFP and the eGFP-transfected Txnrd2 
knockout cells (34% and 45% eGFP-positive cells, respectively). Hence, it was 
concluded from these experiments that cells devoid of Txnrd1, upon GSH depletion, 
are unable to exploit neither the beneficial effects of imported cystine nor that of 
freely available cysteine in the culture medium. Thus, Txnrd1 knockout cells can 
neither be rescued from GSH depletion-induced cell death by antioxidants, by xCT 
over-expression nor by co-culture with xCT-over-expressing cells that condition the 
medium with cysteine. 
 
4.1.10 Reconstitution of Txnrd1 expression in xCT over-expressing 
Txnrd1-/- cells provided resistance against BSO 
To demonstrate that the aforementioned phenotype was exclusively caused by the 
loss of Txnrd1, knockout cells were reconstituted with exogenous Txnrd1 by lentiviral 
transduction. 53ΔE1-xCT and 53ΔE1-eGFP cells were infected with SF-Txnrd1 wt 
(2ATG) recombinant virus, which also expresses puromycin acetyltransferase to 
select for transduced cells. The over-expression of SF-Txnrd1 wt (2ATG) in these 
cells was evaluated by Western blotting using a human TrxR1-specific antibody 
(Figure 22A). Empty virus expressing cells were taken as mock control.  
 
As compared to mock-transduced cells (53ΔE1-xCT mock or 53ΔE1-eGFP mock), 
SF-Txnrd1 wt (2ATG)-transduced cells (53ΔE1-xCT-SF-Txnrd1) showed increased 
resistance towards BSO over a wide range of concentrations (up to 40 µM BSO). 
Furthermore, 53ΔE1-xCT-SF-Txnrd1 wt (2ATG) cells exhibited higher viability 
compared to 53ΔE1-eGFP- SF-Txnrd1 wt (2ATG) cells (Figure 22B). This 
Results 
observation indicates that xCT over-expression protects the cells from GSH depletion 
when Txnrd1 is restored. In addition, restoration of Txnrd1 abrogated JNK/SAPK 
pathway activation in xCT over-expressing cells treated with BSO (Figure 23). Thus, 
reconstitution of Txnrd1 expression fully revert the BSO-induced phenotype. These 
results suggested that the requirement for GSH can only be bypassed by antioxidant 
supplementation or xCT over-expression in the presence of functional Txnrd1. 
 
 
 
Figure 21. Co-culture of Txnrd1 knockout cells with xCT over-expressing Txnrd2 knockout cells. 
A) Schematic outline of the co-culture experiment. Under GSH deficiency xCT over-expression rescues 
the cells by boosting the intracellular and extracellular cysteine concentration. B) The co-culture 
experiments showed that culture of Txnrd1 knockout cells in a reducing extra-cellular condition, provided 
by the xCT over expressing Txnrd2-/- cells had no beneficial effect and failed to rescue the Txnrd1 
knockout cells from BSO-mediated cell death (1.7 % eGFP positive cells). In contrast, co-cultures of 
eGFP-expressing heterozygous Txnrd1 cells and Txnrd2 knockout eGFP control cells with xCT over-
expressing Txnrd2 knockout cells rescued the control cells from BSO- induced cell death (34.5% and 
45.2% respectively at 20 µM BSO). xCT over-expressing Txnrd2 knockout cells thus provide a feeder 
effect and protect co-cultured eGFP-transfected Txnrd2-/- or Txnrd1+/- cells from BSO-induced cell death. 
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Figure 22. Re-expression of Txnrd1 in xCT over-expressing Txnrd1-/- cells confers resistance to 
BSO-mediated toxicity. xCT over-expressing Txnrd1 knockout cells were transduced with empty virus 
(mock control) and a SF-Txnrd1 wt (2ATG) expressing lentivirus. (A) Over-expression of SF-Txnrd1 was 
analyzed by Western blotting using an antibody against human TrxR1 raised in rabbit (a kind gift from 
Dr. Gladyshev). (B) Over-expression of Txnrd1 rescued xCT over-expressing Txnrd1 knockout cells 
over a wide range of BSO concentrations (39% viability at 40 µM BSO) as compared to mock-
transduced cells (2.8% viable cells at 10 µM BSO). M: 442 L1 puro (mock lentivirus), ST: 442 L1 SF-
Txnrd1 wt (2ATG) puro (SF-Txnrd1 expressing lentivirus). 
 
 
 
Figure 23 Reconstitution of Txnrd1 prevented SAPK/JNK activation in xCT over-expressing 
Txnrd1-/- cells upon GSH depletion. Lentiviral add-back of Txnrd1 fully rescued xCT over-expressing 
Txnrd1 knockout cells due to effective reduction of imported cystine and diminished oxidative stress 
upon GSH depletion.  
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4.2 Analysis of Txnrd1 function in oncogene-transformed cell 
lines 
4.2.1 In vitro transformation of MEFs using the c-myc and Ha-rasV12 
oncogenes 
The transformation of primary cells is dependent on the activation of oncogenes. The 
c-myc and Ha-rasV12 oncogenes are well known to synergize in this process (Land et 
al., 1983). In order to establish transformed cell lines, the conditional Txnrd1 
knockout MEFs cell lines Üa46, Üa51 and Üa 53 were transduced with lentiviruses 
expressing the c-myc and Ha-rasV12 oncogenes. While c-myc or Ha-rasV12 alone were 
not able to transform primary MEFS (Figure 24A), the cells were efficiently 
transformed when MEFs were co-transduced with c-myc and Ha-rasV12 expressing 
lentiviruses. Cell transformation is characterized by unlimited growth potential, loss of 
contact inhibition, and anchorage independence. The c-myc and Ha-rasV12 co-
transduced MEFs showed a higher rate of proliferation, grew in multilayered fashion, 
and formed single cell colonies in soft agar. When implanted into mice, these cells 
formed aggressive tumors (see section 4.2.14), which confirmed their transformed 
status. To establish clonal tumor cell lines, 500 c-myc- and Ha-rasV12-transduced 
cells were plated per well of a 6-well plate in 0.3% soft agar. After 10-14 days, 
individual single cell colonies were picked and expanded to establish transformed cell 
lines. The cell lines 46MRA3, 51MRB3, and 53MRC4 were used in the present study. 
Expression of c-Myc and Ha-rasV12 in these clones was confirmed by Western 
blotting (Figure 24B). 
 
4.2.2 Induction of Txnrd1 knockout in transformed cells using Tat-Cre 
protein 
4.2.2.1 Single cell cloning and the generation of knockout cell lines 
The Txnrd1+/fl transformed cell line 46MRA3 and two independent Txnrd1fl/fl 
transformed cell lines, 51MRB3 and 53MRC4, were treated with Tat-Cre protein as 
described in section 4.1.1. Clonal cell lines were generated by limiting dilution in 96-
well plates. Out-growing clones were expanded and the Txnrd1 knockout was 
confirmed by PCR for the deleted Txnrd1 allele (Figure 25), semi-quantitative RT-
PCR, and Western blotting (Figure 26A and B).  
Results 
 
 
Figure 24. In vitro transformation of MEFs by Ha-rasV12 and c-myc oncogenes. (A) Soft agar assay 
(upper panel) and 10 x microscopic view (lower panel). C-myc and Ha-rasV12 transformed cells formed 
colonies in soft agar as they acquired anchorage-independence growth property after transformation. 
(B) Western blot result showed over-expression of c-myc and Ha-rasV12 in the transformed cell lines as 
compared to non-transformed MEFs. 
 
 
 
Figure 25. Genotyping of c-myc and Ha-rasV12 transformed Txnrd1 MEFs cells. The genotype of 
different MEFs cell lines was confirmed by PCR. The lower band corresponds to the wild-type allele (wt), 
the upper to the floxed allele (upper panel). The loss of the floxed allele(s) after Tat-Cre treatment 
indicated the knockout of the Txnrd1 gene. The successful knockout of Txnrd1 was confirmed by the 
specific amplification of a PCR product only obtained after deletion of the loxP-flanked Txnrd1 allele 
(lower panel). The cell line 46MRA3 is Txnrd1+/fl while 51MRB3 and 53MRC4 are Txnrd1fl/fl. After Tat-
Cre treatment the derived cell lines were either heterozygous (46MRA3Δ1C6) or knockout (51MRB3ΔF1 
and 53MRC4ΔE3) for Txnrd1. 
 
4.2.2.2 Confirmation of the Txnrd1 knockout in transformed single cell clones 
After verifying the Txnrd1 deletion in the single cell clones at the genomic level by 
PCR, the clones were additionally analyzed for the deletion of Txnrd1 at the mRNA 
level and at the protein level. No RT-PCR amplification product was obtained after 
Tat-Cre treatment of the cells with the primer pairs Txnrd1 13-15 that are located in 
exon 13 and exon 15, which confirmed the deletion of the gene at the mRNA level. 
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However, when the upstream primer pair Txnrd1 59-60 was used, the same RT-PCR 
amplification products were obtained before and after Tat-Cre treatment, indicating 
that truncated mRNA transcripts were synthesized in knockout clones (Figure 26A), 
confirming the previously described results obtained in Txnrd1 knockout embryos 
(Jakupoglu et al., 2005). Therefore, a putative expression of a truncated Txnrd1 
protein was assessed by Western blotting. These experiments showed that no 
truncated version of Txnrd1 was expressed in these cells (Figure 26B). 
 
 
 
Figure 26. Confirmation of the Txnrd1 knockout in transformed single cell clones. (A) RT-PCR 
amplification using primer pair Txnrd1 13-15 yielded no product, confirming the deletion of Txnrd1 at the 
mRNA level. The upstream primer pair Txnrd1 59-60 generated product in all cases, indicating the 
production of truncated mRNA transcripts. (B) Western blotting results using Txnrd1-specific antibodies 
ruled out the generation of any truncated protein. The monoclonal antibody 1E12 was raised against the 
C-terminal portion of mouse Txnrd1. As the C-terminal portion was deleted and the antibody was raised 
against the C-terminus, the knockout was further confirmed by using a polyclonal anti-human TrxR1 
antibody raised in rabbit. The anti-human TrxR1 antibody was a kind gift of Dr. Gladyshev (University of 
Nebraska, Lincoln, USA). 
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4.2.3 Effect of Txnrd1 knockout on the proliferation of transformed cells 
Several previous reports proposed an indispensable role for Txnrd1 in proliferation 
and tumorigenesis (Gan et al., 2005; Lu et al., 2007; Yoo et al., 2006; Yoo et al., 
2007). However, as shown above, c-myc and Ha-rasV12 transformed Txnrd1-deficient 
cell lines could be successfully established and grown in culture. Therefore, these 
cells were compared to their respective parental cell lines in terms of proliferation, 
clonogenicity and tumorigenicity. The proliferation of the cells was measured by MTT 
assays over a period of 4 days in 96-well plates. Surprisingly, no difference in the 
proliferation of knockout and parental cell lines was observed (Figure 27). 
 
 
Figure 27. Loss of Txnrd1 had no apparent effect on the proliferation of transformed cells. 
Proliferation of cells was measured by MTT assay carried out in 96-well plates. There was no alteration 
in the proliferation of Txnrd1 knockout cells with respect to the parental cell line. Two knockout cell lines 
(51MRB3ΔF1 and 53MRC4ΔE3) showed a similar proliferation rate as the respective parental cell lines.  
 
4.2.4 Txnrd1 knockout cells displayed no substantial alterations in cell 
cycle distribution 
Since Txnrd1 has been implicated in cell proliferation and is known to provide 
reducing equivalents to ribonucleotide reductase, we hypothesized that the cell cycle 
phases might be altered in Txnrd1 knockout cells. Therefore, cell cycle analysis was 
performed by staining the DNA of knockout and parental cell lines with PI. 1x106 cells 
from asynchronously proliferating cell cultures were harvested by trypsinization, 
washed twice with cold PBS, and was fixed in ice-cold 70% ethanol overnight. Then 
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the cells were washed, treated with DNase-free RNase A and stained with PI. The 
samples were analyzed by FACS and data was analyzed by ModFitLT V3.0 software. 
 
As shown in figure 28, there was no alteration in either DNA content or cell cycle 
distribution of transformed Txnrd1 knockout cells (33.85±4.7% cells were in G0/G1 
phase, 52.33±0.8% in S phase, and 13.81±3.8% in G2/M phase) as compared to the 
parental cell line (34.55±1.1% in G0/G1 phase, 48.76±2.3% in S phase, and 
16.68±3.5% cells in G2/M phase). 
 
 
 
Figure 28. Transformed Txnrd1 knockout cells showed a similar cell cycle phase distribution as 
the parental cell line. Asynchronously growing cells were used for cell cycle analysis by PI staining. (A) 
Cell cycle analysis showed no difference in cell cycle distribution of transformed Txnrd1 knockout cells 
as compared to the parental cell line. G0/G1, S and G2/M phase distribution for 53MRC4ΔE3 cells 
(33.85±4.7%, 52.33±0.8% and 13.81±3.8%) were similar to that of the parental cell line 53MRC4 
(34.55±1.1%, 48.76±2.3% and 16.68±3.5% respectively). (B) The pie diagram represents the pooled 
data from two independent experiments (mean±SD in %). 
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These results indicated that cells can survive and proliferate normally in the absence 
of Txnrd1. In stark contrast to the previous findings on the important role of Txnrd1 in 
cell proliferation (Bondareva et al., 2007; Jakupoglu et al., 2005; Yoo et al., 2007), 
these results implicated that cells apparently can compensate for the loss of Txnrd1 
function by possibly up-regulating alternative pathways that render Txnrd1 
dispensable for proliferation and growth of transformed cells. 
 
4.2.5 Cellular response of transformed Txnrd1 knockout cells to 
oxidizing agents 
Since thioredoxin reductase 1 is an antioxidant enzyme involved in redox regulation, 
loss of Txnrd1 function may lead to an increased susceptibility towards oxidative 
stress. To address this, transformed Txnrd1 knockout cells were challenged with 
increasing concentrations of hydrogen peroxide and t-butyl hydroperoxide. As shown 
in figure 27, the viability of neither knockout nor wild type cells was impaired by 
hydrogen peroxide (Figure 29A) or t-butyl hydroperoxide (Figure 29B) at the tested 
concentrations. 
 
 
 
Figure 29. Transformed Txnrd1 knockout cells were not susceptible to oxidants. Transformed 
Txnrd1 knockout cells were challenged with (A) hydrogen peroxide and (B) t-butyl hydroperoxide. Cells 
were treated for 72 h with H2O2 and t-butyl hydroperoxide, and the viability was measured by MTT 
assay. % viability was calculated by taking the OD value of untreated cells of the respective cell lines as 
100%. At the highest concentration of H2O2 (1 mM) and t-butyl hydroperoxide (25 µM) the viability of 
Txnrd1 knockout cells 53MRC4ΔE3 was 100.03±6.3% and 101.88±2.14%, respectively as compared to 
the parental cell line 53MRC4 (101.88±6.2% and 102.65±7.87%), showing no difference at the tested 
concentrations (mean±SD in %).  
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4.2.6 Transformed Txnrd1 knockout cells were moderately resistant to 
chemical inhibitors of  Txnrd1 
Several chemical compounds and chemotherapeutic agents are known inhibitors of 
Txnrd1. Consequently, if the cytotoxic effects of these agents were due to specific 
inhibition of Txnrd1, then the Txnrd1 knockout cells may be more resistant to these 
drugs. A number of heavy metals-containing compounds like arsenic (Lin et al., 2001; 
Lu et al., 2007), platinum (Arner et al., 2001; Witte et al., 2005), organotellurium 
(Engman et al., 2003) and gold (Engman et al., 2006; Marzano et al., 2007) have 
been reported or proposed as Txnrd1 inhibitors at least in in vitro enzyme activity 
assays. Therefore, Txnrd1 knockout cells were challenged with increasing amounts 
of arsenic (III) oxide and the gold compound TEP Au and the viability of the cells was 
measured 72 h later. As shown in figure 30A and B, the knockout cells 51MRB3ΔF1 
were in fact slightly more resistant to both arsenic (III) oxide (63.34±2.44% viability at 
10 µM of arsenic oxide) and TEPAu (59.34±1.8% at 7.5 µM TEPAu) than the 
parental cell line 51MRB3 (27.62±1.03% at 10 µM arsenic (III) oxide and 
17.52±2.04% at 7.5 µM TEPAu). The decreased susceptibility of the knockout cells 
towards these agents suggested that Txnrd1 is indeed a target of these compounds. 
However, these cells became susceptible when higher concentrations of these drugs 
were used, suggesting that these substances most likely also affect other cellular 
enzymes, among those presumably Txnrd2.  
 
4.2.7 Response of transformed Txnrd1 knockout cells to DNA damage–
inducing chemotherapeutics  
Cisplatin and doxorubicin are commonly used chemotherapeutic agents for cancer 
treatment and their effects are known to mainly induce severe DNA damage. It has 
been reported by Witte et al. that cisplatin also inhibits Txnrd1 but not glutathione 
reductase (Witte et al., 2005). In addition, it has been reported that Txnrd1 confers 
resistance towards cisplatin and that knockdown of Txnrd1 sensitizes the cells 
towards cisplatin (Sasada et al., 1999). By contrast, the anthracyclin anticancer agent 
doxorubicin is a poor inhibitor of Txnrd1 (Witte et al., 2005). Therefore, the 
transformed Txnrd1-/- cells were challenged with both compounds and the viability 
was measured after 72 h by MTT assay.  
Results 
 
 
Figure 30. Transformed Txnrd1 knockout cells were less susceptible to thioredoxin reductase 1 
inhibitors. (A) In response to 10 µM Arsenic(III) oxide Txnrd1 knockout cells 51MRB3ΔF1 showed 
higher viability (66.34±2.4%) as compared to the parental cell line 51MRB3 (27.62±1.03%) (B). A similar 
pattern of response was observed with 10 µM TEPAu as knockout cells showed 39.63±2.78% viability 
as compared to 0% viability of parental cells. The heterozygous cell line 46MRA3Δ1C6 showed marginal 
resistance towards these two reagents as compared to parental cell line 46MRA3 (mean±SD in %). 
 
As shown in figure 31A, transformed Txnrd1 knockout cells 51MRB3ΔF1 were 
moderately resistant against 3.5 µM cisplatin (42.31±1.8%) as compared to the 
parental cell line (51MRB) (20.27±0.27%), but were equally susceptible to 
doxorubicin (Figure 31B). The heterozygous control cell line 46MRA3Δ1C6 behaved 
like the parental cell line. 
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Figure 31. Transformed Txnrd1 knockout cells were partially resistant towards cisplatin but not 
to doxorubicin. (A) Transformed Txnrd1 knockout cells 51MRB3ΔF1 were found to be moderately 
resistant against 3.5 µM cisplatin (42.31±1.8%) as compared to the parental cell line (51MRB) 
(20.27±0.27%). (B) With respect to doxorubicin there was no difference between the knockout and wild-
type cell lines (15.42±0.95 % v/s 11.58±1.84 % at 5 µM doxorubicin) (mean±SD in %).  
 
4.2.8 Response of transformed Txnrd1 knockout cells to agents that 
inhibit members of the GSH-dependent pathways 
Txnrd1 knockout cells were highly susceptible to GSH depletion induced by BSO 
(Figure 13), which suggested that the GSH-dependent pathway could be a 
compensatory mechanism. To address whether a similar mechanism is also 
responsible for rendering Txnrd1 dispensable for tumor cells, the members of the 
GSH-dependent pathway were examined in detail in transformed Txnrd1 knockout 
cells (discussed in detail in the following sections). Chemical agents known to inhibit 
the GSH-dependent pathways including BSO (inhibitor of γ-GCS), cadmium chloride 
(known to cause oxidative stress and preferentially oxidize and inhibit glutaredoxins) 
(Chrestensen et al., 2000; Liu et al., 2009) and phenylethyl isothiocyanate (PEITC, a 
naturally occurring compound known to induce ROS accumulation by inhibiting GSH-
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dependent pathways) (Trachootham et al., 2006) were tested on transformed Txnrd1 
knockout cells.  
 
As already observed for immortalized Txnrd1 knockout MEFs (Figure 13), 
transformed Txnrd1 knockout cells were highly susceptible to BSO treatment (Figure 
32A and B). The result confirmed that GSH is essential for the proliferation and 
survival of transformed Txnrd1 knockout cells as well.  
 
 
 
Figure 32. Transformed Txnrd1 knockout cells were highly susceptible to BSO treatment. Viability 
of transformed Txnrd1 knockout cells (51MRB3ΔF1 and 53MRC4ΔE3) was severely compromised upon 
BSO treatment. (A) Dose response experiments revealed that knockout cells were dead already at 10 
µM of BSO at which parental wild-type cells were still fully viable. The heterozygous cell line 
(46MRA3Δ1C6) responded in a similar manner as its parental cell line without showing any impairment 
in viability due to loss of one allele (93.23±4.9% v/s 89.13±8.13% at 30µM of BSO) (mean±SD in %). (B) 
Proliferation curves of two knockout cell lines confirmed the results obtained in (A). 
 
In contrast to the clear effect of BSO, transformed Txnrd1 knockout cells were 
marginally more resistant towards cadmium chloride (27.74±2.67% v/s 16.85±2.65% 
at 10 µM CdCl2) (Figure 33A) and PEITC (50.16±3.12% v/s 40.94±1.53% at 2.5 µM 
PEITC) (Figure 33B) as compared to the corresponding parental cell lines. Although 
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Nishimoto et al. reported that siRNA-mediated knockdown of TrxR1 in Hela cells 
sensitizes the cells to low dose of cadmium but provided resistance to higher toxic 
concentration (Nishimoto et al., 2006), the mechanism of action of these compounds 
is still obscure and it is difficult at present to draw conclusions from the existing data.  
 
 
 
Figure 33. Transformed Txnrd1 knockout cells were marginally resistant against cadmium 
chloride and PEITC. Txnrd1 knockout cells (51MRB3ΔF1) were marginally resistant to (A) cadmium 
chloride (27.74±2.67% v/s 16.85±2.65% at 10 µM CdCl2) and (B) PEITC (50.16±3.12% v/s 
40.94±1.53% at 2.5 µM PEITC) as compared to the parental cell lines (mean±SD in %).  
 
4.2.9 Reconstitution of thioredoxin reductase 1 expression in 
transformed Txnrd1 knockout cells reverted the effects of GSH 
depletion 
To confirm that the above observed effects were caused by specific disruption of 
Txnrd1, strep-FLAG tagged mouse Txnrd1 (SF-Txnrd1 wt (2ATG)) was over-
expressed in transformed Txnrd1 knockout cells using a tetracycline-inducible 
expression vector (Bornkamm et al., 2005). The tetracycline-inducible expression 
vector has the advantage of inducing the trangene expression in a dose-dependent 
and time-dependent manner by addition of tetracycline or doxycycline. Moreover, the 
expression of the transgene can be abrogated by the withdrawal of 
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tetracycline/doxycycline. The SF-Txnrd1 wt (2ATG) gene was cloned into the 
doxycycline-inducible expression vector (pRTS1 SF-Txnrd1 wt (2ATG) (Figure 34A).  
Transformed Txnrd1 knockout cells were transfected with this expression vector by 
electroporation. Transfection efficiency was monitored by co-transfecting the cells 
with a DS-red C1 reporter plasmid and found to be <5% (data not shown). Therefore, 
the cells were selected for two weeks with hygromycin B starting at 50 µg/ml and 
then gradually increasing the final concentration to 300 µg/ml. After two weeks of 
hygromycin B selection, the expression of SF-Txnrd1 wt (2ATG) was confirmed by 
Western blotting using antibodies against FLAG (Figure 34B). These cells were then 
challenged with BSO in the presence (1 µg/ml) or absence of doxycycline. As shown 
in figure 34C and D, transformed Txnrd1 knockout cells survived 20 µM of BSO 
treatment only when doxycycline was included in the cell culture medium. These 
experiments demonstrated that in the absence of Txnrd1, proliferation and/or survival 
of transformed cells relied on the GSH-dependent system. 
 
4.2.10 Analysis of members of the GSH-dependent systems at the 
transcriptional level by qRT-PCR 
Since Txnrd1 knockout cells were highly susceptible to BSO-mediated GSH 
depletion, the hypothesis was formulated that Txnrd1 knockout cells extensively 
relied on the GSH-dependent system. To test this hypothesis, RNA was isolated from 
the transformed Txnrd1 knockout cells lines and their respective parental cell lines. 1 
µg RNA was used for cDNA synthesis. The expression of different genes of the 
GSH-dependent system was quantified by qRT-PCR. Data was normalized against 
18S mRNA levels and represented with respect to the parental cell line. As shown in 
figure 35, the mRNA level of Gclc, Gclm and Gsr was found to be increased in 
knockout cell lines as compared to the respective parental cell lines. While Gclc was 
2.62±0.75- and 3.17±1.5-fold higher in 51MRB3ΔF1 and 53MRC4ΔE3 cell lines 
respectively, the Gclm level was 4- and 7-fold increased in two knockout cell lines. 
This was in the line of a recently published report of Bondareva et al (Bondareva et 
al., 2007). The Gsr was 1.5- and 2.62-fold up regulated in 51MRB3ΔF1 and 
53MRC4ΔE3 cell lines as compared to respective parental cell lines. These results 
indicated that enzymes of GSH-dependent pathway are invariably up regulated in 
transformed Txnrd1 knockout cells. 
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Figure 34. Doxycycline-inducible over-expression of Txnrd1 rescued transformed Txnrd1-/- cells 
from BSO-induced cell death. (A) Schematic representation of the doxycycline-inducible construct. 
The Txnrd1 knockout cell lines 51MRB3ΔF1 and 53MRC4ΔE3 were electroporated with the 
doxycycline-inducible expression vector pRTS1 SF-Txnrd1 wt (2ATG) and selected by hygromycin B. 
(B) SF-Txnrd1 wt (2ATG) expression was confirmed by immunobloting in a doxycycline-inducible 
manner. (C) and (D) The rescue experiments were performed in two independently established 
knockout cell lines after confirming the expression of SF-Txnrd1 wt (2ATG) by Western blot in a time-
dependent manner in the presence of doxycycline (upper panels of C and D). The expression of SF-
Txnrd1 decreased with the removal of doxycycline which was monitored 48 h of withdrawal. Analysis of 
proliferation of Txnrd1 knockout cells after BSO treatment in the presence (1 µg/ml) or absence of 
doxycycline revealed that the reconstitution of Txnrd1 expression provided rescue against BSO-induced 
cell death. Cell proliferation was measured by MTT assay over a period of 3 days in the presence or 
absence of doxycycline (1 µg/ml). 
 
 
 
 
85
Results 
 
 
Figure 35. Up regulation of the GSH-dependent pathway in transformed Txnrd1 knockout cell 
lines. The quantification of mRNA levels for Gclc, Gclm and Gsr revealed that there was an 
approximately more than two-fold up regulation in the respective genes as a compensatory response. 
Data was normalized against 18S mRNA levels and represented with respect to the parental cells line 
taken as 1 (mean±SD).  
 
4.2.11 Quantification of GSH levels in transformed Txnrd1 knockout 
cells 
The results of qRT-PCR were further verified by measuring GSH concentration and 
GR activity (section 4.2.12) in transformed Txnrd1 knockout cells. The total GSH 
(GSH+GSSG), reduced GSH (GSH) and oxidized GSH (GSSG) concentration in 
Txnrd1 knockout cells and their respective parental cell lines were determined by the 
isocratic HPLC method. The concentration of GSH was calculated from the 
integration of the peak area in the chromatogram. As shown in figure 36A, B and C, 
GSH concentrations in Txnrd1 knockout cells were considerably higher than in the 
parental cell lines. Total GSH and reduced GSH concentration in the transformed 
Txnrd1 knockout cell line 53MRC4ΔE3 were both 2.7-fold higher (2.76±0.85) than in 
the parental cell line 53MRC4 (taken as 1); this difference was less pronounced in 
the second Txnrd1 knockout cell line, but total and reduced GSH were still 1.5-fold 
higher than that of the parental cell line. The GSSG concentration was more than 3-
fold higher in the knockout cell lines as compared to the parental cell lines, which 
indicates the existence of oxidative stress in knockout cells. Our findings were in line 
with the previously published report in yeast where loss of both trx1 and trx2 results 
in elevated GSSG, indicating a link between the thioredoxin system and the redox 
status of GSH in the cell (Grant, 2001; Muller, 1996; Trotter and Grant, 2003). 
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Figure 36. GSH concentrations were higher in transformed Txnrd1 knockout cells. (A) GSH 
concentration was determined by HPLC. The chromatogram represented the GSH peak. The 
concentration of GSH was calculated for the area of peak. (B) Total glutathione (GSH+GSSG), GSH 
(reduced glutathione) and GSSG (oxidized glutathione) concentrations were determined. (C) The 
relative level of total GSH, GSH and GSSG were determined by taking the respective values for the 
parental cell line as 1. The total GSH level in transformed Txnrd1 knockout cells was higher than in the 
parental cell lines. Of note, Txnrd1 knockout cells showed a more than three-fold higher concentration of 
GSSG as compared to parental cell lines. Data is pooled from three experiments and represented as 
mean values±SD.  
 
 
87
Results 
4.2.12 Transformed Txnrd1 knockout cells showed higher glutathione 
reductase activity 
The data from qRT-PCR showed more than 1.5-fold up regulation of Gsr at the 
transcriptional level which was further verified at the enzyme activity level. GR activity 
was measured in Txnrd1 knockout cells. As shown in figure 37A and B, the GR 
activity was in fact higher in transformed Txnrd1 knockout cells than in the 
corresponding parental cell line. Compared to the parental cell lines 51MRB3 
(0.612±0.014 U/mg protein) and 53MRC4 (0.87±0.27 U/mg protein), Txnrd1 knockout 
cells 51MRB3ΔF1 (1.178±0.41 U/mg protein) and 53MRC4ΔE3 (2.053±0.36 U/mg 
protein) showed an approximately more than 2-fold higher GR activity. GR activity in 
the heterozygous control cell line was similar to the parental cell line (0.89±0.22 
U/mg protein v/s 0.805±0.26 U/mg protein). 
 
 
 
Figure 37. Transformed Txnrd1 knockout cells displayed higher GR activity. (A) GR activity was 
measured as the rate of consumption of NADPH/H+ which is associated with a decrease in OD at 340 
nm. Yeast GR was used as positive control. (B) GR activity (U/mg protein) and relative GR activity (GR 
activity of the parental cell line sets as 1) was determined from the standard curve obtained from known 
concentrations of yeast GR. The transformed Txnrd1 knockout cells 51MRB3ΔF1 and 53MRC4ΔE3 
showed more than a two-fold higher GR activity (1.178±0.415 and 2.053±0.36 U/mg protein, 
respectively) as compared to the parental cell lines 51MRB3 and 53MRC4 (0.612±0.014 and 
0.877±0.27 U/mg protein, respectively). Pooled data from three experiments (mean±SD).  
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4.2.13 Re-expression of Txnrd1 in Txnrd1 knockout cells reverted GSH 
levels and GR activity 
The augmented GSH concentrations and GR activity of transformed Txnrd1 knockout 
cells compared to parental cells suggested that Txnrd1 knockout cells up-regulated 
the GSH-dependent pathway as a compensatory mechanism for the loss of Txnrd1 
function. If this was the case then the GSH level and GR activity might be reverted to 
wild-type levels when Txnrd1 was re-expressed in these cells. To test this 
hypothesis, SF-Txnrd1 wt (2ATG) was expressed in transformed Txnrd1 knockout 
cells from the previously described doxycycline-inducible expression vector (Section 
4.2.9). As shown in figure 34A, Txnrd1 expression in the transfected cells was 
doxycycline-dependent. GSH levels and GR activity in these cells were determined in 
the presence (1 µg/ml) or absence of doxycycline. As shown in figure 38A and B, the 
addition of doxycycline indeed caused a decrease in GSH levels and GR activity in a 
time-dependent manner.  
 
The total GSH concentration in doxycycline-untreated knockout cells (1.48±0.16 
mM/mg protein) was 3-fold higher than in Txnrd1 knockout cells that were maintained 
on doxycycline (0.547±0.016 mM/mg protein). Transient addition of doxycycline for 
36 h led to a drop in GSH level to 1.04±0.09 mM/mg protein. The reverse effect was 
observed when doxycycline was withdrawn from the long-term treated cells for 36 h 
(0.67±0.09 mM/mg protein). Also, the levels of GSH changed similarly in these cells. 
Continuous treatment of the cells with doxycycline led to a 3-fold reduction in GSSG 
levels (13.0±10 µM/mg protein) as compared to untreated cells (39.4±11.3 µM/mg 
protein) (Figure 38A). The drop in GSH levels after addition of doxycycline was 
paralleled by a reduction in GR activity. As compared to untreated cells (2.8±0.3 
U/mg protein), transformed Txnrd1 knockout cells maintained in the presence of 
doxycycline showed an approximately 50% decrease in GR activity (1.4±0.35 U/mg 
protein) (Figure 38B). 
 
4.2.14 Loss of Txnrd1 had no effect on clonogenicity and tumorigenicity 
of transformed cells 
In order to determine the effect of loss of Txnrd1 on the clonogenicity, soft agar 
assays were performed. 500 cells/well were plated in 0.3% agar in 6-well plates. 
Results 
After 10-14 days the cells were fixed in methanol, stained with 0.5% crystal violet and 
the number of visible colonies was counted. As shown in figure 39A, the knockout 
cell lines were able to form colonies in soft agar, suggesting that the loss of Txnrd1 
function apparently had no effect on the clonogenicity of the cells. 
 
 
Figure 38. Re-expression of Txnrd1 in an inducible manner decreased GSH concentrations and 
GR activity in transformed Txnrd1 knockout cells. (A) GSH concentration was determined by HPLC. 
(B) GR activity was determined by measuring the rate of NADPH/H+ consumption. Transient induction of 
Txnrd1 expression for 36 h led to a decrease in GSH concentration and GR activity. Long-term 
maintenance of these cells in the presence of doxycycline (+Dox LT) led to a 3-fold reduction of total 
GSH, GSH and GSSG levels (1.48±0.16 mM/mg protein to 0.547±0.016 mM/mg protein). Similarly, 
there was a two-fold reduction in GR activity upon re-expression of Txnrd1 (2.8±0.3 U/mg protein to 
1.4±0.35 U/mg protein). An increase in GSH levels and GR activity was observed when Txnrd1 
expression was abolished by doxycycline withdrawal (Dox wd).  
 
The tumorigenic potential of transformed Txnrd1 knockout cells was further assessed 
by transplanting 1x106 cells into C57BL/6 mice (n = 6 per group). The tumor was 
allowed to grow for 10 days. As shown in figure 39B, both the knockout cell lines 
51MRB3ΔF1 (1.52±0.33 g) and 53MRC4ΔE3 (2.45±0.38 g) formed tumors of size 
and mass comparable to the respective parental cell lines 51MRB3 (1.42±0.43 g) 
and 53MRC4 (1.67±0.45 g). These results clearly showed that loss of Txnrd1 had 
apparently no effect on clonogenicity and tumorigenicity of transformed cells. From 
these studies Txnrd1 emerges as being dispensable for tumor growth. Since both 
knockout cell lines showed higher GSH content and GR activity, loss of Txnrd1 
 
90
Results 
function might be compensated for by the GSH-dependent system, at least to some 
extent. Further experiments need to be conducted to address the overlapping 
functions between the GSH-dependent and the thioredoxin-dependent pathway. 
 
 
 
Figure 39. Loss of Txnrd1 had no effect on the clonogenic and tumorigenic potential of 
transformed MEFs. (A) Soft agar assay. 500 cells/well were seeded in 0.3% soft agar and colonies 
were allowed to grow for 10-14 days. The colonies were counted after staining with crystal violet. 
Transformed Txnrd1 knockout cells formed colonies in soft agar without showing any loss of clonogenic 
potential. (B) Tumor transplantation in C57BL/6 mice. 1x106 transformed Txnrd1 knockout cells and the 
parental cell lines were subcutaneously transplanted into the flanks of C57BL/6 mice and allowed to 
grow for 10 days. Animals were sacrificed and tumor mass was determined. The result of the 
transplantation experiment revealed that there was no loss in tumorigenic potential of Txnrd1 knockout 
cells, as both the knockout cell lines 51MRB3ΔF1 and 53MRC4ΔE3 formed tumor mass of comparable 
size (1.52±0.33 and 2.45±0.38) to that of parental cells lines 51MRB3 and 53MRC4 (1.42±0.43 and 
1.67±0.45), respectively. 
 
4.2.15 Txnrd1-deficient tumors were susceptible to pharmacological 
inhibition of GSH 
In vitro experiments had indicated that transformed Txnrd1-deficient cells showed 
higher GSH content and GR activity and were susceptible to BSO-mediated GSH 
depletion. This indicated that Txnrd1 knockout cells relied heavily on the GSH/GSH-
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dependent pathway for survival and proliferation which rendered Txnrd1 dispensable 
for tumorigenesis. If Txnrd1-deficient tumors solely depended on the GSH/GSH-
dependent system then pharmacological intervention of GSH/GSH-dependent 
pathway might be effectively exploited therapeutically in cancer treatment.  
To test this hypothesis, 1x105 transformed Txnrd1 knockout cells along with parental 
cell lines were implanted in both the flanks of C57BL/6 mice (n = 6 per group). The 
cells were allowed to establish and they formed small tumors after 3 days. Then the 
mice were treated with BSO (20 mM) in drinking water for 10 days (Figure 40A). At 
the end of the experiments, mice were sacrificed, tumors were collected and 
analyzed. As shown in figure 40B and C, Txnrd1 knockout tumors were highly 
susceptible to BSO treatment in vivo and formed very small tumors (0.0622±0.051 g) 
as compared to untreated tumors (0.488±0.429 g).  
 
 
 
Figure 40. Txnrd1-deficient tumors were highly susceptible to pharmacological inhibition of GSH 
synthesis. A) Protocol for BSO administration to tumor-bearing mice. B) Txnrd1-deficient tumors were 
highly susceptible to BSO (0.0622±0.051 g) as compared to untreated tumors (0.488±0.429 g). Wild-
type tumors were resistant to BSO treatment. C) Tumor mass was calculated at the end of the 
experiment. Txnrd1-deficient tumors showed an 8-fold reduction in tumor mass upon BSO treatment. D) 
Absence of Txnrd1 in these tumors was confirmed by Western blot. 
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The wild-type tumors were resistant to BSO treatment and formed tumors of 
comparable masses (0.379±0.322 g) as compared to the untreated group 
(0.405±0.205 g). The analysis of the long-term effect of BSO treatment on tumor 
growth and survival of tumor-bearing mice is ongoing. Absence of Txnrd1 in these 
tumors was confirmed by Western blot (Figure 40D). Thus it was concluded from 
these experiments that Txnrd1-deficient tumors are highly susceptible to 
pharmacological inhibition of GSH, which may be utilized as an adjunct to Txnrd1 
inhibition in cancer treatment.     
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5. Discussion 
A growing body of evidence accumulated over the past decade has put the redox 
regulation of cell signaling as pivotal for the regulation of many physiological 
processes like proliferation, differentiation and cell death through reversible 
oxidation-reduction of redox-sensitive proteins. Reactive oxygen species are not only 
detrimental to the cells; at lower concentration they are used as second messengers 
for signaling. While the basal level of ROS plays important roles in normal cellular 
physiology, an increase in the ROS burden or the loss of antioxidant functions has 
detrimental effects on the cells and is reflected in many patho-physiological 
processes like neurodegeneration and cancer. Although the understanding of ROS 
signaling and antioxidant defense is still in its juvenile stage, a better understanding 
of these processes will open new avenues for the treatment of many complex (age-
related) degenerative diseases - the progress made over the years is tremendous 
and showed a promising prospective. The present study sought to address the role 
of one of the major redox enzymes, cytosolic thioredoxin reductase 1, in antioxidant 
defense, growth and proliferation, and transformation. 
 
5.1 Thioredoxin reductase 1 function in MEFs 
5.1.1 Transgenic mouse models for Txnrd1 and Txnrd2 
Txnrd1 has been implicated in proliferation as it is highly expressed in neoplastic 
tissue and in tumor cell lines. Moreover, it was also reported to be a target gene of 
the c-myc oncogene in human B cell lines (Schuhmacher et al., 2001). Using the 
Cre-loxP technology, a conditional Txnrd1 knockout mouse line was generated in our 
laboratory to address the role of Txnrd1 in proliferation and growth. Exon 15 
harboring the C-terminal catalytic centre and SECIS element was flanked by loxP 
sites, which are targeted by Cre recombinase, leading to the disruption of the Txnrd1 
gene and ultimately Txnrd1 functions. Targeted disruption of Txnrd1 resulted in 
embryonic lethality as the knockout embryos died at E10.5. Txnrd1 knockout 
embryos showed marked growth and developmental retardation and exhibited 
severe proliferation defects in all tissues except the heart, implicating the role of 
Txnrd1 in proliferation and early embryogenesis (Jakupoglu et al., 2005). The 
phenotype of Txnrd1 knockout was entirely different from that of the mitochondrial 
isoform (Txnrd2). While Txnrd1 knockout showed severe proliferation defects and 
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growth retardation, Txnrd2 knockout resulted in abnormal hematopoiesis, impaired 
heart development and increased apoptosis due to mitochondrial dysfunctions 
(Conrad et al., 2006; Conrad et al., 2004). Thus, it appears that the two isoforms, 
being located in different sub-cellular compartments and being expressed in different 
tissues, have widely non-redundant functions. In the meantime, by using Cre/loxP 
technology another group reported the generation of conditional Txnrd1 knockout 
mice (Bondareva et al., 2007). They targeted the first two protein-encoding exons 
with loxP sites to disrupt the entire gene. They reported similar findings of early 
embryonic lethality at E7.5 confirming our previous published report that thioredoxin 
reductase 1 is indispensable for proliferation and embryogenesis (Jakupoglu et al., 
2005). In the present study, conditional Txnrd1 knockout mice and MEFs cell line 
derived from the mice generated by Jakupoglu et al. were used as it was not 
possible to establish knockout MEFs cell lines directly from knockout embryos 
(Jakupoglu et al., 2005). 
 
5.1.2 Txnrd1 was dispensable for proliferation of MEFs in culture 
To study the in vitro effects of Txnrd1 disruption, conditional Txnrd1 knockout MEFs 
cell lines were established. The cell lines were treated with the Tat-Cre protein to 
achieve the deletion of Txnrd1. Contrary to our expectations, Txnrd1 knockout cell 
lines could be established and propagated in the cell culture. The diametrically 
opposed observations - the failure to establish Txnrd1-deficient cell lines directly 
from knockout embryos and the successful establishment of Txnrd1 knockout cell 
lines from culture-adapted cells - were indicative of the fact that after adaptation, the 
cells can compensate for the loss of Txnrd1 by up-regulating a yet unrecognized 
pathway. In line of the above observation, Yoo et al. had reported that thioredoxin 
reductase 1 is not required in culture as siRNA-mediated knock-down of Txnrd1 had 
no impact on the cell proliferation in culture, although they loose their metastatic or 
tumorigenic potential (Yoo et al., 2006). But their report did not provide any 
explanation for a putative compensatory mechanism that render Txnrd1 dispensable 
for proliferation. Subsequently, the same group has published another report that 
Txnrd1 is required for proliferation and DNA polymerase activity under serum-
deprived conditions (Yoo et al., 2007). Thus, it is very likely that a complex regulation 
of the cellular redox network must exist in cells, and depending on the cell/tissue 
types, their proliferation rate and differentiation status, loss of Txnrd1 may have 
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different outcomes on cell survival and cell proliferation. In line of this notion, Txnrd1 
was shown to be dispensable for heart development (Jakupoglu et al., 2005), while it 
plays an essential role in cerebellar development (Soerensen et al., 2008). It will be 
interesting to dissect the mechanism which may compensate for the loss of Txnrd1 
functions. 
 
5.1.3 Txnrd1 knockout cells were susceptible to GSH depletion  
Previous work from our laboratory had shown that Txnrd2 knockout cells were highly 
sensitive to GSH depletion and rapidly died, which could be prevented by NAC 
treatment (Conrad et al., 2004). The above observation led to the hypothesis that 
Txnrd1 knockout cells might also be susceptible to GSH depletion. Similar to Txnrd2 
knockout cells, Txnrd1 knockout cells, when challenged with the GSH depleting 
agent BSO, died at a much lower concentration of BSO (5 µM) as compared to wild-
type cells (20 µM or more). Thus the above observation indicated that in the absence 
of Txnrd1, GSH depletion has a detrimental effect on cell survival. To further 
reconfirm that this phenotype was due to loss of Txnrd1, Txnrd1 was reconstituted in 
Txnrd1 knockout cells by over-expressing Strep-FLAG tagged Txnrd1 (SF-Txnrd1 wt 
(2ATG)). The add-back of SF-Txnrd1 wt (2ATG) provided resistance to BSO 
treatment. The rescue of Txnrd1 knockout cells against BSO treatment by SF-Txnrd1 
over-expression was approximately 40%, which could be due to the limited amounts 
of selenium present in normal cell culture medium. Further experimentation is 
needed to study the effects of selenium supplementation. It would not be surprising if 
selenium supplementation would increase the rescue efficiency after re-introducing 
the wild-type Txnrd1 gene into Txnrd1 knockout cells. Site-directed mutagenesis was 
used to alter 4 amino acids previously reported to be involved in catalysis of 
thioredoxin reductase 1. The N-terminal cysteine mutants (C59S, C64S) provided 
rescue comparable to wild-type under normal cell culture conditions. In contrast, the 
C-terminal mutants were enzymatically less efficient in restoring the loss of Txnrd1 
function, highlighting the importance of the C-terminal catalytic centre in catalysis as 
the electrons are finally transferred to the substrate by this redox centre. Although 
the selenocysteine to cysteine mutant showed a partial effect in rescuing the 
phenotype, this indicates that the lack of selenocysteine impairs the enzyme function 
to some extent; but the absence of selenocysteine or cysteine leads to a drastic loss 
of enzyme function (approximately 25% with respect to wild-type and 50% loss in 
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functionality with respect to U498C mutants), which is in line with previous reports. 
As described earlier, the mutation of selenocysteine to cysteine leads to more than 
90 % loss of catalytic function of Txnrd1 (Lee et al., 2000; Zhong and Holmgren, 
2000) highlighting the critical involvement of Sec during the catalytic cycle.  Although 
Sec is critical for the catalytic function, our findings indicate that Cys497 is the most 
important amino acid involved in catalysis as it provides electrons for the reduction of 
thioselenide. Additionally, the orthologous cysteine variants of Txnrd1 were reported 
to exist in Drosophila which exhibit similar catalytic activity as the selenocysteine-
containing Txnrd1 form in mice and humans (Bauer et al., 2003; Gromer et al., 
2003). The occurrance of selenocysteine in the mammalian thioredoxin reductase 
presumably provides a selective advantage through broadening the substrate 
specificity and activity in diverse microenvironments (Gromer et al., 2003).  
 
The localization of these mutants was examined by immunocytochemistry and 
confocal microscopy using an anti-FLAG antibody. Thioredoxin reductase 1 has 
been reported being mainly localised in the cytosol. Although in the case of wt 
(2ATG) Txnrd1 the cellular localisation was predominantly cytosolic, it was also 
detected in nucleus. This showed that Txnrd1 can translocate to the nucleus and 
may exert different functions in the nucleus and in the cytosol. The U498STOP 
mutant and C497S mutant (to a lesser extent) were also detected in the nucleus. 
The other mutant forms of Txnrd1 were located in cytosol. The staining pattern for 
C64S and C497S exhibited granularity, thus localization to other sub-cellular 
compartments can not be ruled out at the moment. Further studies are needed to 
describe in more detail the unusual localization and staining pattern of these mutants 
and their physiological significance. 
 
5.1.4 Antioxidants failed to rescue Txnrd1 knockout cells from cell death 
triggered by GSH depletion  
Since antioxidants were reported to antagonize the GSH depletion-induced cell 
death in various cell types, including γ-GCS-/- (Shi et al., 2000) and Txnrd2-/- cells 
(Conrad et al., 2004), three different antioxidants (NAC, Trolox and 2-ME) were 
tested on Txnrd1 knockout cells treated with BSO. When the Txnrd1 knockout cells 
were cultured in the presence of antioxidants to prevent BSO-mediated cell death, all 
tested antioxidants (NAC, Trolox and 2-ME) invariably failed to rescue the cells from 
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cell death, which was unprecedented. The failure of antioxidants to rescue Txnrd1 
knockout cells was further confirmed by Annexin-PI staining showing comparable 
rate of cell death in antioxidant-treated and untreated samples. In the heterozygous 
control cell line, all the tested antioxidants protected the cells against BSO-induced 
cell death. GSH constitutes the major cellular redox buffer, being present in 
millimolar concentration (1-10 mM). Its importance had been demonstrated in vivo 
and ex vivo, since mice specifically lacking GSH synthesis die at E7.5. Likewise, γ-
GCS knockout cells also die rapidly in cell culture (Shi et al., 2000), which, somehow 
surprisingly, could be prevented by culturing these cells in the presence of thiol-
containing antioxidants (Shi et al., 2000). Similarly, Txnrd2 knockout cells can be 
rescued from GSH depletion-mediated cell death by NAC (Conrad et al., 2004). 
Moreover, xCT knockout cells die within 24 hours after withdrawal of the antioxidant 
2-ME and NAC due to severe oxidative stress in cell culture (Sato et al., 2005). In 
this context it is noteworthy, however, that xCT knockout mice are fully viable! Taken 
together, the requirement for GSH can be bypassed by thiol-containing antioxidants. 
The results of the present study that Txnrd1 knockout cells can not be rescued from 
BSO-mediated cell death by antioxidants led to the conclusion that Txnrd1 is 
required for antioxidant activity to bypass the GSH requirement and therefore, 
antioxidants were ineffective in rescuing the Txnrd1 knockout cells.  
 
5.1.5 xCT over-expression in Txnrd1 knockout cells aggravated the 
detrimental effects of GSH depletion  
Previous work in our laboratory had shown that xCT, the substrate specific subunit of 
system Xc- provides resistance to Burkitt’s lymphoma cells against oxidative stress 
and BSO-induced cell death (Banjac et al., 2008). The mechanism was shown to be 
augmented cystine uptake, thus increasing the intracellular and extracellular cysteine 
level without any impact on GSH synthesis or on the expression of anti-apoptotic 
genes. The work of Ana Banjac had suggested that the Cys2/Cys redox couple 
operated independently of GSH, thus delineating the xCT-driven Cys2/Cys cycle as 
an independent powerful redox cycle that protects the cells from cell death under 
GSH limiting conditions by maintaining the intracellular and extracellular redox 
balance. In the same line of observation, unpublished work of Seiler A. (Seiler, 2008) 
showed that xCT over-expression in γ-GCS knockout cells, which lack endogenous 
GSH synthesis, can successfully bypass their GSH/thiol requirement. This 
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observation was an extension of the published report by Shi et al. which showed that 
the γ-GCS knockout cells can be rescued by exogenously added thiol-containing 
compounds, such as GSH and NAC (Shi et al., 2000). The basic mechanism 
remains the same: antioxidant supplementation, thiol-containing compounds or 
cystine transporter that facilitates the delivery of cystine to sustain the pool of non-
GSH reducing equivalents to the cells can bypass the requirement for GSH. The 
question of how the antioxidants achieve this and what is the driving force for the 
reduction of cystine to cysteine inside the cell under GSH depletion, however, 
remained unanswered in previous studies. The mechanistic answer to this question 
was revealed in the present study when the over-expression of xCT failed to rescue 
the Txnrd1 knockout cells from GSH depletion-induced cell death. Unlike in γ-GCS 
knockout cells, Burkitt’s lymphoma cells, and Txnrd2 knockout cells, where xCT was 
found to be highly protective, xCT over-expression in Txnrd1 null cells appeared to 
be detrimental to the cells under GSH deprivation and even sparked the rapid onset 
of cell death. Although ROS levels in xCT over-expressing Txnrd1 knockout cells 
were comparable to mock transfected cells, there was, within the time frame of the 
experiment, four times more dead cells in xCT over-expressing Txnrd1 knockout 
cells as compared to mock-transfected cells. The rapid induction of cell death in xCT 
over-expressing Txnrd1 knockout cells can be attributed to the concomitant loss of 
GSH and overloading of the cells with cystine which could aggravate oxidative stress 
due to “disulfide-overload”. The assumption that more accumulation of cystine in xCT 
over-expressing cells could lead to toxicity upon GSH depletion by itself, can be 
argued against with the fact that over-expression of SF-Txnrd1 wt (2ATG) fully 
rescued these cells from GSH depletion. Moreover, these xCT-over expressing 
Txnrd1 knockout cells with restored SF-Txnrd1 expression tolerated higher doses of 
BSO as compared to SF-Txnrd1 wt (2ATG)-transduced eGFP control cells (that did 
not express xCT) under GSH depletion and mock-transduced xCT-over expressing 
Txnrd1 knockout cells which were extremely sensitive to GSH depletion.   
 
The failure of xCT over-expression in rescuing the Txnrd1 knockout cells upon GSH 
depletion led to the conclusion that Txnrd1 knockout cells lack the essential 
enzymatic make-up to reduce the imported cystine. xCT over-expression has been 
shown to provide a feeder-like effect to Burkitt´s lymphoma cells (Banjac et al., 2008) 
and to rescue the mock-transfected γ-GCS knockout control cells (Seiler, 2008) by 
secreting cysteine into the medium and maintaining the extracellular environment 
Discussion 
 
100
reducing. Although xCT over-expression failed to rescue the Txnrd1 knockout cells 
form GSH depletion-mediated cell death, it was hypothesized that Txnrd1 knockout 
cells may be rescued from GSH depletion if grown in reducing extracellular milieu by 
co-culturing these cells with xCT over-expressing cells with intact Txnrd1. Even in 
co-culture experiments Txnrd1 knockout cells could not be rescued, indicating that 
they have a severe impairment in the utilization of cysteine. Taken together, it can be 
concluded that Txnrd1 knockout cells are extremely susceptible to GSH depletion, 
which can not be antagonized by antioxidant supplementation, xCT over-expression 
or by culturing them in a reducing extracellular environment. Studies in lower 
organisms had shown that a simultaneous block of both disulfide-reducing pathways 
(thioredoxin and GSH-dependent pathways) is incompatible with growth and survival 
under aerobic conditions (Grant, 2001; Muller, 1996; Prinz et al., 1997), but limited 
growth of these mutants can be restored using anaerobic conditions, indicating that 
oxidative stress may play a crucial role in cell death progression. The redundancies 
between the two pathways are apparent by the fact that in the absence of only one 
of the pathways, bacterial and yeast strains can survive and grow reasonably well. 
But in mammals, disruption of GSH synthesis alone is sufficient to cause embryonic 
lethality (Shi et al., 2000), even in the presence of an intact thioredoxin-system which 
is an alternative pathway involved in the maintenance of the dNTP pool suggesting 
that it is the redox balance which is severely compromised in these cells. This is 
further supported by the finding that the viability of these cells can be restored by 
antioxidant supplementation (Shi et al., 2000), and depletion of GSH has no effect on 
the dNTP pool and DNA synthesis (Spyrou and Holmgren, 1996). The essential 
requirement of ribonucleotide reductase for the maintenance of the cellular dNTP 
pool and DNA synthesis had led to the speculation on the existence of an additional 
hydrogen donor for ribonucleotide reductases apart from the thioredoxin and GSH-
dependent system in mammals (Spyrou and Holmgren, 1996). In E.coli, a third 
hydrogen donor system for ribonucleotide reductase has already being identified in 
double mutants lacking thioredoxin and glutaredoxin (Aslund et al., 1994; Miranda-
Vizuete et al., 1994). Moreover, a thioredoxin/thioredoxin reductase mutant of 
Bacteroides fragilis, which is a facultative anaerobic organism and lacks the 
glutathione/glutaredoxin system, can be grown in culture with the addition of 
reductants (Rocha et al., 2007). Furthermore, in mammals, the disruption of either 
thioredoxin 1 or thioredoxin 2 is incompatible with murine viability (Matsui et al., 
1996; Nonn et al., 2003b) despite the presence of an intact GSH-dependent system, 
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again indicating that compromised viability is due to impaired redox balance rather 
than interference with DNA synthesis. Although disruption of both thioredoxin 
reductase 1 and 2 was associated with embryonic lethality in mice (Conrad et al., 
2004; Jakupoglu et al., 2005), MEFs deficient in thioredoxin reductases can be 
grown in culture (present study and (Conrad et al., 2004). Both Txnrd2 and Txnrd1 
deficient MEFs are highly susceptible to GSH depletion indicating an overlapping link 
between the two disulfide reducing systems. But the contrasting observations that 
antioxidant supplementation rescues Txnrd2 knockout cells, but not Txnrd1 knockout 
cells from GSH depletion, support the fact that Txnrd1 is required for the utilization 
and/or recycling of antioxidants. Several in vitro studies had shown that thioredoxin 
reductase 1 is involved in the recycling of ascorbate (May, 2002; May et al., 1998), 
vitamin E, L-cysteine (Luthman and Holmgren, 1982) and other small metabolites or 
compounds known to harbor antioxidant property (Nordberg and Arner, 2001). Of 
particular importance is the reduction of L-cystine. While characterizing the rat liver 
thioredoxin reductase, Holmgren´s group had shown that L-cystine is efficiently 
reduced in vitro by thioredoxin reductase (Luthman and Holmgren, 1982). Thus, the 
outcome of the present study lends support to the previous in vitro studies and this is 
the first in vivo result that shows that antioxidants are unable to antagonize the GSH-
depletion-mediated cell death of Txnrd1 knockout cells. This could explain the 
observation that rapid onset of cell death in xCT over-expressing Txnrd1 knockout 
cells is due to “disulfide-stress” resulting from cystine overload. This was evident 
from the preferential activation of the stress-activated SAPK/JNK pathway in xCT 
over-expressing Txnrd1 knockout cells upon GSH depletion, although ROS 
accumulation in these cells was comparable to that of mock cells. That disulfide 
overload triggers oxidative stress has long been speculated and the experimental 
evidence is now provided by this study (Aslund and Beckwith, 1999). Thus, based on 
our findings and existing information, we speculate that thioredoxin reductase 1 is 
essential for the utilization and recycling of small thiol-containing compounds and is 
the main driving force for the maintenance of the non-GSH reducing pool. This can 
be explained by the following model being operative in the cells (Figure 41).  
 
The GSH is the main reducing equivalent in the cell being present in millimolar 
concentration. It has been speculated since long that GSH is the main driving force 
for intracellular reduction of cystine (Figure 41A). But the essential requirement of 
GSH can be bypassed by antioxidant supplementation or xCT over-expression that 
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provides cystine. In the absence of GSH, xCT over-expression bypasses the 
requirement for GSH by increasing the cellular uptake of cystine, boosting the 
intracellular and extracellular cysteine concentrations (Seiler, 2008). Thus, it acts as 
a powerful redox cycle across membrane (Figure 41B). 
 
 
 
Figure 41.  Molecular model depicting the essential requirement of Txnrd1 for intracellular 
reduction of cystine under GSH depletion. (A) GSH is the predominant reducing equivalent inside 
the cells counteracting the oxidative stress along with the thioredoxin-dependent system. It is believed 
to be the main driving force for the reduction of cystine inside the cells. (B) Under GSH deficiency xCT 
over-expression can bypass the essential requirement of GSH. (C) The failure of xCT-overexpression in 
rescuing the Txnrd1-/- cells of GSH depletion-induced cell death prompted us to hypothesize that Txnrd1 
is the main driving force for intracellular reduction of cystine. 
 
But the observations that in the absence of GSH and simultaneous over-expression 
of xCT there was effective intracellular reduction of cystine and failure of antioxidant 
supplementation or xCT over-expression to rescue the Txnrd1-/- cells led us to 
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hypothesize that Txnrd1 is the main driving force for the utilization/recycling of 
antioxidants and intracellular reduction of cystine to cysteine as depicted in figure 
41C. The rapid onset of cell death in xCT-over-expressing Txnrd1 knockout cells 
upon GSH depletion can be explained by the fact that Txnrd1 knockout cells not only 
failed to reduce the cystine, but accumulation of imported cystine inside the cells 
leads to “disulfide overload”-mediated oxidative stress. Experimental validation of the 
proposed model is currently being performed.  
 
5.2 Thioredoxin reductase 1 functions in oncogene-
transformed cell lines 
5.2.1 Thioredoxin reductase1 was dispensable for c-myc and Ha-rasV12 
transformed cells 
Thioredoxin reductase 1 has multiple functions in cellular growth, proliferation, and 
defense against oxidative stress. The Trx system is crucially involved in the 
reduction of ribonucleotides to yield deoxyribonucleotides and is indispensable for 
embryogenesis. The mammalian thioredoxin reductases have been implicated in the 
selenium metabolism (Kumar et al., 1992) and thus are in part responsible for a 
putative chemopreventive effect of selenium against cancer. Thioredoxin reductase 1 
is reported to be augmented in many cancers and is positively correlated with 
invasiveness, metastasis and poor survival rate. Hence it might offer an Achilles heal 
for cancer treatment. Previous work in the lab had identified human thioredoxin 
reductase 1 as a target gene of c-myc (Schuhmacher et al., 2001). Therefore, the c-
myc driven tumor model was chosen to dissect the role of Txnrd1 in tumorigenesis 
by genetic means. Conditional Txnrd1 knockout MEFs were transformed by co-
transducing them with c-myc and Ha-rasV12 expressing lentiviruses. The targeted 
disruption of Txnrd1 was achieved by exploiting the Cre-loxP technology.  
 
Contrary to previous reports, which demonstrated that thioredoxin reductase 1 is 
indispensable for proliferation and tumorigenesis (Lu et al., 2007; Yoo et al., 2006; 
Yoo et al., 2007), c-myc and Ha-rasV12 transformed cell lines deficient in thioredoxin 
reductase 1 could be successfully established and maintained in culture. Apparently 
there was no difference in the proliferative capacity and cell cycle distribution of 
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knockout cells with respect to parental cell lines, indicating that the loss of Txnrd1 
had little if any impact on the growth-behavior of tumor cells. In their first report, Yoo 
et al. had reported that loss of Txnrd1 functions by siRNA knock-down led to 
dramatic loss in tumorigenicity and metastatic properties of the Lewis Lung Cancer 
cell line (LLC1) manifested as a reversal in phenotype similar to those of normal cells 
(Yoo et al., 2006). Later they reported that under normal culture conditions, 
knockdown of Txnrd1 has essentially no effect on cell growth, although they lost their 
ability to form colonies in soft agar. But when cultivated under serum-deprived 
conditions, Txnrd1 knockdown led to defective progression through S-phase and 
decreased expression of DNA polymerase α, suggesting that Txnrd1 may act as a 
pro-cancer protein (Yoo et al., 2007) and is required for proliferation. In our system, 
loss of Txnrd1 had no apparent phenotype under normal culture condition, which is 
in line with the previously published report. The effect of low serum on proliferation of 
knockout cells has not been addressed yet. But interestingly, there was no effect on 
the colonigenicity or tumorigenicity of knockout cells suggestive of a yet-
unrecognized compensatory mechanism replacing Txnrd1 (discussed later). 
 
Numerous reports indicated that TrxR1 has opposing effects on tumor development. 
On the one hand it is reported to have a role in cancer prevention as it supports p53 
functions and may induce apoptosis in certain tumors, while the up-regulation of 
Txnrd1 in various cancers is suggestive of a cancer promoting role and is linked to 
the resistance to chemotherapy, metastasis, invasiveness and poor prognosis (Arner 
and Holmgren, 2006). The ambiguous nature of published reports could be due to 
the different tumor cell lines and chemical agents used and the lack of a proper 
genetic model to study the effect of loss of Txnrd1 in tumorigenesis. Another inherent 
problem while addressing the role of Txnrd1 in tumorigenesis is to dissect the 
thioredoxin-dependent role from that of the thioredoxin-independent role of 
thioredoxin reductase 1. As both Trx and TrxR are upregulated in multiple tumors, it 
is hard to distinguish the individual contributions of the two components of the Trx 
system. Although Trx expression is increased in a variety of human malignancies 
including lung, colorectal, cervical, hepatic and pancreatic cancers, the relationship 
between TrxR activity and tumor growth is less clear at present (Arner and 
Holmgren, 2006). It may be possible that tumor cells may need not to increase 
TrxR1 protein levels per se; on the other hand augmented, catalytic activity may be 
sufficient to drive TrxR1-dependent functions. It has also been shown that in human 
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B cell lines and leukemic cell lines derived from B cells, TrxR1 levels remained 
unaltered after selenium supplementation. So it is probable that some cancers rely 
on the Trx system to a greater extent than others. Therefore in some cases it might 
be essential, while in others loss of TrxR1 seems to have no effect on tumor growth 
behavior as they can easily compensate the loss of TrxR1 functions (as discussed in 
following section). 
 
5.2.2 Response of transformed Txnrd1 knockout cells to different 
stress-inducing agents  
Since thioredoxin reductase 1 plays an important role in the maintenance of cellular 
redox balance and defense against oxidative stress, we hypothesized that Txnrd1 
knockout cells would be more susceptible to different stress-inducing agents. 
Surprisingly, when challenged with hydrogen peroxide and alkyl hydroperoxide (t-
butyl hydroperoxide) there was no difference in viability between knockout and wild-
type cells over the tested concentrations. This was unexpected since thioredoxin 
reductase 1 has been linked to the scavenging of lipid hydroperoxide (Bjornstedt et 
al., 1995; May et al., 2002). Also thioredoxin reductase 1 is involved in the reduction 
of different peroxiredoxins, which are crucial for the scavenging of hydrogen 
peroxide, in a thioredoxin-dependent manner. The above observation is suggestive 
of the fact that, as long as thioredoxin 1 is maintained in its reduced state, cells 
deficient in Txnrd1 do not suffer from severe oxidative stress inflicted by H2O2 and t-
BOOH. In the same line of observation, it was reported that thioredoxin 1 is 
maintained in a reduced state in Txnrd1 knockdown cells by an unknown mechanism 
(Watson et al., 2008). This could be done by thioredoxin reductase 2, as one of the 
spliced forms is reported to be localized in the cytosol. In this respect Txnrd1 
knockout cells will be a valuable tool to explore the unidentified reductase 
responsible for the reduction of thioredoxin 1 as so far only thioredoxin reductase 1 
is the known enzyme responsible for reducing thioredoxin 1. The generation of cell 
lines deficient in both thioredoxin reductases is needed to address this question. It 
has been reported that thioredoxin glutaredoxin reductase (TGR) has specificity for 
both thioredoxin and glutaredoxin and could be the common reductase for both 
pathways (Sun et al., 2001a). 
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Heavy metal compounds like arsenic (III) oxide, platinum, gold and organotellurium 
compounds are known inhibitors of thioredoxin reductase 1. The anti-cancer effect of 
arsenic (III) oxide and cisplatin is due to the inhibition of thioredoxin reductase 1 (Lu 
et al., 2007; Witte et al., 2005). Accordingly, if the cytotoxic effects of these agents 
are due to specific inhibition of thioredoxin reductase 1, then Txnrd1 knockout cells 
should be more resistant to these compounds. Three compounds, arsenic (III) oxide, 
TEPAu and cisplatin, were applied to transformed Txnrd1 knockout cells. 
Transformed Txnrd1 knockout cells were moderately resistant to the three agents 
tested; confirming previously published reports that therapeutic efficacy of these 
agents is partially due to inhibition of thioredoxin reductase 1. Txnrd1 knockout cells 
were found to be moderately resistant to arsenic (III) oxide and TEP Au at lower 
concentration, but at higher concentration these cells were equally susceptible which 
showed that at higher concentration inhibition of cellular enzymes other than 
thioredoxin reductase 1 is responsible for cell death. The data obtained in the 
present study rule out a high specificity of arsenic (III) oxide towards Txnrd1 as 
claimed by Holmgren’s group (Lu et al.; 2007) who reported that chemotherapeutic 
efficacy of arsenic (III) oxide is due to inhibition of thioredoxin reductase 1. In 
particular, resistance to cisplatin was an interesting phenotype. In the present study, 
it was found that Txnrd1 knockout cells were only moderately resistant to cisplatin 
suggesting thioredoxin reductase 1 as one amongst other targets of cisplatin. This 
was in line of a published report that cisplatin inhibits thioredoxin reductase 1 but not 
glutathione reductase (Witte et al., 2005). However, the report of Sasada et al. that 
thioredoxin reductase 1 confers resistance towards cisplatin therapy as knockdown 
of thioredoxin reductase 1 sensitizes tumor cells towards cisplatin is contradictory to 
our observation (Sasada et al., 1999).  
 
In response to the DNA-damaging agent doxorubicin, it was found that Txnrd1 
knockout cells were equally sensitive like the parental cell lines. Doxorubicin does 
not inhibit TrxR1 function as it is a poor substrate of TrxR1 (Witte et al., 2005). 
Accordingly, there was no difference in the dose-response between wild-type and 
knockout cells towards doxorubicin. 
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5.2.3 Loss of thioredoxin reductase 1 had little impact on clonogenicity 
and tumorigenicity 
Thioredoxin reductase 1 has been frequently linked to cellular proliferation. However, 
there are some reports showing that over-expression of thioredoxin reductase 1 in 
HEK 293 cells resulted in decreased proliferation (Nalvarte et al., 2004). The odd 
observation that loss of Txnrd1 functions had no impact on the proliferative capacity 
and cell cycle distribution of knockout cells prompted us to identify a putative 
compensatory mechanism operating in the cells. This observation was in line of 
published findings of Yoo et al. that under normal growth condition knock-down of 
thioredoxin reductase 1 has little effect on tumor cell proliferation, although under 
serum deprivation deficiency of Txnrd1 leads to deregulated S-phase transition. But 
the loss of Txnrd1 function, either by chemical inhibition or siRNA-mediated 
knockdown, invariably resulted in loss of clonogenicity and tumorigenicity (Lu et al., 
2007; Wang et al., 2008; Yoo et al., 2006; Yoo et al., 2007). Contradictory to all the 
published reports, Txnrd1 knockout cell lines were able to form colonies in soft agar, 
suggesting that the loss of Txnrd1 function had no effect on the clonogenicity of the 
cells. Most strikingly, the knockout cell lines formed aggressive tumors comparable 
in size to those of parental cell lines when implanted into mice, which further 
corroborated the findings obtained from in vitro soft agar assays.  
 
5.2.4 Up-regulation of the GSH-dependent pathway compensated for the 
loss of Txnrd1 
5.2.4.1 Transformed Txnrd1 knockout cells were highly susceptible to GSH 
Because Txnrd1 knockout cells were highly susceptible to GSH depletion by BSO, 
which could not be rescued by antioxidant supplementation or xCT over-expression, 
it indicated that Txnrd1 knockout cells may adopt components of the GSH-
dependent pathway as salvage for survival. As both, the thioredoxin and the 
glutaredoxin system donate electrons to ribonucleotide reductase thus maintaining 
the dNTP pool and DNA synthesis, loss of one system may be compensated by the 
up-regulation of the other. In all possibilities, tumor cells may exploit the same 
mechanism, i.e. up-regulation of components of the GSH-dependent system to 
sustain the loss of Txnrd1. When GSH was depleted from the transformed Txnrd1 
knockout cells, the knockout cells displayed high sensitvity towards GSH depletion. 
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Thus, like untransformed cells, transformed Txnrd1 knockout cells were also 
susceptible to GSH depletion, which indicated that irrespective of cell growth 
characteristics (untransformed versus transformed), cell survival and proliferation in 
the absence of Txnrd1 relies on the GSH-dependent pathway.  
 
When two other compounds, cadmium chloride and PEITC, which are known to 
inhibit components of the GSH-dependent pathway, were tested, Txnrd1 knockout 
cells exhibited only marginal resistance towards these compounds, which was an 
unexpected finding. The obscure nature and undefined mechanism of action of these 
compounds pose problems in drawing some concrete inference from the existing 
sets of data. But the specific nature of BSO as a GSH-depleting agent led to the 
conclusion that Txnrd1 knockout cells heavily depend on the GSH-dependent 
pathway. 
 
The above notion was further confirmed by reconstitution experiments. SF-Txnrd1 
was over-expressed in a doxycycline-inducible manner (Bornkamm et al., 2005). 
Expression slowly declined after doxycycline withdrawal and was still detectable, 
although at lower level, 48 hours after withdrawal of the drug. In the presence of 
doxycycline, SF-Txnrd1 over-expressing Txnrd1 knockout cells displayed strong 
resistance towards GSH-depletion as compared to the same cells in the absence of 
doxycycline. This provided the final proof that, in the absence of Txnrd1, GSH and/or 
a GSH-dependent pathway become crucial for survival of these cells. Therefore, 
components of the GSH-dependent pathway were examined in detail to identify the 
compensatory mechanism both at the transcriptional and enzyme activity level and 
by GSH/GSSG measurements. 
 
5.2.4.2 Higher GSH concentration and glutathione reductase activity 
compensated the loss of Txnrd1 functions in transformed Txnrd1 knockout 
cells 
Analysis of the components of GSH-dependent pathway in transformed Txnrd1 
knockout cells at the transcriptional level showed that Gclc, Gclm and Gsr were more 
than two-fold higher in knockout cells as compared to parental cell lines. To verify 
the results of qRT-PCR, GSH concentration and GR activity were measured in these 
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cells. GSH concentration was determined by HPLC, which revealed that total GSH 
concentration was considerably higher in transformed Txnrd1 knockout cells. While 
total GSH (GSH+GSSG) and GSH concentration was 1.5- to 3-fold higher in Txnrd1 
knockout cells, a more than 3-fold increase in GSSG concentration was found in 
Txnrd1 null cells. Although cells compensate for the loss of Txnrd1 by increasing 
total GSH concentration, the higher GSSG concentration in these cells is suggestive 
of sustained oxidative stress and increased pressure on the GSH-dependent system 
to compensate for the loss of Txnrd1.  Yeast strains lacking both trx1 and trx2 
showed elevated levels of GSSG (Muller, 1996), indicating a direct link between the 
thioredoxin system and the redox status of GSH in the cell. Thus, the compensatory 
up-regulation of either of the disulfide-reducing pathways in the absence of the other 
is evolutionary conserved, and the thioredoxin and GSH/glutaredoxin systems are 
functionally coupled. 
 
Similarly, GR activity was up-regulated in these cells. Txnrd1 knockout cells showed 
more than a 2-fold increase in GR activity as compared to the respective parental 
cell lines. The increase in GSH and GR activity was quantitatively variable when two 
knockout cell lines were compared. One knockout cell line (53MRC4ΔE3) showed a 
more than 2.5-fold increase in GSH and GR activity, while in the second knockout 
cell line (51MRB3ΔF1) a 1.5-fold increase in GSH and an approximately 2-fold 
increase in GR activity was observed. Therefore, one may conclude that the 
adaptation to Txnrd1-deficiency is more complex and involves at least two 
mechanisms, altered GSH synthesis and augmented GR activity. Needless to say, 
this does not rule out that other enzymes of the GSH-dependent sytems may 
additionally contribute to the salvage pathway. Nonetheless, these findings clearly 
indicate that the GSH-dependent system is the major back-up system for loss of 
Txnrd1. There are at least two published reports which support the findings of the 
present study. It is noteworthy, that in Arabidopsis thaliana and in Drosophila 
melanogaster there is a complex cross-talk between the Txn and GSH system 
(Reichheld et al., 2007). Accordingly, Txnrd1-deficiency could be bypassed by the 
GSH-dependent pathway. So to say, there is a common evolutionary signature with 
regard to the utilization of the GSH and thioredoxin systems. The other 
compensatory mechanism suggested by Bondereva et al. is the up regulation of 
sulfiredoxin (Bondareva et al., 2007).  
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5.2.4.3 Add-back of Txnrd1 caused reduction in GSH and GR activity 
To rule out any clonal effect that Txnrd1 knockout cells may exhibit, Txnrd1 was 
over-expressed in these cells in a doxycycline-inducible manner. If the increase in 
GSH and GR was a compensatory response, then upon re-introduction of Txnrd1, 
there should be a decrease in GSH and GR level. When Txnrd1 was reconstituted in 
the knockout cells, the GSH level and GR activity were indeed decreased in a time-
dependent manner. The total GSH concentration in doxycycline-treated cells 
decreased to one third of that of untreated cells. The decrease in GSH levels after 
addition of doxycycline was paralleled by a reduction in GR activity. Re-expression of 
Txnrd1 led to a decrease in GR activity by approximately 50%. The re-constitution 
experiment finally proved that loss of Txnrd1 could lead to up-regulation of the GSH-
dependent pathway, which could be reverted by re-expression of Txnrd1 in a time-
dependent manner. Thus, the GSH-dependent system can compensate for the loss 
of Txnrd1 rendering Txnrd1 dispensable for tumorigenesis. 
 
5.2.5 Txnrd1-deficient tumors were highly susceptible to 
pharmacological inhibition of GSH 
After proving that the loss of Txnrd1 has no effect on clonogenicity and tumorigenicity 
of transformed cells due to compensatory up-regulation of the GSH-dependent 
pathway, we asked the question if it is possible to exploit this mechanism as a 
therapeutic intervention to treat Txnrd1-deficient tumors. Pharmacological inhibition 
of GSH led to approximately 8-fold reduction in tumor mass, which successfully 
recapitulated the in vitro findings. Thus, these results showed that inhibition of one 
disulfide reducing pathway is not sufficient to combat tumor growth as they can shift 
to the other pathway for survival and proliferation. Long-term studies on the potential 
of GSH inhibition as a therapeutic stratergy for the cure of Txnrd1-deficient tumors 
are ongoing in mice. As the ROS burden is increased in tumor cells due to replicative 
stress, inhibition of both pathways may eventually provide a therapeutic window for 
the treatment of cancer, leaving normal cells unaffected. Drugs targeting both 
pathways like motexafin gadolinium are in clinical trial phase with promising results. 
Motexafin gadolinium not only inhibits thioredoxin reductases but also elevates the 
level of ROS generation by depleting the intracellular reducing metabolites like 
ascorbate, glutathione, and NADPH. It induces cell death by elevating the 
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intracellular zinc concentration and by releasing of mitochondrial caspases (Chen et 
al., 2005; Evens et al., 2005a; Evens et al., 2005b; Hashemy et al., 2006; Lecane et 
al., 2005; Richards and Mehta, 2007; William et al., 2007) .  
 
5.3 Future prospects 
Recent advancement in the field of redox regulation and antioxidant research had 
shown that ROS and antioxidant systems play an important role in tumorigenesis. As 
the basal ROS production is increased in tumor cells as compared to normal cells, 
agents that increase the ROS production or deplete the antioxidant system are 
emerging as novel therapeutics for chemotherapy. Redox modifiers including 
buthionine sulfoximine, ascorbic acid, arsenic trioxide, imexon, PEITC and 
motexafin gadolinium are in pre-clinical or clinical trials as single-agents or in 
combination, and a better understanding of ROS-induced cell death and senescence 
is prerequisite for the development of a rationale chemotherapy against cancer using 
redox modulators (Engel and Evens, 2006). The outcome of the present study 
indicates that inhibition of one component of an antioxidant defense system is not 
sufficient to combat the cancer as tumors can exploit the other pathway for the 
survival. The future therapeutic approaches should target both the thioredoxin and 
the GSH-dependent system, for effective outcome without doing too much harm to 
the normal tissue.  
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6. Summary 
The thioredoxin dependent system consists of thioredoxin reductases, thioredoxins and 
thioredoxin-dependent peroxidases. Along with the glutathione (GSH)-dependent system, it is 
critically involved in the maintenance of the intracellular redox balance. In particular, cytosolic 
thioredoxin reductase (Txnrd1) substantially contributes to proliferation, growth and 
development as Txnrd1 disruption leads to growth arrest and embryonic lethality in mice. 
Being up-regulated in various tumors, Txnrd1 and its major substrate thioredoxin 1 have been 
considered as promising drug targets for cancer therapy. Although various reports implicated 
that Txnrd1 is indispensable for proliferation and tumorigenesis, in this work both 
untransformed and transformed Txnrd1-deficient cell lines could be established that contrary 
to our expectations did not show any proliferation defects or altered cell cycle distribution. 
Like mitochondrial thioredoxin reductase (Txnrd2) null cells they were highly susceptible to 
experimental GSH depletion. 
 
The GSH-depletion in immortalized, untransformed Txnrd1 knockout cells triggered rapid cell 
death, which could not be prevented by antioxidants, by xCT over-expression or by co-
culturing these cells with cells that provide a reducing extracellular milieu. This was a unique 
feature as cells with genetic defects in other redox-regulating enzymes like γ-GCS and Txnrd2 
and xCT cells could be readily protected from GSH depletion-induced cell death by 
antioxidants or xCT overexpression. The present study shows that Txnrd1 is required for the 
utilization and recycling of thiol-containing antioxidants. Reconstitution of Txnrd1 expression 
in Txnrd1-/- cells reversed the aforementioned effects and confirms that the effects were solely 
due to Txnrd1 depletion and not caused by other possible side effects.  
 
The present study thus reveals that Txnrd1 is dispensable for tumor growth as loss of Txnrd1 
function had little impact on proliferation, clonogenicity, and tumorigenicity of transformed 
cells. Detailed molecular and biochemical analysis of transformed Txnrd1-/- cells provided 
evidence that increased GSH synthesis and augmented glutathione reductase activity act as 
compensatory mechanisms that render Txnrd1 dispensable for tumor growth. This was 
evident from the fact that transformed Txnrd1-/- cells were highly susceptible to GSH 
depletion. The fact was further corroborated by in vivo studies, demonstrating an 8-fold 
reduction in the tumor mass of Txnrd1-/- tumors compared to control tumor treated with BSO. 
Thus, it was concluded that growth and proliferation of Txnrd1-/- tumors rely on the GSH-
dependent system, which makes them highly susceptible to pharmacological depletion of 
intracellular GSH levels. 
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7. Zusammenfassung 
Das Thioredoxin-abhängige System bestehend aus den Thioredoxin-Reduktasen, 
Thioredoxinen und Thioredoxin-abhängigen Peroxidasen bestimmt zusammen mit dem 
Glutathion (GSH) -abhängigen System maßgeblich die zelluläre Redox-Balance. Eine 
zentrale Rolle in der Regulation von Proliferation, Wachstum und Entwicklung spielt v.a. die 
zytosolische Thioredoxin-Reduktase (Txnrd1). Die gezielte Inaktivierung der Txnrd1 führt zu 
Wachstumsarrest und früher embryonaler Letalität in Mäusen. Da zytosolisches Thioredoxin 
und Txnrd1 häufig in Tumoren überexprimiert sind, wurden sie als ideale Zielmoleküle für die 
Tumortherapie erachtet. Obwohl einige frühere Arbeiten aus anderen Labors einschließlich 
unserem Labor implizierten, dass die Txnrd1 essenziell für die Zellproliferation und 
Tumorentwicklung sei, konnten in dieser Arbeit immortale und transformierte Txnrd1-
knockout Zelllinien etabliert werden. Entgegen unserer Erwartungen weisen diese Zellen 
keine offensichtlichen Wachstumsdefekte, noch eine veränderte Zellzyklusverteilung auf. 
Allerdings reagieren diese Zellen, ähnlich wie mitochondriale Thioredoxin-Reduktase 
(Txnrd2)-knockout Zellen, sehr sensitiv auf pharmakologische GSH-Depletion. 
 
Die GSH-Depletion löste sowohl in immortalisierten, als auch in transformierten Txnrd1-
defizienten Zellen sehr schnell Zelltod aus, der weder durch Antioxidantien, noch durch die 
xCT-Überexpression oder durch Ko-Kulturen mit Zellen, die ein reduzierendes extrazelluläres 
Milieu verschaffen, verhindert werden konnte. Dies war ein bislang noch nicht beobachtetes 
Phänomen. Frühere Studien mit Zellen, denen Redox-regulierende Enzyme wie z.B. γ-GCS, 
Txnrd2 und xCT fehlen, ergaben, dass Antioxidantien oder die Überexpression von xCT die 
Zellen vor GSH-Depletion-induziertem Zelltod schützen. Deshalb kann behauptet werden, 
dass die Txnrd1 zusätzlich wichtig für die Nutzung und das Recycling von Antioxidantien ist. 
Die Rekonstitution der Txnrd1-Expression in Txnrd1-/- Zellen reversierte alle oben genannten 
Phänotypen, was dafür spricht, dass alle Effekte durch die gezielte Inaktivierung der Txnrd1 
hervorgerufen wurden und nicht durch mögliche Nebeneffekte.  
 
Diese Studie zeigt zum ersten Mal, dass die Txnrd1 nicht essenziell ist für das 
Tumorwachstum, da der Verlust der Txnrd1-Expression kaum Einfluss auf die Proliferation, 
Klonogenität und Tumorigenese von transformierten Zellen hat. Weitere molekulare und 
biochemische Analysen ergaben, dass die gesteigerte GSH-Synthese und die erhöhte GSH-
Reduktase den Verlust der Txnrd1 kompensieren. Deshalb reagierten die Zellen auch sehr 
empfindlich auf GSH-Depletion. Diese Eigenschaft konnte auch in vivo ausgenutzt werden, 
da die BSO-Behandlung von Mäusen mit implantierten Txnrd1-/- Tumorzellen eine 8-fache 
Reduktion des Tumorwachstums im Vergleich zu Kontrolltumoren aufwiesen. Aus diesen 
Daten kann geschlossen werden, dass das Wachstum und die Proliferation von Txnrd1-/- 
Tumoren von einem funktionellen GSH-abhängigen System abhängt, was sie sehr 
empfindlich gegenüber pharmakologischer GSH-Depletion macht.  
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